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ABSTRACT 
L1 retrotransposition is a significant source of endogenous mutagenesis in the human 
genome. This process is driven by a handful of highly active source L1s in each individual. 
L1 mobilization can occur in natural pluripotent cells, such as the stem cells present in the 
early embryo, and during the artificial generation of human induced pluripotent stem cells 
(hiPSCs) via cellular reprogramming. hiPSCs have been proposed for use in regenerative 
medicine, rendering an understanding of L1 retrotransposition and mutagenesis during 
hiPSC induction and cultivation essential. 
Although endogenous L1 insertions are known to arise in hiPSC lines [1], more 
information is required regarding L1 mobilisation and insertional patterns in order to 
elucidate the regulation and impact of L1 activity in this context. For example, transductions 
can be useful to find active, retrotransposition-competent L1s (RC-L1s) responsible for de 
novo retrotransposition events, and infer relationships between progenitor and offspring L1 
copies. It has also been reported that endogenous retrotransposition in hiPSCs may 
generate an elevated fraction of full-length insertions [1, 2]. Crucially, L1 insertions bearing 
transductions have as yet not been identified in hiPSCs or embryonic stem cells (ESCs). 
Additionally, L1 promoters are methylated by the host genome to reduce their potential to 
initiate L1 mRNA transcription [3]. The genome-wide methylation state of L1 families, and 
specific L1 loci, has been analysed in ESCs and hiPSCs, and in neural stem cells (NSCs) 
[4-10]. However, the methylation state of individual L1 loci, including de novo L1 insertions 
and their progenitor elements, has to date not been reported. 
In the research described in this thesis, I identified a full-length de novo L1 insertion 
in a cultured hiPSC line. This L1 insertion was not present in the matched parental human 
dermal fibroblast (HDF) line and, as a result, was annotated as a reprogramming-associated 
event. Notably, the L1 carried transduced genomic sequences at its 5' and 3' termini. Using 
these unique transduced sequences, we identified the associated source (donor) L1 
element, which had previously been reported to retrotranspose in vitro [11]. This donor L1 
was part of an extended group of closely related L1s identified via their shared 3' 
transductions – an L1 transduction family [12]. Interestingly, the ancestral L1 copy, or 
lineage progenitor L1, of this family was previously reported as being inactive in vitro [13]. 
However, we found that the de novo L1 insertion, its immediate donor L1, and some other 
members of the transduction family, retrotransposed efficiently in vitro, indicating that these 
L1s comprise a lineage still capable of mobilisation, including during reprogramming. 
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I next analyzed DNA methylation amongst the L1 transduction family prior to 
fibroblast reprogramming, in hiPSCs, and during neuronal differentiation. Notably, members 
of the family were demethylated during reprogramming and were then progressively 
methylated during neuronal differentiation. The de novo L1 insertion was hypomethylated 
compared to its donor L1, and the donor L1 was in turn less methylated than the older family 
members.  
 This thesis therefore identifies an extended L1 transduction family that is mobile 
during reprogramming, likely as a result of specific relaxation of DNA methylation via an 
unknown mechanism. Using an in vitro system, my experimental data allows us to predict 
dynamic L1 methylation patterns during neurodifferentiation in vivo. Finally, my work further 
highlights L1 mutagenesis as a potential obstacle to the use of hiPSCs in biomedical 
applications. 
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INTRODUCTION 
1 Types of mammalian mobile DNA. 
Mobile DNA has played a major evolutionary role in shaping eukaryotic genomes 
[15]. These sequences, also known as “jumping genes”, are classified by the intermediate 
they use to mobilise: either DNA (transposons) or RNA (retrotransposons) (Figure 1) [16]. 
DNA transposons use a cut-and-paste mechanism involving a transposase, entirely 
comprise fossils of ancient elements in the human genome, and are inactive in humans [15]. 
Retrotransposons use a copy-and-paste mechanism and are found in the vast majority of 
mammalian genomes. Retrotransposons are also classified by whether they are 
autonomous or non-autonomous, i.e. if they encode their own proteins to mobilise 
independently, or if they rely on proteins from other elements to jump [17]. Autonomous 
retrotransposons are further divided into long terminal repeat (LTR) retrotransposons, which 
resemble retroviruses in both their mobility mechanism and structure [18], and non-LTR 
retrotransposons, which includes the prime protagonist of this thesis: Long interspersed 
element (LINE-1 or L1) (Figure 1).  
L1 is the only autonomous, active human retrotransposon [15, 16]. Approximately 
~45% of the human genome is composed of retrotransposons; ~17% is occupied by L1 
copies [15]. Non-autonomous human retrotransposons include the short-interspersed 
elements (SINEs) Alu and SVA, which rely on the machinery of L1 to mobilise [19, 20]. One 
million Alu copies account for ~10% of the human genome [15, 16, 19, 21, 22]. By contrast, 
genomes of other organisms such as fruit fly, worm, and Arabidopsis may comprise less 
than 10% transposed elements, while some plant genomes contain >80% [15, 16, 23-25]. 
Thus, mobile DNA elements are dynamic molecular entities that change eukaryotic genome 
landscapes by their amplification and contribution to structural variation, and are therefore 
key components of genome evolution [16].  
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Figure 1: Types of human mobile elements: Displayed are the different types of mobile 
elements found in humans. This figure was adapted from [17]. 
 
2 L1 retrotransposons. 
Approximately 500,000 L1 copies are present in the human reference genome (HRG) 
[15]. To estimate how many retrotransposition-competent L1s (RC-L1s) were present in the 
human population, Brouha et al. [13] i) interrogated the HRG to identify L1s with intact ORFs 
and ii) estimated the allele frequency of these L1s in the human population. Using genomic 
DNA and bacterial artificial chromosomes (BAC) DNA, the authors PCR amplified 82 out of 
90 of the L1s with intact ORFs identified in the HRG, 67 clones from human gDNA and 15 
from BAC DNA from 2 independent PCRs. As nearly 50% of the cloned L1s were 
retrotransposition competent in an in vitro retrotransposition assay [22], and considering that 
the HRG version used only represented 95% of a complete haploid genome, the authors 
estimated around 93 RC-L1s were found per diploid genome. In a second estimation, taking 
into account reports of polymorphic L1s in the human population not present in the HRG 
[26-29] and the estimated allele frequencies of 40 active reference L1s, the authors arrived 
at an average of 66 RC-L1s per average diploid genome [13]. Based on their estimates 
using these 2 different approaches, and the likely existence of undiscovered L1s, Brouha et 
al. reported that each individual human carries between 80 and 100 RC-L1s.  
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Additionally, Brouha et al. identified that 84% of assayed retrotransposition capability 
was the result of 6 highly active, or ‘hot’, L1s. The definition used to define “hot” L1s in this 
study was based on observing one third of the retrotransposition activity of the disease 
causing L1 insertion L1RP [30, 31]. Hence, the authors concluded that most of L1 
retrotransposition in the human population stems from these “hot” L1s [13].  
Subsequently, Beck et al. expanded upon the work of Brouha et al. by sequencing 
fosmid libraries generated using genomic DNA from six individuals from diverse geographic 
populations, identifying polymorphic L1 copies absent from the HRG. Differing from Brouha 
et al., Beck et al. used a PCR-free approach to clone L1 sequences. In this study, L1s were 
cloned directly from the produced libraries after enzymatic digestion. This approach 
eliminated the risk of PCR-induced substitutions being introduced into the L1 sequence, and 
therefore improved the accuracy of in vitro L1 activity estimates. A new set of 68 full-length 
polymorphic L1s was identified, of which half were highly active or “hot” in the 
retrotransposition assay. In this case, the term “hot” L1 was defined based on those 
elements that exhibited more than 10% of the retrotransposition activity of L1.3 [27]. It was 
demonstrated that the number of “hot” L1s can vary from person to person, and some were 
found only in specific populations [11]. Moreover, specific L1 copies can present 
heterogeneity in their activity due to allelic variants [32]. Therefore, it still is not fully known 
how many “hot” L1s are found in the human population. Most active L1s belong to the 
hominid specific L1-Ta family [30, 33] which was first identified in human teratocarcinoma 
cells and was termed “Ta” (for transcribed, subset a [34]). The remaining L1 copies (>99.9%) 
are defective due to 5’ truncations, inversions, deletions, and other mutations [13, 15, 16].  
A retrotransposition-competent L1-Ta is 6 kilo basepair (kbp) in length and contains 
a 5’ untranslated region (UTR), two non-overlapping Open Reading Frames (ORF1 and 
ORF2) that encode proteins required for L1 mobility, and a 3’UTR that is punctuated by a 
poly(A) tail [26, 35]. The L1 5’UTR has an internal RNA polymerase II promoter that directs 
transcription from the 5’ end of the element [36] and presents cis-acting binding sites for 
multiple transcription factors (TF) [37-42]. The 5’UTR also contains a potent antisense 
promoter (L1 ASP) [43, 44]. Another promoter was recently discovered in the 3’UTR region. 
Transcripts initiated at this 3’ promoter are found in a wide variety of somatic tissues, 
including brain [45]. A relatively recent study demonstrated the presence of a primate 
specific ORF, called ORF0. This ORF0 is in the 5’UTR, anti-sense orientated with respect 
to the L1 copy [46]. ORF1 and ORF2 are separated by a ~60bp spacer [22]. ORF1 encodes 
a 40kDa protein, called ORF1p with RNA binding domain and chaperone activity [47, 48]. 
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ORF2 encodes a 150kDa protein called ORF2p, with endonuclease (EN) [49] and reverse 
transcriptase (RT) activities [50]. These activities are required for canonical L1 
retrotransposition [22].  
 
3 L1 retrotransposition mechanism. 
L1 retrotransposition begins when RNA polymerase II initiates transcription of a full-
length L1 from its internal 5’ sense promoter [36] (Figure 2). The L1 mRNA is transported 
to the cytoplasm where the translation of ORF1p and ORF2p [16] occurs via an 
unconventional termination-reinitiation mechanism [51, 52]. ORF1p and ORF2p exhibit cis 
preference, meaning that in the cytoplasm the two proteins bind to the L1 mRNA that 
encoded them [53] to form a ribonucleoprotein particle (RNP), the hypothesised 
retrotransposon intermediate [54-58]. The L1 RNP then migrates from the cytoplasm to the 
nucleus using a mechanism that is still unknown [16] but can occur independently of cell 
division [10, 59]. Once the RNP enters the nucleus, integration of the L1 sequence into the 
host genome is thought to proceed in most cases via Target Primed Reverse Transcription 
(TPRT). The TPRT mechanism was discovered by Luan et al., studying the retrotransposon 
R2 in Bombyx mori [60]. In this process, the L1 EN cleaves the first strand of the new L1 
genomic locus with a preference for 5’-TTTT/A-3’ motifs [61]. The EN-induced DNA break 
creates a free 3’-OH group, which is then used as a primer for reverse transcription of the 
L1 mRNA by the L1 RT [62]. The second DNA strand is usually cleaved some distance 
downstream of the initial cut [63] leaving single stranded regions that are eventually filled, 
forming direct repeats named target site duplications (TSDs) [64]. The end result of L1 
integration is a new insertion flanked by these TSDs, which are characteristic of TPRT. 
Second strand cleavage can also occur directly opposite the first strand cleavage site, giving 
rise to blunt insertions without TSDs [64].  
In addition to TPRT, there are other less common, and less understood, mechanisms 
of L1 mobilisation that deviate from the canonical mechanism of retrotransposition [62]. The 
EN-independent pathway is one of these examples [65]. In that case, L1 takes advantage 
of existing double-strand breaks (DSBs) in genomic DNA (gDNA) to initiate reverse 
transcription from the broken DNA fragment [66]. Products of this EN independent process 
typically lack hallmarks (i.e., TSDs, canonical L1 cleavage motif) of TPRT mediated 
insertions [65, 66]. 
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Figure 2: The L1 retrotransposition cycle.  A full-length L1 is transcribed from its original 
location in the genome, represented in green situated in the purple chromosome; the 
transcript is exported and translated to produce ORF1p (represented in small blue circles) 
and ORF2p (represented in big blue circle). Both proteins bind to the L1 mRNA to form an 
RNP. The L1 RNP enters the nucleus and initiates TPRT in another region of the genome 
(represented as a turquoise chromosome). The L1 EN nicks the DNA, generating a free 3’-
OH’ residue that is used as a primer by the L1 RT to reverse transcribe the L1 mRNA 
template (green). The mechanism of second strand cleavage, second strand cDNA 
synthesis, and the completion of L1 integration are currently unclear. In this representation, 
TPRT results in a new L1 5’-truncated copy (orange bar in the turquoise chromosome). New 
L1 insertions are usually flanked by TSDs (dark orange arrows). This figure was adapted 
from [17, 67, 68]. 
 
4 Impact of L1 retrotransposition on the mammalian genome. 
Retrotransposition is a major cause of genome structural variation, and is 
disproportionately likely to bring about phenotypic change. Unusually, for example, L1 
retrotransposition is the source of resistance to human immunodeficiency virus type 1 (HIV) 
in owl monkeys. Owl monkey cells express a TRIM5–Cyclophilin A (CypA) fusion protein 
that blocks HIV-1 infection. This was the first example found in vertebrates of a chimeric 
gene generated by exon shuffling, where L1 trans mobilised CypA cDNA into the TRIM5 
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locus [69]. However, most new L1 insertions are neutral or deleterious. Since the original 
discovery by Haig Kazazian and colleagues in 1988 that L1 retrotransposition events could 
cause disease in humans, when they discovered de novo L1 insertions in the clotting Factor 
VIII gene of 2 unrelated patients with Haemophilia A [70], ~100 disease-causing mutations 
have been attributed to L1-mediated retrotransposition [3, 71, 72]. By disrupting exons [70] 
L1 insertions can disrupt gene coding sequences, induce mis-splicing, exon skipping and 
frameshift mutations [67, 73]. Moran et al. for example demonstrated, performing in vitro 
experiments, that engineered L1s (see below section 9.1) modified with artificial splice 
acceptor sites placed in the indicator cassette, can land in coding genes, oriented in sense 
or antisense [74]. That new L1 insertions can have such profound effects on gene function 
and expression means they have a disproportionate impact per event when compared to 
the 500,000 fixed L1 copies already found in the human genome, as most of the latter 
elements have been subject to aeons of evolutionary selection. 
In addition, recent studies discovered that the L1 EN may produce double strand 
breaks that can contribute to genomic instability [75, 76]. Intronic L1 insertions can also 
impair genes via several routes (Figure 3). For example, due to the adenosine rich-content 
of L1 sequence, target genes can be inhibited by premature mRNA polyadenylation, 
transcriptional pausing or inhibition of transcription elongation that naturally affects L1s as 
well [77, 78]. Less commonly, antisense intronic L1 insertions can interrupt genes through 
a phenomenon known as gene breaking [79]. Due to these effects, L1 is considered a major 
factor in mammalian gene structural and functional evolution [17, 80]. 
  
Figure 3: Schematic representation of the different ways by which L1 insertion can 
alter gene composition. A hypothetical gene locus is used to represent six different 
scenarios for L1 insertions: disruption of exons, exon skipping, incorrect splicing, provision 
of new sense and antisense promoter activities, epigenetic alterations and premature 
polyadenylation. 
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5 L1 retrotransposition can involve transductions. 
L1 insertions carrying transductions (Figure 4) are of particular importance to this 
thesis. Transductions can flank L1 sequences that are mobilised along with the L1 into a 
new genomic location. These often unique “tag” sequences carry the necessary information, 
if long enough, to help identify the source element of a de novo retrotransposition event. 
Both 5’ and 3’ transductions can occur and these are generated in different ways; 3’ 
transductions are produced when the canonical L1 Poly-A signal is not used, generating an 
L1 mRNA where polyadenylation is directed by an alternative downstream Poly-A signal [74, 
81, 82]. By contrast, 5’ transductions are far less common because they only appear if the 
L1 sense promoter, or another adjacent promoter, initiates transcription upstream of the L1 
position +1, and the consequent L1 mRNA undergoes retrotransposition without being 5’ 
truncated [17]. L1 transductions can include exons and promoters and could therefore 
generate new genes [83].  
 
Figure 4: A L1 3’ transduction. A. A full length donor L1 is represented as a blue rectangle 
at chromosomal location A, which is represented as a green rectangle. An L1 mRNA 
containing RNA transcribed from the 3’ flank is reverse transcribed and integrated in a new 
location (ChrB, represented in orange) during retrotransposition. B. Daughter element; new 
insertion with a 3’ transduced sequence. The new L1 insertion is represented as a blue 
rectangle in chromosomal location B (ChrB) as an orange rectangle. The 3’ transduction is 
represented as a green rectangle in the new chromosomal location ChrB. Poly-A tracts are 
represented as An. 
19 
 
3’ transductions are highly variable in length but have an average size of 207 
nucleotides [8, 81]. These sequences provide L1 insertions with a molecular link to their 
parental L1 and therefore allow us to track L1 elements that are still active [12]. Notably, the 
average length of human L1 3’ transductions is significantly less than would be predicted by 
random incidence of suitable Poly-A signals on the genome, either due to less efficient 
retrotransposition of these chimeric L1 mRNAs, or because L1 integrates preferentially in 
AT-rich regions [74, 81], increasing the likelihood of a strong Poly-A signal being located 
downstream of mobile L1s. The first example of an L1 3’ transduction was found to 
accompany a pathogenic, exonic insertion in the dystrophin gene of a muscular dystrophy 
patient [84]. The authors of this study referred to the transduction as a Unique Sequence 
Component (USC). The transduced sequence indicated a donor L1, known as LRE2, which 
was found to mobilise in vitro. Additional evidence for 3’ transductions was then obtained 
from an L1 retrotransposition assay conducted in cultured cells [74]. In this study, Moran et 
al. demonstrated that 2 more donor L1s responsible for pathogenic insertions could mobilize 
in vitro, and further identified the major functional domains necessary for efficient 
retrotransposition [22]. High frequency L1-mediated transduction was shown using a 3’ 
genetrap cassette containing an L1 Poly-A signal placed upstream of the reporter cassette 
gene (please refer to section 9.1 to see retrotransposition assay rationale). This vector 
system also contained a SV40 Poly-A signal which was moved downstream of the L1 copy 
and reporter cassette [74]. To select cells which carried retrotransposition events, G418 was 
added to the cell culture media. The elegant design of this system allowed antibiotic 
expression, and hence G418 resistant (G418R) colonies, only if cells contained engineered 
L1 retrotransposition events generated from mRNAs employing the SV40 Poly-A signal. 
Cells containing retrotransposition events involving mRNAs polyadenylated at the direction 
of the L1 Poly-A signal were, by contrast, not G418 resistant. This engineered system 
allowed Moran et al. to specifically assess the characteristics of L1-mediated 3’ 
transductions in vitro, including their capacity to include exons and gene regulatory elements 
[74]. A speculative inference from these observations is that the weak native human L1 Poly-
A signal supports genetic diversification during evolution, assisting retention of mobile L1 
sequences in our ancestral genomes, at the cost of reduced L1 retrotransposition efficiency.  
Analysing the HRG, two subsequent studies estimated the frequency of L1 mediated-
3’ transductions in vivo, calculating the phenomenon was responsible for 0.6% [81] and 1% 
[82] of the human genome, respectively. The discrepancy in these percentages likely arose 
from the first study, Goodier et al., searching for L1 sequences bearing 100 nucleotides on 
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their 3’ end before the downstream TSD [81], whereas the other study only considered full-
length L1 copies with 3’ transduced sequences [82]. Goodier et al. also discovered the first 
evidence for 3’ transduction families in human and mouse genomes, based on transductions 
with the same nucleotide sequence being presented by distinct L1 insertions and indicating 
a common progenitor element [81]. In vivo evidence for human L1-mediated transductions 
has subsequently been obtained from various normal and abnormal cellular contexts, 
including cancer (e.g. colon, hepatocellular, prostate, ovarian, lung) and in mice [6, 7, 9, 11, 
12, 81, 82, 84-92]. 
5.1 Tracing internal mutations and 3’ transductions as a means to identify 
active progenitor L1s. 
Mutations can be encountered anywhere along a given L1 sequence, due to errors 
in L1 reverse transcription [93], as well as mutations arising in subsequent generations. 
These mutations can be used to group L1 sequences into families. However, human-specific 
subfamilies are evolutionary young, and their sequences are highly similar to each other. 
For example, the sequences of members of the L1 pre-Ta and –Ta family are, on average, 
>99% similar to other members of their family [94, 95]. Therefore, it is hard but not impossible 
to distinguish progenitor/offspring relationships between L1s without additional information, 
such as a transduction. Single-nucleotide resolution analyses of L1 sequences has been 
performed with a variety of approaches. However, it remains challenging to accurately 
sequence the entirety of a full-length L1 copy, or even one that is not heavily 5’ truncated, 
requiring PCR and capillary (or PacBio) sequencing to validate insertions. For example, 
Scott et al. identified a tumour-specific L1 insertion in the tumour suppressor gene APC, 
which can result in Colorectal Cancer (CRC) if both copies are mutated [9, 96, 97]. In order 
to identify the source element which produced the insertion, Scott et al. analysed the internal 
mutational profile of the insertion, and compared it to a total of 295 full-length donor L1s that 
were identified in the genome of the CRC patient carrying the APC L1 mutation. These donor 
L1s carried between 7 and 147 unique mutations each. By evaluating the mutation profile of 
the tumour-specific L1 insertion in the APC gene, additional related L1 copies were identified 
apart from the source or progenitor element [9].  
A more recent study by Gardner et al. analysed additional human genomes, 
sequenced by prior studies focused on population and clinical genetics, to identify mobile 
element insertions. The bioinformatic tool Mobile Element Locator Tool (MELT) used and 
developed by Gardner et al. was created to analyse high coverage Illumina whole genome 
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sequencing (WGS) data from 2534 human genomes [87, 98]. The interior L1 mutations 
identified, and subfamily analysis performed, by MELT confirmed the distribution of active 
L1s in the 1000 Genomes Project data sets [98] were similar to those observed in previous 
studies, providing additional validation for this method. Gardner et al. also identified 38 full-
length donor L1s responsible for 121 L1 insertions bearing 3’ transductions. Overall, 2.9% 
of L1 insertions carried 3’ transductions and, notably, 56.2% of these were traced to 3 highly 
active progenitor L1s.  
Gardner et al. then combined their 3’ transduced-based analysis with data from 
previous studies of human cancer genomes, identifying a total of 113 full-length donor L1s. 
Of these, 40.7% were active exclusively in the germ line, 42.5% were only active in cancer 
and 16.8% were active in both the germline and cancer [87]. Moreover, using prior 
retrotransposition assay data for a subset of the donor L1s [11, 13, 22, 29], they studied if 
there was any correlation between the endogenous activity of a given L1 in the germ line or 
cancer with its activity in engineered cultured cell assays. In addition to donor L1s that were 
highly active in all three of the studied scenarios (germ line, cancer and in vitro), e.g. LRE3, 
other elements were only active in one or two contexts, such as a donor L1 on chromosome 
22, which was highly active in cancer genomes [8]. Other studies, such as Nguyen et al. 
have also tested the retrotransposition competency, in a cultured cell assay, of donor L1s 
that mobilise in human cancer genomes [6], as did an analysis of murine 
hepatocarcinogenesis by retrotransposon capture sequencing (RC-seq), which found 
another donor L1 mobile in cancer due to an insertion carrying a 3’ transduction and tested 
its retrotransposition capability in vitro [7]. 
3’ transduced sequences have also been used to extensively identify lineage 
progenitor L1s found amongst the human population. Of the 68 full-length polymorphic L1s 
identified by Beck et al. [11], 25 carried a 3’ transduction and, in turn, 17 of these could be 
grouped into L1 transduction families. A likely source element was found for one of these 
subfamilies and for two other cases [29, 99] 3’ transductions were shared with pathogenic 
L1-Ta insertions [11]. Another system developed to detect active L1 transduction families is 
Transduction-Specific Amplification Typing of L1 active subfamilies (TS-ATLAS), which built 
upon the transposon display system ATLAS (Amplification Typing of L1 active subfamilies) 
designed for selective and specific amplification of L1 junctions at both termini of elements 
that are not present in the HRG [100]. In this study, Macfarlane et al. amplified L1s containing 
shared 3’ transduced sequences and discovered new members of 3 L1 transduction 
families: L1RP, AC002980 and LRE3 [29, 99, 101, 102]. Furthermore, a likely lineage 
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progenitor element for a disease-causing insertion (L1RP) was identified and found to have 
high activity in an in vitro retrotransposition assay [12]. Finally, the authors showed evidence 
for variable Poly-A tract length in the mentioned L1 transduction lineages, and demonstrated 
highly variable allele frequencies amongst individuals, showing that retrotransposition 
continues to play a role in human genetic evolution [12].  
Retrotransposition events, including those carrying transductions, can occur during 
embryogenesis and in somatic cells. For example, van den Hurk et al. reported a pathogenic 
L1 insertion into the CHM gene, responsible for the progressive eye disease choroideremia 
[103]. The 3’ transductions carried by this insertion elucidated a donor L1 elsewhere on the 
genome. Through insertion-side specific PCR assays, the authors then determined that the 
CHM L1 insertion arose during the embryonic development of the affected patient’s mother, 
hence demonstrating endogenous L1 mobilisation during human embryogenesis [103]. 
Single-cell genomic analyses of human neurons have also revealed somatic L1 mutations 
carrying transductions [89, 104], enabling the tracing of cell lineage clones in the healthy 
human brain [89] and the identification of donor L1s potentially active during 
neurodevelopment due to cell-type and locus-specific euchromatinisation [105, 106]. One 
L1 insertion carried a 3’ transduced sequence of 614 bp, which allowed the identification of 
the source element [89], whilst another insertion carried a 5’ transduced sequence of 101 
bp that similarly indicated a distal donor L1 [104]. In mice, among insertions that occurred 
during early embryonic development, Richardson et al. identified three L1 insertions carrying 
3’ transduced sequences out of eleven de novo L1 insertions discovered by RC-seq [88, 
107], and demonstrated the activity in vitro of two of these de novo L1 insertions. These 
analyses collectively demonstrate endogneous donor L1 activity in the mammalian germline, 
early embryo and tumour cells. 
 
6 L1 mobilisation in pluripotent human cells. 
To be inherited by progeny, new retrotransposon insertions must occur in cells 
contributing to the parental germline, either prior to germ cell specification in the early 
embryo, or later in development, during oogenesis or spermatogenesis [29, 103, 108-111]. 
New heritable L1 insertions are still occurring in the human population [70, 112, 113]. 
Despite recent work in mouse suggesting most of these events arise during embryogenesis 
or primordial germ cells [88], the developmental timing of most new heritable L1 insertions 
remains unclear and, aside from case studies involving pathogenic L1 mutations [70, 88, 
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103], our knowledge in this area is mostly derived from studies of engineered and 
endogenous L1 activity in cultured pluripotent cells.  
6.1 L1 activity in hESCs. 
Human embryonic stem cells (hESCs) are pluripotent cells derived from the 
blastocyst inner cell mass [114]. They can differentiate to the 3 embryonic germ layers, 
endoderm, mesoderm and ectoderm, and have been used extensively to model likely L1 
activity during very early human development. Several studies have reported elevated L1 
expression in hESCs [1, 2, 45, 115, 116]. For instance, Garcia-Perez et al. reported 
engineered L1 mobilisation in 3 different hESC lines and, by recovering the genomic 
coordinates of 7 insertions, demonstrated that L1 can insert into genes expressed in hESCs, 
and that some of those insertions can contain deletions in their nucleotide sequence. 
Remarkably, hESC lines containing an engineered L1 retrotransposition event could be 
differentiated into embryoid bodies and express mRNAs characteristic of the 3 germ layers. 
Hence, these data suggested that L1 retrotransposition could happen at early stages in 
human embryogenesis [115]. Wissing et al. elucidated full-length L1 mRNAs in two hESC 
lines, H9 and H13. Moreover, they observed decreased DNA methylation in 20 CpG 
dinucleotides located within the L1 5’UTR promoter region [2]. Using RC-seq, Klawitter et 
al. investigated endogenous L1, Alu and SVA mobilisation during the cultivation of 3 hESC 
lines. One Alu retrotransposition event was found in a cultured H9 cell population that was 
absent from a prior passage, supporting the view that L1, and L1-mediated, mobilisation 
was possible in the blastocyst [1, 103, 115]. This study did not identify any endogenous L1 
insertions in the 3 hESC lines analysed, an outcome the authors ascribed to a lack of clonal 
expansion causing extensive genomic heterogeneity in the cell populations [1]. In sum, the 
consistent detection of L1 activity in hESCs suggests but does not prove that the early 
embryo is a major niche for heritable L1 insertions to arise in humans. 
6.2 L1 activity in hiPSCs. 
Human induced pluripotent stem cells (hiPSCs) are produced via directed ectopic 
expression of transcription factors, e.g. Sox2, Oct4, Nanog, Klf4 and c-Myc, in fibroblasts or 
other cell types [117]. Like hESCs, hiPSCs are capable of unlimited proliferation and can 
also generate the three primary germ layers. For biomedical applications, hiPSCs have the 
advantage of being compatible with the immune system of transplant recipients, thereby 
circumventing the problem of host immune rejection. Another advantage of hiPSCs is that 
they are free of the ethical barriers related to the use of materials derived from human 
24 
 
embryos [118]. Nonetheless, during reprogramming or expansion of hiPSCs in vitro, genetic 
and epigenetic aberrations can occur [119-123], including L1 mobilisation [1]. One 
explanation for L1 activity here is that during hiPSC reprogramming chromatin relaxation 
and epigenome-wide remodelling occur [124], providing a window of opportunity for L1 to 
retrotranspose [1, 5, 115] when L1 promoters are hypomethylated and undergo 
transcriptional activation.  
The first reported study of L1 mobilisation in hiPSCs was performed by Wissing et 
al., who demonstrated that reprogramming somatic cells into hiPSCs allowed mobilisation 
of engineered L1 reporter constructs [2]. Apart from showing that full-length L1 mRNA 
transcripts were upregulated and that L1 ORF1p was present in hESCs, they also studied 
L1 regulation in hiPSCs, finding hypomethylation of the L1-Ta family 5’UTR in 3 hiPSC lines, 
when compared to their parental human dermal fibroblast (HDF) cell lines. Wissing et al. 
also observed the same hypomethylation amongst 3 previously identified hot RC-L1s. To 
confirm endogenous retrotransposition could also occur in hiPSCs, Klawitter et al. applied 
RC-seq to a panel of 8 hiPSC lines and their parental fibroblast or endothelial cell lines [1], 
detecting and PCR validating 10 de novo retrotransposition events (7 L1, 2 Alu, 1 SVA). 
Four of these de novo retrotransposition events landed in protein-coding genes that are 
expressed in pluripotent stem cells [1] and, notably, 4/7 L1 insertions were full-length. 
Although none of these insertions carried transductions, Klawitter et al. tested two of them 
in the cultured cell retrotransposition assay [22] and found both retained mobility in vitro, 
thus showing that de novo L1 insertions could further propagate during hiPSC cultivation. 
Interestingly, in a previous study of hiPSCs, no de novo retrotransposition events were 
identified via Whole Genome Sequencing (WGS) applied to 9 hiPSC lines [125]. Another 
study reported de novo L1 insertions in hiPSCs via targeted L1 sequencing but could not 
PCR validate these [126]. Sequencing depth, bioinformatic parameters and PCR validation 
methods, potentially along with stem cell culture conditions and population bottlenecks in 
cell culture may explain these discrepancies [127]. 
Importantly, Klawitter et al. followed a de novo L1 insertion found in an intron of the 
CADPS2 gene of one hiPSC line, calculating the prevalence of the mutation alongside 
CADPS2 mRNA abundance via quantitative PCR after extended time in cell culture. 
CADPS2 expression and prevalence of the L1 insertion were anticorrelated, suggesting the 
mutation may have interfered with CADPS2 expression, although the mechanism of this 
interference was unresolved [1]. Given this observation was correlative, and the hiPSC line 
was not differentiated into a cell type where CADPS2, a key factor in neuronal biology [128], 
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was critical to cellular function, additional work is required to assess whether endogenous 
retrotransposition arising during hiPSC derivation has a functional impact.   
6.3 The potential impact of L1 mobilisation on hiPSC biomedical applications. 
The ability to generate hiPSCs has greatly impacted the stem cell field, opening 
multiple avenues in biological research and biomedical applications, including regenerative 
medicine. For example, hiPSCs have been used to create sheets of retinal pigment 
epithelium (RPE) to successfully treat patients with age-related macular degeneration [129]. 
hiPSC genome stability during culture, including perturbations caused by L1 mobilisation, 
nonetheless needs to be evaluated further before they are widely used as a source of cells 
in medical therapies [130]. Moreover, although the use of hiPSCs is becoming more and 
more widespread in research, consistency in quality control is often highly variable  [131]. 
The hiPSC field has taken positive steps to introduce these potential issues. For instance, 
c-Myc is less commonly used now as a reprogramming factor due to its potential to act as a 
proto-oncogene [132]. Reprogramming technology has also been optimised to use non-
integrating delivery vectors to circumvent the possibility of insertional mutagenesis [133]. In 
my view, it is remarkable that most of the endogenous L1 insertions found by Klawitter et al. 
were full-length and retained retrotransposition capability [1]. This observation suggests L1 
may be an important and underrated source of mutagenesis during hiPSC production and 
cultivation, where the insertional pattern of de novo L1 insertions is unknown and largely 
random, which should be considered when using hiPSCs in biomedical therapies.    
 
7 L1 mobilisation in the neuronal lineage. 
Barbara McClintock first described somatic genome mosaicism due to mobile DNA 
activity in maize more than 70 years ago [134]. Nonetheless, retrotransposition was for many 
years thought to primarily occur in the germline, following the ‘selfish DNA’ model where 
retrotransposons would seek to propagate in situations where their transmission to 
subsequent generations was feasible [108]. Recently, however, it was discovered that L1 
retrotransposition can also produce somatic mosaicism at discrete times during 
development, perhaps at a frequency actually higher than that of germline events [29, 88, 
103, 110, 111, 115, 135].  
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Of particular relevance to this thesis is the surprising discovery by Muotri et al. of L1 
retrotransposition events in the mammalian brain, and particularly in the neuronal lineage 
[136]. To place this observation in context, in the central nervous system (CNS), the lineage 
precursors of all neuronal and glial cells are neural stem cells (NSCs) [137]. These cells 
have the capacity to self-renew and differentiate into neurons, astrocytes and 
oligodendrocytes [114]. In the adult brain, NSCs are limited to neurogenic niches, such as 
the subventricular zone (SVZ), and the subgranular zone (SGZ) of the hippocampal dentate 
gyrus (DG) [138]. These resident NSC populations are of importance here, as the 
neuroanatomical regions they belong to were observed by Muotri et al., and later works, to 
support L1 mobilisation. Muotri et al. found that rat neuronal precursor cells (NPCs) derived 
from hippocampal NSCs supported L1 mobility, as indicated by an engineered L1-EGFP 
(enhanced green fluorescent protein) reporter [31]. Furthermore, Muotri et al. saw L1 
retrotranspose at a low frequency in NSCs, but observed an increase of L1 
retrotransposition events only 48 hours after differentiation [136]. Coufal et al. subsequently 
demonstrated that human NPCs can also support retrotransposition [4]. In this case, cells 
were derived from human foetal brain and hESCs, and retrotransposition was again 
measured using an engineered human L1-EGFP reporter. In addition, Coufal et al. 
developed a quantitative multiplex polymerase chain reaction (TaqMan qPCR) assay to 
check the copy number variation (CNV) of endogenous L1s. They estimated 80 additional 
L1 ORF2 copies per cell in the hippocampus as a result of somatic retrotransposition, 
normalised to a plasmid control [4]. Additionally, Macia et al. demonstrated exogenous 
mobilisation can occur in post-mitotic human neurons using the L1-EGFP reporter [10]. 
These works, predominantly employing engineered L1 retrotransposition assays, broadly 
established the neuronal specificity of L1 mobilisation. 
Somatic L1 retrotransposition may be enabled in the brain by two main regulatory 
pathways: Sox2/HDAC1 and Wnt-mediated TCF/LEF transcriptional activation [40]. The 
transcription factor Sox2, which is essential to maintain self-renewal of undifferentiated 
hESCs, binds to the L1 5’UTR and acts as a repressor, inhibiting L1 expression [4]. If the 
Wnt signalling cascade is activated, Sox2, a negative regulator of neuronal differentiation, 
is removed from the L1 promoter, activating L1 expression. Sox2 down regulation also 
promotes the expression of NeuroD1, a neurogenic transcription factor which promotes 
neuronal differentiation in hippocampus [40]. DNA methylation also regulates L1 promoter 
activity [36] by altering the capacity of transcription factors to bind the L1 5’UTR. MeCP2, 
for example, is a transcriptional repressor and DNA-methyl-binding protein that is particularly 
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important for the normal function of nerve cells [139] . MeCP2 mutations are responsible for 
the X-linked severe neurodevelopmental disorder Rett syndrome [140]. Interestingly, 
MeCP2 and L1 expression are inversely correlated throughout NSC differentiation and 
neuronal maturation, suggesting that MeCP2 modulates L1 activity during neural 
development [141, 142]. MeCP2 mutations in L1-EGFP transgenic mice also appeared to 
elevate neuronal L1 retrotransposition rates in vivo [136]. Thus, epigenetic regulation and 
transcription factors together modulate dynamic L1 activity in the brain. 
Despite advances showing potential for L1 retrotransposition in neurons, and insights 
into how that process is regulated, the seminal studies by Muotri et al. and Coufal et al. were 
subject to significant caveats. Firstly, the L1-EGFP reporter system, introduced as a 
transgene and relying heavily on heterologous promoter sequences, may not recapitulate 
the regulatory landscape encountered by endogenous L1 retrotransposons in vivo. 
Secondly, the L1 CNV assay developed by Coufal et al. and based on qPCR does not 
characterise the sequences or genomic location of L1 insertions. To address these 
shortcomings, and directly detect endogenous L1 insertions in neurons, Baillie et al. 
developed a new technique called retrotransposon capture sequencing (RC-seq) [107]. RC-
seq employs hybridisation to nucleic acid probes to enrich Illumina libraries for L1-genome 
5’ and 3’ junction sequences, and has now been employed in mouse and human samples, 
in normal tissues, cancers and cultured stem cells [1, 6, 7, 88, 91, 107, 143]. By applying 
RC-seq to “bulk” DNA extracted from human hippocampus samples, Baillie et al. mapped 
the genomic integration site of thousands of putative somatic L1, showing L1 mobilisation 
into active protein-coding genes expressed in the brain, and therefore demonstrating 
endogenous L1 retrotransposition in this context. 
Single-cell genomic analyses using RC-seq, other target approaches, and WGS, 
subsequently identified somatic L1 insertions in cortical and hippocampal neurons [89, 104, 
143, 144]. Whole genome amplification (WGA) also generated sufficient material for PCR 
validation of L1 insertions in individual neurons, and quantification of how often somatic 
retrotransposition occurs in the brain. Notably, although these single-cell genomic analyses 
all reported neuronal L1 insertions, the estimated rate of L1 mobilisation remains debated, 
ranging from <0.1 to ~10 insertions per neuron, depending on the method, anatomical region 
and assumptions made during bioinformatic analysis [127]. In one study, Upton et al. 
reported a large number of somatic L1 insertions in hippocampal neurons and glia, and 
highlighted the potential for these events to generate a functional impact as they landed 
mainly in euchromatic regions of the genome [143]. Insertions were particularly enriched at 
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genes transcribed in the hippocampus and also in neuronal stem cell enhancer elements 
[143]. Given L1 integrates nearly randomly genome-wide [145, 146], these patterns may 
have been a result of post-integration selection. In another study, Evrony et al. identified two 
somatic L1 insertions in the cortex of an individual and, through lineage tracing, determined 
that both events occurred during brain development [89]. Erwin et al. found that 
rearrangements involving germline L1 copies in neurons may produce deletions in 
neuronally expressed genes [144]. Finally, Hazen et al. used somatic cell nuclear transfer 
to clonally amplify mouse olfactory neuron genomes, avoiding WGA, and finding 0-2 L1 
insertions in 6 neuronal clones [147]. These studies collectively established the occurrence 
of endogenous L1 retrotransposition in the mammalian brain. 
7.1 Potential impacts of L1 retrotransposition in neurogenesis.  
Genomic stability is, for the most part in somatic tissues, clearly essential to protect 
cellular integrity and prevent neoplastic transformation [16]. Nonetheless, mitotic errors 
during DNA replication and recombination can cause intercellular genomic differences, i.e. 
somatic genome mosaicism [80, 108]. Notably, most of the early reported examples of 
somatic genome mosaicism in humans were associated with pathogenesis, including cancer 
and developmental syndromes [148]. There are some exceptions to this rule among healthy 
cells, such as V(D)J recombination in the adaptive immune system [149], where the 
domesticated transposase genes RAG1 and RAG2 produce somatic rearrangements, 
creating different receptors to elicit an immune response to foreign antigens [150]. As for 
lymphocytes, somatic mosaicism driven by retrotransposition and other genomic 
abnormalities [151-153] might be a source for functional diversification among neurons [143] 
and, to speculate, a route to neuronal plasticity underpinning cognition [108]. This process 
may be influenced by environmental factors, giving a possible mechanism for generating 
neuronal diversity in response to changes in the environment [108].. Moreover, in terms of 
hominid evolution, different L1 families are active in our nearest ancestors [33, 154] and, 
potentially, more or less mobile than L1-Ta in humans. Though it is interesting to question 
the role of L1 in many of the grander aspects of brain function, such as the evolution of 
cognition among hominids [80], we still lack essential information regarding L1 activity in the 
human brain, such as whether this phenomenon varies significantly amongst individuals, 
whether there is any correlation with ageing and, indeed, if certain neurodevelopmental 
stages accommodate somatic retrotransposition more than others. It is entirely possible that 
the main contribution of L1 to neuronal diversity involves cell-specific regulation of neuronal 
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genes by nearby L1 copies, which may be polymorphic [106, 155, 156]. Finally, despite 
reports of elevated L1 activity in neurological conditions, such as schizophrenia [157], it is 
still very unclear whether L1-driven mosaicism in the brain plays any role in psychiatric 
illnesses or neurodegeneration [158]. 
 
8 Obtaining a view of L1 in neurodifferentiation and neurological disease via 
hiPSCs. 
Accessing endogenous neuronal cell populations from humans during 
neurodevelopment can be extremely challenging. As an alternative, hiPSCs can be derived 
from healthy and diseased individuals and then differentiated in vitro to yield cell types of 
interest, including neurons [117]. hiPSCs are also themselves roughly akin to hESCs in their 
genome-wide transcriptional profile and functional properties [159], enabling studies of early 
human embryogenesis with hiPSCs. In addition, hiPSCs provide an excellent model to study 
various stages of neurogenesis and neuronal maturation in healthy individuals and in the 
context of neurological disease because, complemented with post-mortem brain tissues, 
they allow us to obtain data by different approaches, enhancing the strength of conclusions. 
Therefore, hiPSCs are useful for studies of human neurobiology, and also can be used to 
test compounds that may modulate molecular processes, such as L1 retrotransposition, in 
vitro.  
 
9 How to detect L1 retrotransposition: 
9.1 Engineered L1 reporter assays in cultured cells and transgenic animals. 
In 1996, Moran et al. reported a seminal method to create and detect engineered L1 
retrotransposition events in cultured mammalian cells [22]. In this work, the authors 
transfected cells with vectors based on the L1 elements L1.2 and LRE2 to determine 
whether these could jump in vitro, and then examined their integration sites. Detection of 
new insertions was enabled by constructs where L1s were tagged with an indicator gene. 
Here, the indicator was an antibiotic resistance gene placed at the 3’ end of the L1, antisense 
to the L1, disrupted by an intron in the same orientation as the L1 and carrying its own Poly-
A signal. In sense to the L1, and placed 3’ of the antisense oriented reporter gene, was an 
SV40 Poly-A signal. In this elegant system, a new retrotransposition event will be observed 
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only if the element was transcribed, processed by splicing, and then reverse transcribed and 
integrated into the host genome (Figure 5). Using this assay, Moran et al. demonstrated L1 
mobilisation in vitro and, moreover, performed various mutational analyses showing that 
changes to key residues in ORF2 abrogated ORF2p reverse transcriptase activity. ORF1 
mutations also reduced the retrotransposition rate [22]. Finally, Moran et al. found TSDs and 
other hallmarks of TPRT at the L1 integration sites. This study greatly illuminated the 
mechanistic basis for L1 mobilisation in mammalian cells, and provided a key method now 
used widely in the field to assess the retrotransposition competence of a given L1. 
Subsequently, Ostertag et al. [31] used enhanced green fluorescent protein (EGFP) 
as an indicator gene, instead of an antibiotic resistance cassette, to assay L1 
retrotransposition in cultured HeLa cells. They detected retrotransposition (i.e. EGFP 
expression) 48hr post-transfection. Using this L1-EGFP system, Ostertag et al. could track 
retrotransposition in individual cells in real time, greatly expediting calculations of 
retrotransposition rate in comparison to the antibiotic-resistance based L1 reporter, which 
requires at least 14 days in culture before cells are fixed and stained [22]. The assay is also 
sufficiently sensitive to detect changes in the retrotransposition rates among similar L1 
elements [31].  
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Figure 5: Retrotransposition assay schematic. The vector L1-G418 is represented at top, 
where L1 ORFs, L1 UTRs and the backbone are coloured blue, grey and black, respectively. 
Below the L1 is displayed the G418 expression cassette (light purple) tagged with an intron 
(red) and with a Poly-A signal (An). Also shown are the steps that the system needs to 
undergo to observe a new retrotransposition event, resulting in G418 gene expression: 
Transcription, splicing of the intron, reverse transcription and genomic integration and 
expression from the integrated genomic G418 (purple rectangle). This figure was adapted 
from [136]. 
As an additional control, Ostertag et al. built upon an intron removal PCR assay [22] 
from Moran et al. where DNA extracted from cells transfected with the reporter plasmid was 
used as the input template for a PCR reaction, where primers were placed at the beginning 
and end of the reporter gene flanking the intron. The resultant DNA fragments were 
diagnostic for L1 retrotransposition, as an amplicon lacking the EGFP intron indicated 
retrotransposition had occurred. 
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Transgenic L1-EGFP reporter assays have been used in rodents to study L1 
mobilisation in vivo, which has mainly been found in early embryonic states and in the male 
germline [110, 111, 135, 136, 160-162]. In these experiments, the spatiotemporal extent and 
frequency of retrotransposition can be determined by counting the number of EGFP positive 
cells in sections of animal tissue by microscopy, or by sorting EGFP positive cells by flow 
cytometry. These rodent models have been used to test the activity of numerous human 
L1s, including L1RP [110, 111, 160] and LRE3 [111, 161], as well as mouse L1s including 
TGF21 [111] and the synthetic codon-optimised ORFeus_Mm [163], which supports efficient 
transcription elongation of ORF1 and ORF2 sequences [78]. Transgenic L1s have been 
tested with their expression driven by their endogenous promoter, or by a heterologous 
promoter [110, 111, 135, 136, 160-162], often showing mobilisation in either design. 
Conversely, there are two important caveats that must be considered when evaluating the 
retrotransposition rate of transgenic L1s. Firstly, the location of the transgene, which has 
only been established by some studies [135, 162, 163], may impact its expression. 
Secondly, epigenetic silencing of the reporter cassette upon retrotransposition can also 
occur [164]. For these reasons, engineered L1 reporter systems provide proof-of-principle 
evidence for L1 mobilisation in vitro but require corroboration by other approaches to assess 
endogenous retrotransposition patterns. 
 9.2 Whole-genome and targeted approaches to map L1 insertions. 
           Two general strategies are commonly used to identify endogenous L1 
retrotransposition events: WGS and targeted sequencing of L1-genome junctions [113]. 
Several approaches, including RC-seq, are encompassed by the latter category [90, 100, 
107, 112, 127, 165].  All involve bioinformatic analysis followed by PCR validation and 
Sanger sequencing of putative insertions to confirm they are truly de novo [166-168]. It is 
particularly important to recall that L1s are not fixed in the human population and, as a result, 
polymorphic L1 insertions are sometimes called as de novo by the initial sequencing 
analysis and this annotation needs to be corrected by PCR experiments [169-171]. PCR 
validation is further aided by characterisation of TPRT hallmarks to confirm 
retrotransposition, as opposed to another molecular process, has occurred to generate an 
L1 copy at a particular genomic locus. The length (6kb) and genomic copy number of L1 
presents major challenges in trying to identify new L1 insertions, given that Illumina reads 
and insert sizes are typically ~150bp and <700bp, respectively. These features mean that 
Illumina sequencing cannot resolve the whole length of most new L1 insertions. As a result, 
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WGS and targeted sequencing approaches both rely on the detection of L1-genome 
junctions for the identification of L1 copies.  
The main drawback, which can be prohibitive depending on the application, of WGS 
versus targeted approaches, is its cost. Otherwise, WGS presents a major advantage as it 
has the potential to identify both genomic junctions of a given L1 insertion, irrespective of 
whether the L1 is 5’ truncated or inverted, or carries a transduction [70, 74, 81, 82, 172]. 
The detection of both ends of an L1 insertion allows characterisation of TPRT hallmarks a 
priori, allowing bioinformatics filtering of chimeric molecules generated during Illumina 
sequencing. Another, lesser but still important advantage of WGS, is its ubiquity; many labs 
use this technique, simplifying interpretation and dissemination of results. Conversely, the 
lower cost of targeted L1 sequencing approaches means that they can be applied to much 
larger cohorts, or applied at higher depth to bulk tissue samples to identify somatic L1 
insertions or subclonal events in tumours [91, 107] and cultured cell lines [1, 6], as has been 
performed extensively with RC-seq in the work reported in this thesis.  
 9.3 The hunt for endogenous retrotransposition: RC-seq. 
Retrotransposon capture sequencing (RC-seq) was first developed in the Faulkner 
laboratory to map somatic L1 insertions in human brain samples at single-nucleotide 
resolution [107]. RC-seq employs DNA capture probes targeting the 5’ and 3’ extremes of 
the human L1-Ta consensus sequence to enrich Illumina libraries for L1-genome junctions, 
including those of new L1 insertions (Figure 6). The method has evolved over several 
iterations to achieve higher capture efficiencies with different RC-seq probe designs [91, 
107, 143], has been applied to cultured human stem cells and tumours [1, 6, 7, 91, 173, 
174], mouse samples [7, 88], and to individual human hippocampal neuron genomes after 
WGA [143]. RC-seq can identify full-length L1s, which can be detected at both their L1-
genome junctions, as well as 5’ truncated L1s, which are detected by RC-seq probes only 
at their 3’ junction [107, 143].  
 
Figure 6: RC-seq workflow. A) Library preparation with Illumina adapters. B) Enrichment 
for L1-genome junction sequences using biotinylated capture probes. C) Enriched libraries 
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are processed and sequenced in paired-end 2×150mer mode on an Illumina platform. D) 
Computational analysis. 
 
Empty/filled, 5’ junction and 3’ junction PCR assays are commonly used in the L1 
field to confirm the presence of a de novo L1 insertion [166]. In the empty/filled assay, the 
filled site represents the L1 insertion. If the insertion is somatic or heterozygous, an empty 
site representing the allele lacking an L1 insertion will also be amplified. As their names 
suggest, 5’ and 3’ junction PCR assays specifically target L1-genome junctions. By Sanger 
sequencing the amplicons generated by these assays, one can assess whether a given L1 
insertion carries TPRT hallmarks, including TSDs, a 3’ Poly-A tract and integration at 
degenerate L1 EN motif. A common scenario for PCR validation of an L1 insertion is 
displayed in Figure 7. 
 
Figure 7: Structure and PCR validation of an L1 insertion. A) A typical L1 insertion with 
a 5´ truncation, TSDs (red nucleotides) and a Poly-A tract. P1, P2, P3 and P4 indicate 
primers used PCR amplify and validate the insertion. P1 and P4 are used in an Empty/filled 
PCR assay, P1 and P2 are used in a 5’ junction PCR assay and P3 and P4 are used in a 3’ 
junction PCR assay. B) The empty site prior to L1 integration, with the EN cleavage site 
highlighted in green. This figure was adapted from [166]. 
 
10 Disease-causing L1 insertions. 
L1 insertions can disrupt gene function and expression, and cause pathogenesis [17, 
71, 72]. To date, more than 100 cases of disease mediated by L1 have been described in 
the literature [17, 71].  The first of these were reported in ground breaking work by Kazazian 
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et al. in 1988. In this study, two independent L1 insertions were found in exon 14 of the blood 
clotting Factor VIII gene, causing haemophilia A [70]. Another remarkable early example of 
L1 as a mutagen was found by Miki et al., who observed an exonic L1 insertion into the 
tumour suppressor gene APC of a colon cancer patient [9, 85]. The impact of L1 insertions 
in tumours has since been considered in numerous cancer types by genomic analyses, 
including in lung cancer [90], ovarian carcinoma [6], hepatocellular carcinoma (HCC) [7, 91], 
colorectal cancer [9, 174], oesophageal adenocarcinoma [175] and glioblastoma [173] and 
others [17, 86]. However, very few exonic insertions of the kind reported by Miki et al. have 
been found by these genome-wide studies [8, 35, 85, 86, 176], although it has been 
proposed that intronic L1 insertions, and those occurring after tumorigenesis, may also be 
important to cancer patient clinical outcomes [6, 91]. 
Pathogenic L1 insertions can be helpful to identify RC-L1s [26], as in the case of a 
rearranged L1 insertion found in the dystrophin gene of a muscular dystrophy patient, where 
a 3’ transduced sequence allowed the authors, for the first time, to trace its source RC-L1 
[84]. L1 insertions causing disease can also shed light on the mechanisms by which mobile 
elements can disrupt coding gene sequences [17, 71] and generate new transcriptional units 
through a phenomena called “gene breaking” [79]. Additionally, the adenosine-rich 
composition of L1 sequences can promote premature protein-coding gene mRNA 
polyadenylation, and attenuate gene expression by causing RNA polymerase II pausing [77, 
78]. Ongoing L1 activity can impact host genome function in a variety of different cell types 
and developmental stages, as has been shown by a range of studies [70, 85, 103, 174], and 
new scenarios for L1 causing pathogenesis are likely to continue to be elucidated. In this 
way, we obtain a better understanding of L1 biology and, perhaps in the future, will be able 
to develop treatments or prognostic markers based on L1 activity, for example in cancer 
[177]. 
 
11 Mechanisms of L1 repression: the host genome defends itself. 
L1 is repressed by the host genome at multiple steps of the retrotransposition cycle. 
To be able to mobilise, L1s need to initiate and transcribe a full-length mRNA from the 
internal promoter located in their 5’UTR. The majority of this promoter is located in the first 
100bp of the L1-Ta 5’UTR [36]. Although the defences against L1 retrotransposition are 
multilayered, epigenetic repression, as a first-line obstacle to transcription, is arguably the 
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most significant [167]. Central to L1 epigenetic regulation is a CpG island present in the L1 
5’UTR [178] that, via DNA methylation, can mediate L1 repression. L1 methylation has been 
investigated in various contexts, either looking genome-wide [4, 5] or at specific L1 loci [6-
9]. One key study investigated the genome-wide methylation state of the L1-Ta family in 3 
hiPSC lines and 2 hESC lines, finding lower methylation in hiPSCs and in hESCs when 
compared to parental fibroblasts. The same work also studied the methylation state of 3 
“hot” RC-L1 loci, also observing hypomethylation in pluripotent cells [2]. Significant genome-
wide L1-Ta hypomethylation has also been demonstrated in hiPSCs generated from 
fibroblasts and human cord blood endothelial cells (hCBECs) [1]. L1-Ta promoter 
hypomethylation in hiPSCs [164], hESCs [179] and in hESC-derived neural progenitor cells 
(NPCs) [4] coincides with elevated L1 mRNA levels, establishing a relationship between L1 
promoter hypomethylation and L1 transcription during development. In cancer, DNA 
methylation analyses targeting specific RC-L1s in the same tumours where they have 
generated somatic L1 insertions have been performed by several studies [6-9]. For example, 
an RC-L1 on chromosome 17 was found by one study to be responsible for an exonic 
insertion in the APC gene of a colorectal cancer patient and, in the normal and tumour 
samples of this individual, the RC-L1 5’UTR was hypomethylated [9]. In another study, L1 
locus-specific bisulfite sequencing indicated hypomethylation of RC-L1s mobile in HCC 
patient samples, and a mouse model of HCC [7]. These works collectively show how the 
absence or depletion of DNA methylation from RC-L1 promoter sequences is a precursor to 
L1 mutagenesis.  
DNA methyltransferases (DNMTs), including DNMT1, DNMT3a and DNMT3b, 
establish and maintain DNA methylation [180]. As mentioned in previous sections, MeCP2 
inhibits L1 retrotransposition by binding to methylated CpG dinucleotides in the L1 promoter 
[141]. Additionally, the nucleosome and deacetylase multiprotein complex (NuRD) is 
enriched at the L1 promoter, along with the histone deacetylases (HDACs) HDAC1 and 
HDAC2 [181]. E2F-Rb family complexes influence the epigenetic regulation of human and 
mouse L1s via nucleosome modifications and recruit HDAC1 and HDAC2 during early 
embryonic development. Hence, L1 sequences are centres for heterochromatin formation 
in a Rb family-dependent manner [182, 183]. Otherwise, in primordial germ cells (PGCs), 
deletion of the de novo methyltransferase 3-like protein (DNMT3L) results in overexpression 
of L1 mRNA in the mouse male germline, indicating it may be required to methylate L1s de 
novo [184].  
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To control L1 transcription and further attenuate the mobilisation of RC-L1s, 
numerous transcription factors regulate L1 expression, such is the SRY proteins SOX2 and 
SOX11 [38, 136], YY1 [41], RUNX3 [37], p53 [185] and NeuroD1 [40]. In addition, L1 can 
be transcriptionally silenced by Kruppel-associated protein, zinc-finger protein (KAP1, also 
known as TRIM28). Another protein described to repress L1 mobility by ribosylating KAP1, 
a cofactor which serves as a scaffold for heterochromatin complex comprising the SETDB1 
[186], is the protein deacylase and mono-ADP ribosyltransferase Sirtuin (SIRT6). SIRT6 
helps KAP1 to interact with the heterochromatin factor HP1α. Therefore, SIRT6 contributes 
to the packaging of L1 into transcriptionally repressive heterochromatin [187]. Another 
transcription factor, also a zinc finger protein, is PLZ, which maintains and mediates 
epigenetic silencing of L1 in germ cells, progenitor and haematopoietic stem cells [188]. 
Hence, transcriptional repression is a second major layer of L1 control. 
If, however, L1 achieves transcription of a full-length L1 mRNA, its mobility can still 
be limited at the post-transcriptional level. MicroRNAs, a class of small RNA, can for 
example suppress endogenous retrotransposition, such as in the case of miR-128, which 
inhibits L1 mobility by binding to L1 RNA [189]. The biogenesis of microRNAs mediated by 
the Microprocessor (Drosha-DGCR8) complex also leads to L1 mRNA degradation [190]. 
L1 mRNA and L1-encoded proteins accumulate in cells lacking a functional Microprocessor 
[190]. The piwi-interacting RNA (piRNA) pathway also seems to be involved in adaptive 
methylation of retrotransposons [191, 192]. A recent study showed the possible involvement 
of piwi proteins in controlling L1 retrotransposition in primate iPSCs [159]. Interestingly, 
these proteins act upstream of DNMT3L upon mouse retrotransposons [191, 192]. Piwi 
proteins also interact with the helicase MOV10, playing a role in silencing retrotransposons 
in the mouse germline [193]. At the post-translational level, ORF1p phosphorylation is 
necessary for L1 retrotransposition [194]. Novel anti-L1 retrotransposition mechanisms have 
also been shown to involve several proteins of the cytidine deaminase family, APOBEC3A, 
APOBEC3B and APOBEC3F [195, 196]. For example, APOBEC3A deaminases transiently 
exposed single-strand DNA during the process of L1 integration [197]. Additionally, RNase 
H2 has been reported to promote L1 mobilisation, probably acting on L1 mRNA:cDNA hybrid 
molecules, facilitating second strand production during TPRT [198]. Inhibition of 
retrotransposition has also been demonstrated in stress granules when promoting the 
sequestration of L1 RNPs [199]. Altogether, these studies demonstrate the complexity and 
importance of host genome defences against retrotransposition.  
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12 To recapitulate. 
Early embryogenesis provides a major developmental niche for heritable L1 
retrotransposition events to arise in mammals [88, 103, 200]. Cultivated human embryonic 
stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) resembling the cells of the 
embryonic inner cell mass also express L1 mRNAs and support engineered and 
endogenous L1 retrotransposition [1, 10, 115, 116, 179]. De novo L1 insertions arising 
during embryogenesis or later development can cause somatic mosaicism [88, 111, 127, 
135]. In particular, somatic L1 insertions have been reported in brain tissue [4, 89, 104, 107, 
143, 144,Hazen, 2016 #302, 147]. Engineered L1 reporter genes also mobilise in vitro during 
neurogenesis and in post-mitotic neurons [4, 10, 136]. Importantly, the L1-Ta subfamily is 
hypomethylated in hESCs and hiPSCs, when compared to neurons and other differentiated 
cells, suggesting genome-wide developmental enforcement of L1-Ta promoter methylation 
[1, 4, 10, 116]. However, the related temporal profiles of DNA methylation and somatic 
retrotransposition for individual RC-L1s during neurogenesis are unclear. 
Hence, in this thesis, I identified a reprogramming-associated de novo L1 insertion in 
a cultivated hiPSC line. The L1 insertion was traced to a “hot” donor RC-L1 that was part of 
an extended and recently active transduction family. I then measured locus-specific DNA 
methylation for the individual de novo, donor and transduction lineage family L1 promoters, 
as well as the L1-Ta subfamily overall, at multiple points of neurodifferentiation. These 
experiments significantly elucidate the dynamic temporal profile of epigenetic L1 repression 
applied to new and extant L1 insertions during neurogenesis in vivo.  
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CHAPTER 1: DETECTION AND CHARACTERISATION OF ENDOGENOUS L1 
MOBILISATION IN hiPSCs. 
hiPSCs serve as an in vitro model of the inner cell mass of human blastocysts [114, 
117, 118]. In principle, heritable L1-mediated retrotransposition events should occur during 
gametogenesis or during the early stages of embryogenesis, where new L1 copies can be 
transmitted to progeny [201]. In recent work, Richardson et al., demonstrated that 
endogenous L1 retrotransposition occurs in mouse primordial germ cells and pluripotent 
embryonic cells [88]. L1 is also expressed in human male and female germ cells and hESCs 
[1, 2, 103, 202]. Consistently, studies of endogenous and engineered L1 mobilisation 
suggest that retrotransposition can occur in the germ line and during early embryonic 
development, as well as in certain somatic tissues [4, 29, 70, 136, 160]. hESCs and hiPSCs 
most likely have permissive epigenomes where L1 elements can potentially find a window 
of opportunity to mobilise [2]. Although reprogramming triggers retrotransposition [1], further 
investigation of L1 mobilisation and insertional pattern in hiPSCs is needed to fully 
understand the regulation and impact of L1 activity on the genomes of reprogrammed cell 
lines. Notably, de novo L1 insertions carrying 3’ transductions have not been described in 
hESCs or in hiPSCs, which has to date hindered efforts to identify specific RC-L1s that are 
active in these biological contexts, and infer relationships between parental and offspring L1 
copies.    
In the work reported in this chapter, I investigated endogenous L1 activity in hiPSCs. 
I performed bulk RC-seq using gDNA from two hiPSCs lines, and analysed these data in 
conjunction with previously published RC-seq data generated from the corresponding 
fibroblast populations [1]. The two hiPSC lines employed, hiPSC-CRL1502 (female) and 
hiPSC-CRL2429 (male), were derived from fibroblasts from healthy patients with 
oriP/EBNA1-based pCEP4 episomal vectors: pEP4EO2S, CK2MEN2L and pEP4EO2-
SET2K [203]. Using RC-seq, I compared each hiPSC line (labelled as time point 1: T1) with 
the corresponding parental fibroblasts (T0) to identify insertions present in the hiPSCs but 
not the fibroblasts, representing presumed de novo insertions arising during or after 
reprogramming. RC-seq was also applied to each hiPSC line after prolonged 
neurodifferentiation in vitro (T2-T6). Germline insertions present in the fibroblast genomes 
prior to reprogramming were identified and filtered. I sought to characterise reprogramming-
associated retrotransposition events carrying transduced sequences that could allow me to 
identify the corresponding donor RC-L1s. I identified and characterised a single 
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reprogramming-associated L1 retrotransposition event carrying both 5’ and 3’ transductions, 
allowing identification of its immediate donor L1. No de novo L1 insertions were found by 
RC-seq in the latter stages of neurodifferentiation at the detection thresholds used here. 
1.1: Identification of putative retrotransposition events arising during hiPSC 
reprogramming or during neurodifferentiation. 
To identify endogenous de novo L1 mobilisation events in hiPSCs and during 
neurodifferentiation, seven time points (T0-T6) from two cell lines were assessed in parallel. 
The time points consisted of fibroblasts (T0), hiPSCs (T1), neural epithelium (T2), neural 
rosettes, 29 days after neural induction, denoting immature neurons (T3) and three stages 
of prolonged neuronal maturation (T4-6) at differentiation days 72, 112 and 156, respectively. 
Immunocytochemistry was performed on the various time points to verify cells expressed 
markers consistent with their annotation (Figure 8).  
 
Figure 8. Above: schematic of the experimental approach of neurodifferentiation of 
hiPSCs reprogrammed from fibroblasts. TP, time point; T0, fibroblasts; T1, hiPSCs, 18 
days post differentiation; T2, neural epithelium, 29 days post differentiation; T3, neural 
rosettes and immature neurons, 84 days post differentiation; T4, neural rosettes and neurons 
I, 112 days post differentiation; T5, neural rosettes and neurons II, 156 days post 
differentiation; T6, neural rosettes and neurons III. Below: Characterisation of each time 
point: T1, OCT4, NANOG and Hoechst; T2, PH3 and Hoechst; T3, PAX6 and Hoechst; T4, 
TUJ1 and Hoechst; T5, CUX1, TUJ1 and Hoechst; T6, TUJ1, GFAP and Hoechst by 
immunocytochemistry. Note: The experiments shown were performed by Prof. Wolvetang’s 
laboratory. 
 
Next, RC-seq was performed on bulk genomic DNA (gDNA) extracted from the 
hiPSC-CRL1502 and hiPSC-CRL2429 cell lines at each time point. A cohort of 22 putative 
novel L1 insertions, denoted as “TC” for time course, and one SVA insertion, were identified 
by a stringent TEBreak analysis (https://github.com/adamewing/tebreak) and annotated as 
either polymorphic (previously published or present at T0) or de novo (only present at T1 or 
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later in one time course and not previously published in Klawitter et al., [1]) (Table 1A, B, 
C). 
According to the RC-seq output data table, from these 22 candidates, 17 were from 
the L1 family Ta [34], and 5 of them were from the family pre-Ta [11, 13]. Four putative de 
novo insertions landed in four different gene regions. Seven were detected at both L1-
genome junctions, 5’ and 3’, and insertion TC_22 was only detected at its 3’ end. 
Table 1: List of putative de novo insertions. The following table shows the list of putative 
de novo insertions found in each cell line. Refer to Appendix 4 for TSD_5prime, 
TSD_3prime, Genomic_Consensus_5p and Genomic_Consensus_3p sequence data.  
 
Table 1. A. Putative de novo L1 and SVA insertions: List of putative de novo candidates 
and their nomenclature. Chr: Chromosome where the putative de novo insertions mapped. 
Superfamily: The broadest retroelement classification. Subfamily: The L1-Ta subfamily is 
the most active in humans [13]. 5_Prime_End: L1 5’ end genomic coordinate (hg19 
reference genome). 3_Prime_End: L1 3’ end genomic coordinate.  
Putative de 
novo  L1 
insertions 
Chr Superfamily Subfamily 5_Prime_End 3_Prime_End
Timecourse_1 10 L1 L1Ta 130448104 130448098
Timecourse_2 12 L1 L1preTa 60413508 60413466
Timecourse_3 12 L1 L1Ta 89804489 89804494
Timecourse_4 12 L1 L1Ta 107960664 107960593
Timecourse_5 14 L1 L1Ta 55416805 55416749
Timecourse_6 18 L1 L1preTa 67763593 67763585
Timecourse_7 21 SVA SVA_D 37160955 37160975
Timecourse_8 22 L1 L1Ta 32311246 32311234
Timecourse_9 4 L1 L1Ta 182778720 182778704
Timecourse_10 6 L1 L1preTa 134707566 134707605
Timecourse_11 6 L1 L1Ta 140975548 140975543
Timecourse_12 7 L1 L1Ta 69828257 69828287
Timecourse_13 9 L1 L1preTa 68202772 68202756
Timecourse_14 9 L1 L1Ta 83150175 83150175
Timecourse_15 X L1 L1Ta 138146435 138146428
Timecourse_16 1 L1 L1Ta 59676272 59676261
Timecourse_17 1 L1 L1Ta 147333046 147333035
Timecourse_18 1 L1 L1Ta 231719300 231719315
Timecourse_19 12 L1 L1Ta 22116883 22116981
Timecourse_20 12 L1 L1Ta 75150880 75150913
Timecourse_21 3 L1 L1preTa 180758683 180758695
Timecourse_22 5 L1 L1Ta 37709844 37709844
Timecourse_23 7 L1 L1Ta 64554115 64554153
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Table 1. B. Putative de novo L1 and SVA insertions: List of the putative de novo 
candidates and their nomenclature. Orient_5p: Orientation of the 5’ end of the insertion 
relative to the reference genome. Orient 3p: Orientation of the 3’ end of the insertion. 
TE_Align_Start: Start position of the new insertion relative to L1 or SVA consensus. 
TE_Align_End: End position of the new insertion. Inversion: Presence or absence of an 
inversion in the new L1 insertion. Sample_count: Number of samples in which an insertion 
was detected. Split_reads_5prime: Number of unique RC-seq reads supporting the 5’ end 
of the insertion. Split_reads_3prime: Number of unique RC-seq reads supporting 3’ end of 
the insertion.  
 
 
Putative de 
novo  L1 
insertions 
Orient_5p Orient_3p
TE_Align
_Start
TE_Align
_End
Inversion
Sample_
count
Split_reads
_5prime
Split_reads
_3prime
Timecourse_1 - + 4866 6054 Y 1 3 1
Timecourse_2 - - 3592 6126 N 5 8 1
Timecourse_3 - - 3947 6093 N 2 5 1
Timecourse_4 + + 497 6059 N 2 4 1
Timecourse_5 + + 1790 6057 N 5 1 7
Timecourse_6 - - 606 6102 N 2 3 1
Timecourse_7 - - 339 1434 N 5 1 9
Timecourse_8 + + 244 6121 N 1 1 4
Timecourse_9 + + 5556 6121 N 5 4 9
Timecourse_10 + + 3 5994 N 2 4 1
Timecourse_11 + + 5099 6121 N 8 22 14
Timecourse_12 - - 5769 6121 N 2 5 1
Timecourse_13 + + 5073 6126 N 5 13 7
Timecourse_14 None - 3964 6065 NA 1 0 4
Timecourse_15 + + 1569 6121 N 4 8 1
Timecourse_16 + + 5332 6117 N 2 1 1
Timecourse_17 + + 5538 6048 N 2 1 1
Timecourse_18 - - 1 6118 N 4 10 4
Timecourse_19 + + 1481 6048 N 2 1 1
Timecourse_20 + - 5009 6121 Y 2 1 1
Timecourse_21 - - 5550 6045 N 2 1 1
Timecourse_22 None - 6002 6053 NA 2 0 3
Timecourse_23 - - 3939 6121 N 2 2 1
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Table 1.C. Putative de novo L1 and SVA insertions: List of the putative de novo 
candidates and their nomenclature. Gene_Region: In case of finding an insertion within a 
gene, this column indicates the gene name. Sample_Support: Samples in which the 
TEBreak pipeline found each insertion. 
 
1.2:  Manual analysis of RC-seq reads indicating putative de novo L1 insertions.  
Each insertion was analysed in silico (Appendix 1). These analyses consisted of 
looking for the molecular features of TPRT [60]: Target Site Duplications (TSDs), integration 
at a degenerate endonuclease motif [49, 61] and a Poly-A tract [26, 35] upstream of the 3’ 
TSD [64]. This part of the analysis was conducted to discard possible chimeras or PCR 
artefacts that passed the filters of the TEBreak pipeline [166]. Such artefacts can result from 
the random joining of two or more pieces of DNA that can be generated during multiple 
different steps in Illumina library preparation [166]. In many cases, the formation of chimeras 
is facilitated by the presence of microhomologies amongst two DNA fragments. For 
example, the putative de novo L1 insertion candidate TC_20 was called by TEBreak 
(https://github.com/adamewing/tebreak) as an inverted insertion, but the analysis of its 
sequence showed it was a recombination event or a PCR artefact. In addition, if a putative 
de novo insertion was found in one of the two hiPSC lines or its derivatives, it should not be 
present in the other cell line. It would be very unlikely that two different independent events 
Putative de novo 
L1 insertions
GeneRegion Sample_support
Timecourse_1 NA hiPS_CRL2429: TP1.p40
Timecourse_2 NA hiPS_CRL1502: TP1.p40, TP1.p76, TP2, TP4, TP6
Timecourse_3 NA hiPS_CRL2429:  TP1.p11, TP4
Timecourse_4 BTBD11,+,gene,transcript hiPS_CRL2429: TP1.p40, TP6
Timecourse_5 WDHD1,-,gene,transcript hiPS_CRL2429: TP1.p11, iPSC.C11.P1.p70, TP3, TP4, TP6
Timecourse_6 RTTN,-,gene,transcript hiPS_CRL2429: TP1.p40, TP4
Timecourse_7 RUNX1,-,gene,transcript hiPS_CRL2429: TP1.p11, TP1.p40, TP1.p70, TP3, TP6
Timecourse_8 NA hiPS_CRL2429: TP6
Timecourse_9 NA hiPS_CRL1502: TP1.p15, TP1.p40, TP3. TP4, TP6 
Timecourse_10 NA hiPS_CRL2429: TP1.p40, TP6
Timecourse_11 NA hiPS_CRL1502: TP1.p15, TP1.p40, TP1.p76, TP2, TP3, TP4, TP5, TP6
Timecourse_12 AUTS2,+,gene,transcript hiPS_CRL1502: TP1.p40, TP1.p76
Timecourse_13 NA hiPS_CRL1502: TP1.p40, TP1.p76, TP3, TP5, TP6
Timecourse_14 NA hiPS_CRL1502: TP1.p76
Timecourse_15 FGF13,-,gene,transcript hiPS_CRL1502: TP1.p15, iPSC.C32.TP1.p76, TP3, TP4 
Timecourse_16 NA hiPS_CRL2429: TP1.p40, T.P 6
Timecourse_17 NA hiPS_CRL2429: P1.p40, TP6
Timecourse_18 TSNAX-DISC1,+,gene,transcript hiPS_CRL2429: TP1.p40, T.P2, TP3, TP6
Timecourse_19 NA hiPS_CRL2429: TP1.p40, T.P3
Timecourse_20 NA hiPS_CRL1502: TP1.p40, TP1.p76, 
Timecourse_21 SOX2-OT,+,gene,transcript hiPS_CRL1502: TP1.p40, TP6
Timecourse_22 WDR70,+,gene,transcript hiPS_CRL2429: TP1.p70, TP2
Timecourse_23 RP11-460N20.5,+,gene,transcripthiPS_CRL2429: TP3, TP6
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would have happened at the same genomic location and carry identical molecular features. 
Hence, insertions found in both cell lines would be considered as polymorphic germ line 
insertions, as there are many L1s in the human population that are not present in the 
reference genome sequence [8, 11, 86, 90, 91, 112, 113, 170, 171, 176, 204, 205]. 
RC-seq produces ~150bp paired-end reads that for a given insertion span the 3’ L1-
genome junction and, for full-length L1 insertions, the 5’ L1-genome junction. Each read 
therefore contains a part of the L1 sequence and a part of its flanking genomic region. I used 
the sequencing output data from the RC-seq Appendix 4, Insert Consensus_5p, for the 
study of the 5’ end and Insert_Consensus_3p, for the study of the 3’ end. In both cases, the 
analysis consists of checking for an L1 sequence (either 5’ end or 3’ end) and its flanking 
regions. Below it is explained how the sequence of a new insertion (TC_18, shown as an 
example) should appear (Figure 9) in our study. The necessary steps to perform this in silico 
analysis are detailed in material and methods. 
Insert consensus_5p:  
CCATATTTTACATAATTTATAATTTATGAAATAGAATATTTGAATAATAAACCAATTCCATTTTGAAGGCTTCTGATGTAGTACTCTGT
TAAAAAAAAAAAAAAAAACTACTTGAGAAAAGTATGGATTGACTATATTGGAAGTTGCAAGGCCTGAGGAATGTTTTCCCGTGATTTTA
GTCCCTCTCATCAGTGTTCTATGCCTCAGTTCTGGTAACCCCAGAATGACGCTGTTACCTGACAGTATTCTAATGAAGATTAAAGAAAT
GACATCTGAAATAATGGAGGGGAGGAGCCAAGATGGCCGAATAGGAACAGCTCCGGTCTACAGCTCCCAGCGTGAGCGACGCAGAAGAC
GGTGATTTCTGCATTTCCATCTGAGGTACCGGGTTCATCTCACTAGGGAGTGCCAGACAGTGGGCGCAGGCCAGTGTGTGTGCGCACCG
TGCGCGAGCCGAAGCAGGGCGAGGCATTGCCTCACCTGGGAAGCGCAAGGGGTCAGGGAGTTCCCTTTCCGAGTCAAAGAAAGGGGTGA
CGGACGCACCTGGAAAATCGGGTCACTCCCAC 
Insert consensus_3p:  
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAATGACATCTGTTAATCTTATTAAGTTC
GCTGAGGCAGGATGAGGCTGGGTGCTGGTAAATGGAGCAGATAAATGATCTGAGACATCTACACTTTATTTTTCATGTTGAAAAGTCAT
CATAGAGAAACTTTCTCCTTTGGT 
Figure 9: Example of a good candidate for PCR validation (sequences from TC_18 
insertion). Insert consensus 5p: The genomic consensus sequence of the 5’ end of a 
possible new L1 insertion should have (from 5’ to 3’) a gDNA sequence (represented in 
black letters with 259 nucleotides in this case) from the same genomic location as referred 
in the table, a Target Site Duplication (represented in blue letters and underlined (in this 
case, 16 nucleotides)) and a part of the L1 sequence (represented in red letters with 281 
nucleotides in this case). We also observe a 5’ transduced sequence (represented in green 
letters having 10 nucleotides). Depending if the L1 element was truncated or not we will find 
the 5’ end of the L1 sequence at different positions with respect to the L1 reference 
sequence. TSDs are annotated by TEBreak (https://github.com/adamewing/tebreak) in 
Appendix 4 but then they need to be analysed by manual inspection of the different genomic 
consensus sequences. Insert consensus 3p: The genomic consensus sequence of the 3’ 
end of a possible new L1 insertion should have (from 5’ to 3’) L1 sequence which may begin 
at different positions with respect to the L1 reference sequence, but which should always 
end with a Poly-A tract (represented in red letters with 56 nucleotides). The Poly-A tract 
should be followed by a TSD (identical to the one we observed on the 5’ end insert 
consensus sequence data; it is represented in blue letters and underlined with 16 
nucleotides) and the gDNA sequence from the same genomic location as referred in the 
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table and present on the 5’end consensus sequence (represented in black letters with 130 
nucleotides in this case).  
 
1.3:  PCR validation of endogenous L1 insertions. 
After the analysis of the sequencing reads of the 23 putative de novo insertions, 15 
were discarded due to being located in repetitive elements or showing obvious signs of being 
artefacts (see Materials and Methods). and the 8 remaining candidates were selected for 
PCR validation (Table 2): TC_2, TC_11, TC_13 TC_17, TC_18, TC_21, TC_22 and TC_23. 
For these 8 candidates, PCR primers were designed (Figure 10, Appendix 2) and then 
Empty-Filled and 3’junction PCR assays were performed (Figures 11-14).  
Nomenclature 
Expected  
Filled size (bps) 
Expected  
Empty size (bps) 
Expected 3'junction 
size (bps) 
TC_2 2803 269 165 
TC_11 1245 291 210 
TC_13 1235 249 235 
TC_17 895 385 181 
TC_18 6213 96 294 
TC_21 860 365 204 
TC_22 425 374 286 
TC_23 2815 633 194 
Table 2. Expected sizes of the amplification products from the time course L1 
candidate insertion PCRs. 
 
 
Figure 10: Schematic representation of PCR validations commonly attempted in the 
L1 field. Black boxes represent L1 elements. A. 5’ junction PCR. Orange arrows represent 
primer position with respect the L1 sequence at the 5’ end. B. 3’ junction PCR.  Blue arrows 
represent primer position with respect the L1 sequence at the 3’end. C. Empty-Filled PCR. 
Green arrows represent primer position with flanking the L1 copy. Above: Filled site. Below: 
Empty site. 
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The empty/filled PCR validation assay gel panel results (Figures 11, 12 and 13) 
confirmed validated for 3 of the 8 candidate L1 insertions. One insertion, TC_18, was a de 
novo retrotransposition event, whilst the other two were present at T0 and were therefore 
polymorphic. Five L1 insertion candidates (TC_17, TC_22, TC_2, TC_21, TC_23) did not 
produce any validation products (Figure 11). 
 
Figure 11: Empty-filled PCRs. On the left hand of the agarose gel panels are written the 
names of each putative de novo L1 insertion candidate. Insertions TC_17, TC_18 and 
TC_22, should be present in the cell line hiPSC-CRL2429 but absent in the cell line hiPSC-
CRL1502. Insertions TC_2, TC_21 and TC_23, should be present in the cell line hiPSC-
CRL1502 but absent in the cell line hiPSC-CRL2429. Colour code: Red arrows, expected 
filled size of the amplicons. Black arrows, expected empty size of the amplicons.  
 
As expected from the results of the RC-seq output data table, the amplification 
product for TC_18 was present only in the cell line hiPSC-CRL2429, was around 6 Kb in 
length, and there was no amplification product at T0. TC_11 and TC_13 were present at T0 
as well as the hiPSCs (T1), making them polymorphic insertions. Figure 12 and Figure 13 
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show the empty-filled PCR validation panels of the insertion TC_11 and TC_13, respectively. 
The cell line hiPSC-CRL2429 was used in both cases as a negative control. The 
amplification products in both cases at T0 in the cell line hiPSC-CRL1502 confirmed that the 
candidates were not de novo retrotransposition events. The polymorphic insertions TC_11 
and TC_13 were detected by RC-seq in hiPSCs or T1 but not in HDFs or T0. RC-seq failed 
to detect this insertion at T0. Hence, this insertion was a false-negative result from the RC-
seq approach. This fact emphasizes the necessity for PCR validation of L1 insertions. 
 
Figure 12: Empty-filled PCR validation of the polymorphic insertion TC_11. The 
insertion TC_11 found in T0-T6 in the cell line hiPSC-CRL1502. Colour code:  Red arrow, 
size of the expected filled site band (1245 base pairs (bp)); Black arrow, size of the expected 
empty site band (291 bp). 
 
 
Figure 13: Empty-filled PCR validation of the polymorphic insertion TC_13. The 
insertion TC_13 found in the T1, T3, T5 and T6 derived from the cell line hiPSC-CRL1502. 
Colour code: Red arrow, size of the expected filled site band (1235 base pairs (bp)); Black 
arrow, size of the expected empty site band (249 bp). 
 
The results obtained from the 3’ junction PCR assay complemented results from the 
Empty-filled PCR assay (Figure 14). Amplification of the 3’ end can be seen in the case of 
TC_18 in T1 but not in T0 in the hiPSC-CRL2429 cell line, and is entirely absent from the 
hiPSC-CRL1502 cell line and its derivatives. A 3’ junction PCR was not performed in the 
case of TC_11 and TC_13 as these were clearly polymorphic from the Empty-filled assay.  
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Figure 14: 3’Junction PCRs. On the left hand of the agarose gel panels are written the 
names of each putative de novo L1 insertion candidate. Insertions TC_17, TC_18 and 
TC_22, should be present in the cell line hiPSC-CRL2429 but absent in the cell line hiPSC-
CRL1502. Insertions TC_2, TC_21 and TC_23, should be present in the cell line hiPSC-
CRL1502 but absent in the cell line hiPSC-CRL2429. Colour code: Black arrows, expected 
size of the 3’junction amplicons. +C; positive PCR control using Fwd and Rv L1 primers with 
gDNA from T0 to prove that the PCR was successful. 
 
1.4:  Sequence characterisation of PCR validated L1 insertions. 
Once TC_11, TC_13, and TC_18 were confirmed as genuine L1 insertions, their filled 
site PCR amplification products were cloned in Topo-XL vector and capillary/Sanger 
sequenced (Appendix 2) to fully characterise their structural features (Figure 15-17).  
Sequence analysis of the insertion TC_18 (also named as de novo L1 in this thesis) 
demonstrated a de novo full-length retrotransposition event of 6118 nucleotides which 
carried 2 transduced sequences flanking the L1 copy (Figure 15). The 5’ transduced 
sequence observed was 10 nucleotides in length from the gDNA of its immediate donor 
element (called here the “donor L1”) a previously-described “hot” polymorphic L1 [11], and 
the 3’ transduced sequence presented 44 nucleotides from the gDNA of a reference L1 
element [13], which we called the “lineage progenitor L1”, being the source or parental 
element of both the de novo and donor L1s. Consistently, the lineage progenitor L1 
presented only one Poly-A tract. The de novo L1 TC_18 presented two Poly-A tracts: the 
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first one was 17 nucleotides and the second one was 33 nucleotides. The TSDs of the 
TC_18 insertion were 16 nucleotides and the EN-motif was 5’-TT/AAAG-3’. The insertion 
was antisense to chromosome 1 (chromosomal location: Chr1:231,719,316). The family of 
the insertion was L1-Ta [30, 33]. This insertion landed in the TSNAX-DISC1 gene which is 
an RNA Gene and is classified as a RNA molecule non-translated into protein, a non-coding 
RNA (ncRNA). Diseases associated with TSNAX-DISC1 include Schizophrenia 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=TSNAX-DISC1&keywords=TSNAX). 
 
Figure 15: Genomic location and structural features of the insertion TC_18 (de novo 
L1) detected by RC-seq in the cell line hiPSC-CRL2429. Filled site. This figure shows a 
full-length L1-Ta element [34]. The insertion is 6118 nucleotides in length and contains 2 
transduced sequences, one in the 5’ end of 10 nucleotides (green letters) and another one 
in the 3’end of 44 nucleotides (purple letters). Black letters indicate genomic DNA (gDNA) 
where the insertion landed; Coordinates (Chr1:231,719,316), indicate the genomic position 
of insertion site. Red letters show the sequence of the TSDs flanking the L1 upon 
retrotransposition. Following the L1 sequence is a first Poly-A tract of 17 nucleotides in 
length and a second Poly-A tract of 33 nucleotides. Empty site. Red letters indicate TSDs; 
Black letters indicate gDNA; Black arrow, site of first strand cleavage by the L1 
endonuclease. 
 
Sequence analysis of the insertion TC_11 showed a 5’ truncated polymorphic L1 
element of 954 nucleotides (Figure 16). The L1 element was accompanied by a Poly-A tract 
of 44 nucleotides. The TSDs of the insertion were 6 nucleotides in length and the EN-motif 
was 5’-TT/GAAA-3’. The insertion was oriented in sense to chromosome 6, chromosomal 
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location: Chr6:140,975,331. The family of the insertion was L1-Ta [34]. This insertion landed 
in an intergenic region. 
 
Figure 16: Genomic location and structural features of the polymorphic insertion 
TC_11 detected by RC-seq in the cell line hiPSC-CRL1502. Filled site. This figure shows 
the 3’ end the polymorphic L1 element (ORF2) from the family Ta [34]. The insertion is 954 
nucleotides in length and is truncated at the position 5106 with respect to a full-length L1 
reference sequence. Black letters indicate genomic DNA (gDNA) where the insertion landed; 
Coordinates (Chr6:140,975,331), indicate the location of the insertion site. Red letters 
indicate TSDs flanking the L1 sequence upon retrotransposition. A Poly-A tract of 28 
nucleotides follows the L1 sequence. Empty site. Red letters indicate the TSD; Black letters 
indicate gDNA sequence. Black arrow indicates the site of first strand cleavage by the L1 
endonuclease. 
 
Sequence analysis of the insertion TC_13 revealed a 5’ truncated polymorphic L1 
element of 986 nucleotides with an inversion of 171 nucleotides and a deletion of 177 
nucleotides (Figure 17). The L1 element presented a Poly-A tract of 28 nucleotides. The 
TSDs of the insertion were 17 nucleotides in length and the EN-motif was 5’-TT/AAAA-3’. 
The insertion landed in the positive strand of chromosome 9, chromosomal location: 
Chr9:68,202,547. The family of the insertion was L1 pre-Ta [34]. This insertion landed in an 
intergenic region. 
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Figure 17: Genomic location and structural features of the polymorphic insertion 
TC_13 detected by RC-seq in the cell line hiPSC-CRL1502. Filled site: This insertion 
consists of a polymorphic L1 element (ORF2) from the L1 pre-Ta family. The insertion TC_13 
is 986 nucleotides in length.  This insertion has an inversion (nucleotides 5234 to 5063 with 
respect to a full-length L1 reference sequence) deletion (the sequence that is deleted is 
nucleotides 5063 to 5240). Black letters indicate gDNA where the insertion landed; 
Coordinates (Chr9:68,202,547), indicate the insertion site. Red letters indicate TSDs 
flanking the L1 sequence. A Poly-A tract of 44 nucleotides follows the L1 sequence. Empty 
site: Red letters indicate TSDs; Black letters indicate gDNA; Black arrow indicates the site 
of first strand cleavage by the L1 endonuclease. 
 
CONCLUSIONS OF CHAPTER 1: 
Of the 23 candidate de novo insertions detected by RC-seq [107], 8 were assessed 
to be strong candidates for PCR validation. One insertion, TC_18 (de novo L1) was 
successfully validated, characterised, and sequenced. The de novo L1 insertion was present 
in hiPSCs, throughout the neurodifferentiation time course, and was absent from the 
corresponding parental fibroblasts. As predicted by the RC-seq output data table, the 
insertion was full-length and was absent from the control cell line hiPSC-CRL1502. The 
sequencing results for the de novo L1 insertion demonstrated the presence of 2 transduced 
sequences flanking the L1 copy. This de novo L1 insertion was the first retrotransposition 
event reported in hiPSCs with both 5’ and 3’ transduced sequences. The nucleotide 
sequence of the 3’ transduction allowed identification of the donor and lineage progenitor 
L1s that gave rise to the de novo L1 insertion. The identification of an extended L1 
transduction family generated by the lineage progenitor L1 is described in Chapter 2.   
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CHAPTER 2: IDENTIFICATION AND CHARACTERISATION OF AN EXTENDED L1 
TRANSDUCTION FAMILY.  
In this chapter, I discovered that the de novo L1 insertion (TC_18) was part of an 
extended L1 transduction family comprising at least 14 elements. Various members of the 
transduction family, named here as L1_1-14, have been previously described [8, 11, 86, 90, 
91, 112, 113, 170, 171, 176, 204, 205] (Table 3) but, importantly, the relationships amongst 
them have not previously been elucidated. Several members of the family are still potentially 
active in the human population and, as demonstrated by TC_18, can generate 
reprogramming-associated L1 insertions in hiPSCs. 
2.1: Identification of L1_1-14 transduction family members.  
Below is shown a summary of the L1_1-14 family members described in this thesis, 
including the nomenclature I am using, their chromosomal location and whether they are 
reference L1s or non-reference elements. 
      Nomenclature Coordinates (hg19) Chr. location  Ref. element  Full-length 
De novo L1 (TC_18) Chr1:231,719,316 q42.2 No Yes 
Lineage progenitor  Chr11:95,169,381 q21 Yes Yes 
Donor L1 Chr3:38,626,082 q22.2 No Yes 
Ref_Chr7_q21.3  Chr7:96,475,963 q21.3 Yes Yes 
Ref_Chr1_p31.1_a  Chr1:84,518,060 p31.1 Yes Yes 
Non-ref_Chr3_p24.3 Chr3:20,748,904 p24.3 No Yes 
Non-ref_Chr3_p12.2_a Chr3:80,590,176 p12.2 No Yes 
Non-ref_Chr3_p12.2_b Chr3:82,144,869 p12.2 No Yes 
Non-ref_ChrX_p11.4 ChrX:38,097,551 p11.4 No Yes 
Ref_Chr1_p31.1_b Chr1:83,125,969 p31.1 Yes No 
Ref_Chr9_p23 Chr9:12,556,931 p23 Yes No 
Non-ref_Chr17_q12 Chr17:32,813,609 q12 No No 
Non-ref_Chr1_p22.2 Chr1:90,914,512 p22.2 No No 
Non-ref_Chr4_q12 Chr4:53,628,490 q12 No No 
Nomenclature: Ref, reference L1 element; Non-Ref, Non-Reference L1 element; 3’ transd, 3’ transduction 
Table 3: List of L1_1-14 transduction family members. 
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2.1.1: Identification of transduction family members present in the reference 
genome. 
The 3’ transduction carried by TC_18 was crucial to finding the other members of 
L1_1-14: 5’-GAATTGTAAAAAAAAAAATTATAAATAAAACAAAGAAGAATATG-3’. When this 
44nt sequence was mapped to the hg19 reference genome using BLAT in the UCSC 
genome browser, 5 different genomic loci presented full-length alignments with ≤2 
mismatches [11]: Chr1:84,518,060, Chr11:95,169,381, Chr1:83,125,969, Chr9:12,556,931, 
and Chr7:96,475,963. In silico analysis in each case revealed an L1 immediately upstream 
of the transduced sequence, a first Poly-A tract and a second Poly-A tract, with the exception 
of the example of the alignment to Chr11:95,169,381, which had no second Poly-A tract. 
The lack of a second Poly-A tract and the precedence of the nucleotide sequence of the 3’ 
transduced sequence indicated that this element, the lineage progenitor L1, is the likely 
original source element which gave rise to this L1 family. The 5 family members of L1_1-14 
identified in the reference genome comprised 3 full-length elements, named as 
Ref_Chr1_p31.1_a, lineage progenitor L1, and Ref_Chr7_q21.3, and two 5’ truncated L1s, 
denoted as Ref_Chr1_p31.1_b and Ref_Chr9_p23. 
Primers were designed to PCR amplify the lineage progenitor L1 and to subsequently 
clone it and then test its retrotransposition activity in vitro. The element was successfully 
amplified (Figure 18) and Sanger sequenced. Interestingly, this element was previously 
reported to be inactive by Brouha et al. [13], probably due to allelic variants disabling the 
version of the lineage progenitor L1 tested by that study. The lack of amplification product 
in the empty site demonstrated the homozygosity of the lineage progenitor in the cell line 
hiPSC_CRL2429. After Sanger sequencing, two different alleles were identified (Results 
section 2.4). 
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Figure 18: PCR validation panel of the lineage progenitor L1. 5’ junction PCR, 3’ junction 
PCR and empty/filled PCR gels. Amplification was observed in T0 in the cell line hiPSC-
CRL2429 in 5’ junction PCR, 3’ junction PCR and in the filled site (red arrow) of the 
empty/filled PCR assay. The absence of amplification product in the empty site confirmed 
the homozygosity of this element. NTC, non-template control. 
 
The other full-length elements, Ref_Chr7_q21.3 and Ref_Chr1_p31.1_a, were 
flanked by repetitive sequences. Nevertheless, primers were designed, and amplification 
was attempted. The primers for Ref_Chr7_q21.3 produced an amplicon of the expected 
size, but subsequent cloning and Sanger sequencing of this amplicon failed (Figure 19). 
The PCR for Ref_Chr1_p31.1_a produced a high number of non-specific amplification 
products (data not shown). 
                      
Figure 19: Empty/filled PCR validation of Ref_Chr7_q21.3 element. Amplification was 
observed in T0 in the cell line hiPSC-CRL2429 in the filled site (red arrow) of the empty/filled 
PCR assay and in the empty site (black arrow). NTC, non-template control. 
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2.1.2: Identification of transduction family members absent from the reference 
genome.  
Once reference genome members of L1_1-14 were identified, I sought to find 
additional polymorphic family members that were absent from the reference genome. 
Analysis of the RC-seq data produced by Klawitter et al. [1] for cell lines hiPSC_CRL2429, 
hiPSC_CRL1502, and others, showed 5 candidate L1 insertions that carried the 3’ 
transduced sequence shared by the transduction family. Three of these elements were 
amplified by PCR and Sanger sequenced from fibroblasts corresponding to cell line hiPSC-
CRL2429. The elements were: the donor L1 (Non-ref), Non-ref_Chr3_p24.3 and Non-
ref_Chr3_p12.2_b and their genomic locations were: Chr3:38,626,082, Chr3:20,748,904, 
Chr3:82,144,869, respectively. As mentioned in Chapter 1, the donor L1 was previously 
described in Beck et al., [11] and was identified to be the immediate progenitor of the de 
novo L1 insertion. The activity of the donor L1 and Non-ref_Chr3_p24.3 was further 
assessed in a cultured cell retrotransposition assay (see Results section 2.5). PCR 
amplification was also attempted for the other two potential full-length L1s, Non-
ref_Chr3_p12.2_a and Non-ref_Chr17_q12, with genomic locations Chr3:80,590,176 and 
Chr17:32,813,609, respectively, using as a template genomic DNA from additional cell lines 
in which they were detected by Klawitter et al. [1] by at least one sequencing read. PCR 
validation was not immediately successful for these elements. As they carried the hallmarks 
of retrotransposition, as well as the 3’ transduction shared amongst the L1_1-14 family, I did 
not pursue further optimisation of the PCR conditions. 
Identification of the donor L1 as the immediate progenitor of the de novo L1 insertion 
was possible due to the 10 nucleotides of 5’ transduced sequence present adjacent to the 
de novo L1. This sequence fully matched the flanking genomic sequence of the polymorphic 
element previously identified by Beck et al. on Chromosome 3 [11]. Hence, it was possible 
to determine that the remaining family members lacked this unique upstream region. PCR 
validation against the donor L1 demonstrated that this element was present in the parental 
fibroblasts of the cell line hiPSC-CRL2429, where the de novo insertion was discovered. 
The empty/filled PCR validation assay in hiPSC_CRL2429 revealed a filled site of around 
~6 Kb in length and amplification of the expected empty site band of 130 nt, confirming the 
heterozygosity of the element (Figure 20). This polymorphic element was previously 
characterised by Beck et al. [11] with nucleotide reference number AC211854. It was 
described to be an active element showing 101% of the in vitro activity of L1.3 [11]. 
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Figure 20: PCR validation panel of the donor L1. 5’ junction PCR, 3’ junction PCR and 
Empty/Filled PCR gels. Amplification was observed in T0 in the cell line hiPSC-CRL2429 in 
the 5’ junction PCR, the 3’ junction PCR, in the filled site (red arrow) and in the empty site 
(black arrow) of the empty/filled PCR assay. The presence of amplification product in the 
empty site confirmed the heterozygosity of this element. NTC, non-template control. 
 
 
 
 
Figure 21: Empty/filled PCR validation of Non-Ref_ Chr3_p24.3 element. Amplification 
is observed in T0 in the cell line hiPSC-CRL2429 in the filled site (red arrow) of the 
empty/filled PCR assay and in the empty site (black arrow). NTC, non-template control. 
 
The polymorphic full-length L1 Non-ref_Chr3_p24.3 was also successfully PCR 
validated via an empty/filled PCR assay (Figure 21), presenting the expected amplification 
product in the filled site. The amplification product observed in the empty site, with 428 
nucleotides, confirmed the heterozygosity of the element. This element was described in 
Beck et al. as being inactive, with nucleotide reference number: AC203662 [11]. The full-
length L1 Non-ref_Chr3_p12.2_b [8, 86, 91, 113, 170, 176, 205] was not present in the cell 
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lines hiPSC-CRL2429 or hiPSC-CRL1502 and therefore it was PCR amplified using gDNA 
from Hela cells and an empty/filled PCR assay (Figure 22). The amplification product 
observed in the empty site with 386 nucleotides of fragment size confirmed the presence of 
an empty-site allele in HeLa cells and the L1 insertion was full-length.  
 
 
Figure 22: Empty/filled PCR validation of Non-Ref_Chr3_p12.2_b. Amplification is 
observed in Hela cells of the filled site (red arrow) from the empty/filled PCR assay and of 
the empty site (black arrow). NTC, non-template control. 
 
According to the RC-seq data from Klawitter et al. paper [1] the other full-length 
element, named as Non-ref_Chr3_p12.2_a, was located at Chr3:80,590,176 and has also 
been described in other studies [8, 11, 87, 90, 91, 113, 176]. The final family member 
identified from the data of Klawitter et al. was named as Non-ref_Chr17_q12 [1, 86, 90, 91, 
112, 171, 176, 204], was located at chromosomal location Chr17:32,813,609 and, according 
to sequencing reads obtain from 2 different studies [1, 176], this element was 5’ truncated 
and inverted/deleted (Figure 26).  
 
2.2: Identification of transduction family members absent from the reference 
genome and detected by other studies. 
The L1_1-14 transduction family was further elucidated by directly aligning the 3’ 
transduced sequence carried by the de novo L1 to previous WGS and RC-seq reads 
generated by the Faulkner laboratory [1, 6, 7, 91, 143, 173]. Three additional polymorphic 
family members were found. According to the sequencing data, one was a full-length L1 and 
two were 5’ truncated. The full-length element was previously described [8, 170] at the 
chromosomal location ChrX:38,097,551 and was named here as Non-ref_ChrX_p11.4. One 
non-reference 5’ truncated element was named Non-ref_Chr1_p22.2 [8, 86, 91, 113, 170, 
205] located in Chr1:90,914,512. The other non-reference truncated element was named 
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Non-ref_Chr4_q12 [8, 86, 90, 91, 113, 170, 176] and was located at Chr4:53,628,490. 
Interestingly, two other L1 insertions were previously described by Tubio et al. [8] in 
an analysis of tumour genomes as “solo” L1 insertions, which could not be partnered with a 
matching source L1. These two L1 insertions each carried a relatively short, 18 nucleotide 
(GAATTGTAAAAAAAAAAA) 3’ transduced sequence that matches the lineage progenitor 
L1. The insertions have the identifiers PD7355f and PD7355a in Tubio et al. and they were 
in the chromosomal locations: Chr10:110,250,765 and Chr3:70,096,455, respectively. 
According to the Tubio et al. analysis, these elements were 5’ truncated. By characterising 
the L1_1-14 transduction family, the origins of these two annotated solo L1 insertions are now 
clear, showing that the L1_1-14 lineage is active in cancer. 
 
2.3: Characterisation of an extended transduction family. 
Altogether, the transduction family L1_1-14 accounted for 14 elements, as well as two 
related instances carrying 18 nucleotides of the common 3’ transduced sequence, 
considered to be separate as they were identified only in tumour samples [8]. All of these 
corresponded to the L1-Ta subfamily  [34]. Nine of the 14 were full-length L1s and 5 were 5’ 
truncated. Five were present in the reference genome and 9 were non-reference L1s (Table 
4A). The length of the 5’ transduced sequences varied between 10 and 539 nucleotides. 
Ref_Chr7_q21.3 and Non-ref_Chr3_12.2_a presented the smallest first Poly-A tract length, 
with 16 adenines, whilst Non-ref_Chr17_q12 had the longest, with 46 adenines. The 
observed variation in L1 Poly-A tract length is thought to be caused by non-random 
degradation during DNA replication [206]. The length of the 3’ transduced sequence varied 
between 19 and 75 nucleotides amongst all the family members, and the length of the 
second Poly-A tract sequences ranged from 15 adenines in the Non-ref_Chr1_p22.2 to 80 
adenines in the Non-ref_Chr3_12.2_a. Overall, the second Poly-A tract was longer than the 
first Poly-A tract (Table 4A), in line with expectations [127]. 
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Nomenclature 
 
 
Family 
 
Length (nt) 
 
1st  
Poly-A                        
 
3' transd 
length (nt) 
 
2nd  
Poly-A  
 
Lineage progenitor L1 
 
 
L1-Ta 
 
6043 
 
29 
 
 
 
Absent 
Donor L1 
 
L1-Ta 6041 17 44 21 
De novo L1 (TC_18) L1-Ta 6118 17 44 33 
Ref_ Chr1_p31.1_a 
 
L1-Ta 6046 29 75 29 
Ref_ Chr7_q21.3 
 
L1-Ta 6016 16 42 17 
Non-ref_ Chr3_p24.3 L1-Ta 6042 22 27 22 
Non-ref_ Chr3_p12.2_a L1-Ta 6041 16 41 80 
Non-ref_ Chr3_p12.2_b L1-Ta 6041 43 35 25 
Non-Ref_ChrX_p11.4 L1-Ta 6121 18 43 18 
Ref_Chr1_p31.1_b L1-Ta 1485 42 51 23 
 
Ref_Chr9_p23 L1-Ta 2703 29 41 29 
 
Non-ref_Chr17_q12 L1-Ta 1011 46 19 21 
 
Non-ref_Chr1_p22.2 L1-Ta 144 28 40 15 
 
Non-ref_Chr4_q12 L1-Ta 173 18 44 26 
 
Nomenclature: Ref, reference L1 element; Non-Ref, Non-Reference L1 element; 3’ transd, 3’ transduction 
 
Table 4: A. Features of transduction family L1_1-14. In the table it is shown: Location; 
family; nucleotide length; first Poly-A tract length, 1st PolyA; 3’ transduction length, 3' 
transduction length (nt); second Poly-A tail length, 2nd Poly-A. 
 
Surveying the literature for in vitro estimates of L1 retrotransposition efficiency for full-
length members of the transduction family revealed measurements for the lineage 
progenitor, donor L1, de novo L1 (same nucleotide sequence as the donor L1) and Non-
ref_Chr3_p24.3. Non-ref_Chr3_p24.3 was reported to be inactive by Beck et al [11]. In the 
same study, the donor L1 was found to present 101% the activity of L1.3 in the 
retrotransposition assay. The lineage progenitor L1 was described to be virtually inactive, 
with 1.2% of the activity of the hot element L1RP [13] (Table 4B).  Most of the elements were 
inserted in intergenic regions (Table 4C), except the donor L1, which was located in an 
intron of the gene SCN5A, and the de novo L1 insertion, which was positioned in an intron 
of the transcript TSNASX-DISC1. 
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Nomenclature 
 
 
Previously reported  
 
ID previously 
reported 
 
Activity 
previously 
described 
 
Lineage progenitor L1 
 
 
Reference genome and Brouha et al.[13] 
 
 
 
AP000652 
 
1.2% of L1RP 
Donor L1 (Non-ref) 
 
Beck et al. [11], Ewing et al 2010.[112], Ewing et 
al.2011.[113], Helman et al.[176], Kuhn et al.[204], 
Lee et al.[86], Shulka et al.[91], Stewart et al.[205], 
Sudmant et al.[170], Tubio et al.[8], Wang et al.[171] 
and Iskow et al.[90] 
 
AC211854 101% of L1.3 
De novo L1 (TC_18) This study     
Ref_ Chr1_p31.1_a 
 
Reference genome 
 
  
Ref_ Chr7_q21.3 
 
Reference genome   
Non-ref_ Chr3_p24.3 Beck et al.[11], Ewing et al.2011. [113], Helman et 
al. [176], Lee et al. [86], Shukla et al. [91], Tubio et 
al. [8], Wang et al. [171] and Iskow et al. [90] 
 
AC203662 Inactive 
Non-ref_ Chr3_p12.2_a Gardner et al.[87], Tubio et al. [8], 
 Beck et al. [11], Ewing et al.2011[113], Helman et 
al. [176], Shukla et al. [91] and Iskow et al. [90]   
 
  
Non-ref_ Chr3_p12.2_b Ewing et al. 2011[113], Tubio et al. [8], Helman et 
al. [176], Shukla et al. [91], Stewart et al. [205], 
Sudmant et al. [170] and Lee et al. [86] 
  
Non-ref_ChrX_p11.4 
 
Tubio et al. [8] and Sudmant et al. [170]  
 
  
Ref_Chr1_p31.1_b 
 
 
Reference genome   
Ref_Chr9_p23 Reference genome   
Non-ref_Chr17_q12 
 
Iskow et al. [90], Ewing et al 2010. [112], Helman et 
al. [176], Kuhn et al.[204], Lee et al. [86], Shulka et 
al. [91] and Wang et al. [171] 
 
  
Trunc-Non-ref_Chr1_p22.2 
 
Tubio et al. [8], Ewing et al.2011. [113], Lee et al. 
[86], Shulka et al. [91], Stewart et al. [205] and 
Sudmant et al. [170] 
 
  
Non-ref_Chr4_q12 Tubio et al. [8], Ewing et al.2011. [113], Helman et 
al. [176], Lee et al. [86], Shulka et al. [91], Sudmant 
et al. [170] and Iskow et al. [90] 
  
Nomenclature: Ref, reference L1 element; Non-Ref, Non-Reference L1 element. 
Table 4: B. Features of transduction family L1_1-14..  
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Nomenclature 
 
 
TSD 
 
Endo-Motif (5'-3') 
 
Gene Region 
 
Lineage progenitor L1 
 
 
AAAGAATTGTA 
 
TT/AAAG 
 
Intergenic 
Donor L1 (Non-ref) 
 
AGAATGAGTAAATAATG AC/AGAA SCN5A (intron) 
De novo L1 (TC_18) AAAGAAATGACATCTG TT/AAAG TSNAX-DISC1 
(intron;transcript variant) 
Ref_ Chr1_p31.1_a 
 
AGAAAAACAAATCA AT/AGAA Intergenic 
Ref_ Chr7_q21.3 
 
GAAAGTTCCAGTTGC AT/GAAA intergenic 
Non-ref_ Chr3_p24.3 TAAAGACAC GT/TAAA Intergenic 
Non-ref_ Chr3_p12.2_a GAAAATGGAATGGG AT/GAAA Intergenic 
Non-ref_ Chr3_p12.2_b AGAAATAATAATTTCC TT/AGAAA Intergenic 
Non-ref_ChrX_p11.4 AAAAGCGATATG 
 
AT/AAAA Intergenic 
Ref_Chr1_p31.1_b AAAAAAAATGGTTCATGC TT/AAAA Intergenic 
Ref_Chr9_p23 GAAAAGTATTGTATTG AA/GAAA Intergenic 
Non-ref_Chr17_q12 AAGAAGGTAAGATGG 
 
TT/AAGA Intergenic 
Non-ref_Chr1_p22.2 AAAAAGCTCTTTCAG 
 
TC/AAAA Intergenic 
Non-ref_Chr4_q12 TAAATTACAGGTTA 
 
TT/TAAA Intergenic 
Nomenclature: Ref, reference L1 element; Non-Ref, Non-Reference L1 element; Trunc, Truncated L1 element 
Table 4. C. Sequence features of L1_1-14. transduction family members. Target site 
duplications, TSDs; Endonuclease motif, Endo-Motif (5’-3’). 
 
2.3.1: Sequence analysis of reference elements. 
The internal sequences of the reference element members of L1_1-14 (lineage 
progenitor, Ref_Chr7_q21.3, Ref_Chr1_p31.1_a, Ref_Chr1_p31.1_b and Ref_Chr9_p23) 
were obtained from the UCSC genome browser after BLAT searching [207] the 3’ 
transduced sequence. Then, L1 sequences upstream of the transduced sequence were 
identified. The element Ref_Chr7_q21.3 contained a Poly-A tract of 16 nucleotides and the 
second Poly-A was 17 nucleotides in length, bracketing a 3’ transduced sequence of 42 
nucleotides. The element Ref_Chr1_p31.1_a presented a first and a second Poly-A tract of 
29 nucleotides in each case. This element had also a 5’ transduced sequence 539 
nucleotides in length (Figure 26). This 5’ transduced sequence belonged to the genomic 
flanking DNA upstream of the lineage progenitor L1. A single untemplated guanine preceded 
this 5’ transduction upstream of the Ref_Chr1_p31.1_a element, indicating capping of the 
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mRNA template, and used a transcription start site in the 5’ long terminal repeat (LTR7Y) 
sequence corresponding to a HERV-H provirus integrated ~126kb upstream of the lineage 
progenitor L1. Interestingly, this 5’ transduction contained 3 exons (176, 356 and 7 
nucleotides) resulting from 2 RNA splicing events. The element Ref_Chr1_p31.1_b was 5’ 
truncated, and was 1485 nucleotides in length. The element Ref_Chr1_p31.1_b presented 
a first Poly-A tract of 42 nucleotides and a second Poly-A tract of 23 nucleotides, and carried 
a 3’ transduced sequence of 51 nucleotides. The element Ref_Chr9_p23 was truncated at 
L1 position 4073, with an inversion of 754 nucleotides. This 5’ truncated element was 
therefore 2703 nucleotides in length, with first and second Poly-A tracts of 29 nucleotides, 
and a 41 nucleotide 3’ transduction. 
2.3.2: Sequence characterisation of the lineage progenitor and donor L1. 
After PCR amplification, the filled site products of the lineage progenitor and donor 
L1s were cloned and Sanger sequenced, as previously described for the de novo L1 and 
the other polymorphic insertions such as Non-ref_Chr3_p24_24.3 and Non-
ref_Chr3_p12.2_b. This allowed verification of their genomic location and their structural 
features (Figure 23 and 24).  
 
Figure 23: Genomic location and structural features of the lineage progenitor L1. 
Filled site. This figure shows a full-length L1 from the family L1-Ta [34, 207]. The insertion 
is 6043bp in length and is upstream of the characteristic genomic sequence (purple letters) 
which is found in the 3’ transductions of the rest of the family members. Insertion site 
coordinates Chr11:95,169,381. The TSDs, red letters, flank the L1 sequence and after the 
L1 sequence is a Poly-A tract of 29 nucleotides in length (bright yellow). Empty site. Red 
letters, TSD; Purple letters, gDNA from the Chromosome; Black arrow, site of first strand 
cleavage by the L1 endonuclease. 
 
63 
 
Comprehensive sequence analysis of the lineage progenitor L1 indicated a full-length 
L1 of 6043 nucleotides (Figure 23) that did not carry any transduced sequence and 
presented a single Poly-A tract of 29 nucleotides. The TSDs of the insertion were 11nt and 
the EN-motif was 5’ TT/AAAG 3’. The insertion was situated in the positive strand of 
chromosome 11, chromosomal location: Chr11:95,169,381. This insertion was in an 
intergenic region. Sequence analysis of the donor L1, which bore the de novo L1 insertion, 
indicated a full-length element of 6041 nucleotides (Figure 24) with a transduced sequence 
of 44 nucleotides and two Poly-A tracts of 17 and 21 nucleotides, respectively. The TSDs of 
the insertion were 17 nucleotides long and the EN-motif (AC/AGAA) only loosely matched 
the canonical endonuclease motif: The insertion was not located on the reference genome 
[11] and was situated on the sense strand of chromosome 3, chromosomal location: 
Chr3:38,626,082, within an intron of the gene SCN5A. The protein encoded by this gene is 
an integral membrane protein and tetrodotoxin-resistant voltage-gated sodium channel 
subunit. This protein is found primarily in cardiac muscle and is responsible for the initial 
upstroke of the action potential in an electrocardiogram. 
 
Figure 24: Genomic location and structural features of the donor L1. Filled site. This 
figure shows a full-length L1 (from the family L1-Ta [34]). The insertion is 6041 nucleotides 
in length and contains a 3’ transduced sequence (purple letters) of 44 nucleotides and 
genome flanking the L1 copy (green letters). Highlighted in green, immediately upstream of 
the element, is 10 nucleotides of genomic sequence that was incorporated into a 5’ 
transduction found on the de novo L1 insertion, from these 10 nucleotides; the 4 nucleotides 
flanking the L1 copy at the 5’ end were untemplated nucleotides and the rest were part of 
the TSD situated upstream of the L1 element (bold letters). Red letters indicate TSDs 
flanking the L1 sequence. Following the L1 sequence is the first Poly-A tract of 17 
nucleotides in length and a second Poly-A tract of 21 nucleotides. Empty site. Red letters 
indicate TSDs; Green letters indicate gDNA from the Chromosome; Black arrow indicates 
the site of first strand cleavage by the L1 endonuclease. 
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2.3.3: Sequence analysis of full-length transduction family members. 
To fully characterise the sequences of the transduction family members, I performed 
independent PCR reactions using gDNA extracted from the cell line hiPSC-CRL2429 where 
the de novo L1 insertion was discovered, followed by Sanger sequencing, to discard PCR-
induced mutations and distinguish possible allelic variants from elements that were 
determined to be homozygous due to lack of an empty-site amplicon. I obtained a consensus 
sequence for each L1. To reconstruct the consensus sequence from each element, avoiding 
PCR induced mutations from individual clones, non-mutated nucleotide sequence fragments 
were chosen to reconstruct the original consensus for each element. The resulting clones 
were verified by Sanger sequencing using 12 different primers covering the entire L1 
sequence (Figure 25).  
 
Figure 25: Cloning strategy diagram. A. Representation of the Topo-XL vector with an 
inserted L1 element. B. Representation of the overlapping sequence reads generated from 
the 12 stepping primers designed across the L1 sequence.  
 
Once I had obtained the entire sequence of the desired L1, I manually assembled 
each of the 12 independent Sanger sequencing reactions of ~500 nucleotides in length, 
which overlapped their neighbouring sequencing reads, excluding the first and the last 
sequencing reactions that only overlapped with the next and with the previous sequencing 
reaction, respectively, to create a consensus ~6 Kb of each L1. Then I aligned the 
consensus L1 sequences to one another doing a multiple sequence alignment using Clustal 
omega software (https://www.ebi.ac.uk/Tools/msa/clustalo/). Additionally, to unambiguously 
determine their retrotransposition activity, the exact sequence of each element was rebuilt 
by strategic restriction digest and reassembly of the PCR amplification products. In this way, 
a clone of each element that was identical to the consensus for that element was generated. 
Each element was reconstructed in the retrotransposition indicator backbone prior to in vitro 
retrotransposition activity assessment. 
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2.4: Comparative nucleotide and amino acid sequence analysis of the 
transduction family L1 1-14. 
I next compared the transduction lengths and Poly-A tract lengths, as well as internal 
L1 sequences where available, of the 14 transduction family members. For the de novo, 
lineage progenitor, and donor L1s, as well as Non-ref_Chr3_p24.3, I obtained accurate 
sequences for the alleles present in hiPSC-CRL2429 as described above 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) (please refer to material and methods for more 
details). I also analysed the reference nucleotide sequence of 2 full-length members of the 
family (Ref_Chr1_p31.1_a and Ref_Chr7_p21.3) found in the reference genome that, 
because of their genomic location in repetitive sequences, could not be PCR amplified and 
cloned, as described above. Two other truncated reference L1s carrying the distinguishing 
3’ transduced sequence were identified: Ref_Chr1_p31.1_b and Ref_Chr9_p23. In addition, 
three full-length (Non-ref_Chr3_p12.2a, Non-ref_Chr3_p12.2b and Non-ref_ChrX_p11.4) 
and three truncated non-reference elements (Non-ref_Chr17_q12, Non-ref_Chr1_p22.2 and 
Non-ref_Chr4_q12), were included, although the internal sequences of these elements were 
not available for comparison. Where available, the nucleotide and amino acid changes found 
among the family members were annotated relative to the previously-described “hot” L1.3 
element, relationships among family members inferred from 3’ transduction length, and the 
presence of 5’ transductions, as indicated in Figure 26. The features of these insertions are 
also summarised in Table 4.  
Notably, two allelic variants of the lineage progenitor L1 carried by the homozygous 
individual CRL2429 were identified by the presence of 4 distinct nucleotides along the L1 
sequence. Both allelic variants shared, with the rest of the family members, several 
mutations along the L1 sequence. There were 6 other mutations present in both alleles, in 
the 3’UTR and in the ORFs as indicated in Figure 26. Additionally, there were unique 
mutations carried only by one of the alleles. Allele 1 (Lineage progenitor Allele 1) contained 
1 mutation in the 5’ UTR and 2 mutations in ORF2 (Q159H and D523H), one of which 
(D523H) was located in the ORF2p RT domain (Figure 26). Allele 2 (Lineage progenitor 
Allele 2) contained a unique silent mutation not shared by the rest of the family members, 
located in the ORF2 sequence (Figure 26). I also observed that the donor L1 and the de 
novo L1 had identical nucleotide sequences. The element Non-ref_Chr3_p24.3 presented 
a stop codon at the amino acid position 559 and was hence predicted to lack 
retrotransposition capability. The de novo L1 did not present deleterious mutations in 
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conserved functional residues, indicating that this insertion (and its donor L1) could 
potentially retain retrotransposition competence.  
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Figure 26: Schematic representation of transduction family L1_1-14 members. The 
nucleotide position relative to the sequence of L1.3 is indicated with numbers on each L1 
element; changes present in all the different family members (grey), changes unique to one 
element (blue), changes present in donor L1 and de novo L1 (pink), changes present in 
some elements but not in all of the family members (black dashed lines). Specific amino 
acid changes relative to the L1.3 sequence (purple letters, next to each nucleotide change). 
Stop codon mutations (STOP). TSDs (dark blue triangles flanking the L1 copies); 5’UTR and 
3’UTR (left and right grey boxes respectively); ORF1 and ORF2 (white boxes for sequences 
which are known and grey boxed for polymorphic L1s with unknown sequences); First and 
second PolyA (An); 3’ transduced sequences with gDNA from Lineage progenitor element 
(purple line) with different nucleotide lengths depending on its case (purple line); 5’ 
transduced sequences in the de novo L1 element (orange line, 10 nucleotides), 
Ref_Chr1_p31.1_a (purple, 539 nucleotides) and Non-ref_ChrX_p11.4 (pink line; 18 nt) with 
gDNA from each immediate donor element. The donor elements that originated the 
elements presenting the mentioned 5’ transduced sequences were Donor L1 (orange line), 
Ref_Chr7_q21.3 (pink line, represents the gDNA that was transduced at the 5’genomic 
flanking DNA) and lineage progenitor (purple line, represents the gDNA that was transduced 
at the 5’genomic flanking DNA), the elements that were originated from these parental 
elements were: De novo L1, Non-ref_ChrX_p11.4 and Ref_Chr1_p31.1_a respectively.  
 
2.5: Analysis of retrotransposition activity in cultured cells.  
To evaluate the mobility and ORF1p and ORF2p biochemical activity of several 
members of the L1_1-14 transduction family, I used an established cell culture-based reporter 
assay [22]. Briefly, in this retrotransposition assay an L1 of interest is cloned into a suitable 
vectors for retrotransposition that contains an L1 driven by a promoter, in this case, its native 
internal promoter (Figure 27), and a reporter gene encoding antibiotic resistance that is in 
antisense orientation with respect to the L1 copy and is interrupted by an intron, in this case, 
neomycin phosphotransferase (NEO). In this reporter cassette, the intron is sense orientated 
with respect to the L1 copy and the reporter cassette contains its own polyadenylation signal. 
Hence, the reporter cassette is active and expresses antibiotic resistance only after splicing 
and retrotransposition, meaning that each new colony under antibiotic selection represents 
the product of a novel retrotransposition event.  
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Figure 27: Retrotransposition reporter cassette schematic. Representation of the 
unspliced retrotransposition reporter cassette, neomycin phosphotransferase gene or G418 
(purple box, named NEO), after the 3’UTR (right grey box) and spliced cassette activated 
upon retrotransposition, plus a polyadenylation signal [22]. The cassette is in antisense 
orientation relative to the L1 and carries its own polyadenylation signal, and is interrupted 
by an intron with splice donor and acceptor sites in sense orientation relative to the L1. 
 
Hela cells are well known in the L1 field to support endogenous and engineered L1 
retrotransposition [7, 22], hence I used Hela cells here to test the activity of the L1s. The 
RTSN assay rationale is represented below (Figure 28). 
 
 
Figure 28: RTSN assay timeline. Circles represent relevant days during the performance 
of the assay. Day 1 (d1), plate cells; day 2 (d2), transfection; day 3 (d3) and day 4 (d4) feed 
with media, day 5 (d5), start antibiotic selection (neomycin, +G418); days 6 to day 17, 
antibiotic added in media every other day until day 18 when the cells were fixed and stained 
for colony counting.  
 
The elements tested in this retrotransposition assay included: L1.3 as a positive 
control [28], L1.3 RT- as a negative control (reverse transcriptase mutant) [53], the donor 
L1, which was the parental element of the de novo L1 (bearing the same nucleotide 
sequence as the donor L1, and therefore not cloned and tested independently), the two 
different alleles of the lineage progenitor L1, and Non-Ref_Chr3, which was discovered in 
the RC-seq output data table of Klawitter et al. [1] and carried a predicted disabling ORF2 
mutation. The retrotransposition activity of the elements is relative to L1.3. We observed that 
the lineage progenitor Allele 2 construct exhibited the highest frequency of retrotransposition 
activity. Lineage progenitor Allele 2 exhibited higher retrotransposition activity than Lineage 
progenitor Allele 1 from the same locus but less activity than the donor L1, and hence the 
de novo L1. The donor L1 was also more active than L1.3. Compared to the positive control 
L1.3, the lineage progenitor Allele 1 presented less activity. Non-Ref_Chr3 did not show any 
L1 activity, as expected, given its mutated amino acid sequence (Figure 29). Hence, these 
results prove the retrotransposition capability of de novo L1, donor L1, and 2 different alleles 
of the lineage progenitor, which gave rise to the entire family. 
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Figure 29: RTSN cultured-cell assay shows frequent mobilisation of L1s driven by 
their native promoter. Below the histograms: RTSN assay 6 well plate pictures for each 
element. Positive control: L1.3 wild-type human L1 reference element; Negative control: RT- 
reference human L1 (L1.3 mutated) element deficient at the reverse transcriptase domain 
(RT-).  This assay was repeated 3 times (biological replicates) with similar results. Colony 
number values in each construct were normalized to wild-type L1, L1.3 reference element. 
Values represent the mean ± SD of colonies counted in 3 biological replicates with three 
technical replicates, n=9. 
 
CONCLUSIONS OF CHAPTER 2: 
In this chapter, I described an extended L1 transduction family. Although most of the 
members of this family were found by previous publications, this is the first time that the 
extent of the family has been established, with the lineage progenitor identified as its source 
element. Here, 14 different members of the transduction family have been identified, and 
the internal sequences of 8 members were thoroughly characterised. Retrotransposition 
competence in a cultured cell assay was observed for both alleles of the lineage progenitor 
L1, in the donor L1 and hence in the identical de novo L1 element. Therefore, this family 
contains members of which are still active in the human population, and can generate 
reprogramming-associated insertions in hiPSCs, such as the case of the de novo L1 
insertion, which is full-length and still capable of mobilisation. 
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CHAPTER 3: DYNAMIC METHYLATION OF THE TRANSDUCTION FAMILY AND DE 
NOVO L1 INSERTION DURING NEURODIFFERENTIATION. 
 To achieve mobilisation, a given L1 first needs to be transcribed from its 5’UTR 
sense promoter. In turn, the host genome silences L1 by methylation of the 5’UTR, reducing 
or eliminating L1 mRNA production and therefore lessening the probability of 
retrotransposition [3]. Previous studies have investigated the overall methylation status of 
the L1-Ta family in various cellular contexts, including NSCs, hESCs and hiPSCs [4, 5]. 
Other more recent studies [6-9] have investigated the methylation status of particular L1 
copies via locus-specific PCR and bisulfite sequencing. L1 has been reported as active in 
NSCs and mature neurons [4, 10, 89, 104, 136, 143]. However, the methylation status of a 
de novo L1 insertion and its donor element during neurodifferentiation has not been 
examined to date.  
 In this chapter, I investigate the methylation status of several members of the 
L1_1-14 transduction family, including the de novo L1, its donor and the lineage progenitor 
L1, in fibroblasts, hiPSCs, and during neuronal differentiation. Additionally, I sought to 
determine whether the de novo L1 insertion was hypomethylated upon retrotransposition 
and if its donor was hypomethylated at the time point where the insertion occurred.  
3.1: L1 promoter methylation changes during neurodifferentiation. 
I employed targeted bisulfite sequencing (Figure 30) to evaluate promoter 
methylation of the de novo, donor and lineage progenitor L1s in the hiPSC-CRL2429 and 
hiPSC-CRL1502 cell lines. Primers internal to the L1-Ta family 5’UTR were used to study 
the L1-Ta subfamily as a comparison. A schematic representation of the CpG dinucleotides 
within the L1 CpG island, as well as a representation of the bisulfite sequencing by locus 
specific PCR assay, are provided in Figures 30 and 31.  
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Figure 30: Schematic representation of CpG dinucleotides in the 5’UTR of an L1 
element and bisulfite sequencing work flow followed in this chapter. A. CpG 
dinucleotide positions in the L1 promoter representation: gDNA, black line; TSD, white 
triangle on the left side; 2 CpG islands; different transcription factors that bind to the L1 
promoter, YY1, RUNX and SRY; CpG dinucleotides, red vertical lines; ORF1, white box on 
the right side. B. Locus specific PCR. Specific primers and gDNA are represented in 
matching colours: overall L1 population, in this case the L1-Ta subfamily, dark blue primers 
aligning to the 5’UTR of the L1 copy; lineage progenitor, light blue; donor L1, purple; de novo 
L1, green. Elements of this figure were adapted from Faulkner & Garcia-Perez  [127]. 
For technical reasons, the Illumina MiSeq platform cannot fully span fragments bigger 
than 600 nucleotides, as paired-end sequencing is limited to 2300bp reads. To include 
genomic DNA upstream of each specific L1 copy, and therefore be able to unequivocally 
assign reads to that L1, meant a maximum of 35 CpG dinucleotides in the L1 5’UTR could 
be studied for each elements (Figure 31).  
 
 
Figure 31: Schematic representation of the L1-specific bisulfite sequencing analysis. 
Black circles represent CpG nucleotide positions. Black arrows represent the reverse primer 
that was used in all the PCR amplification reactions. Pink arrow represents the location were 
the primers were designed to perform locus specific PCR with a maximum of 600 nucleotides 
72 
 
fragment size. Purple arrow represents the location were the primers were designed to 
perform the study of the overall L1-Ta population. Note: the L1-Ta subfamily amplicon 
covers 28 CpGs, whilst the L1-specific reactions cover 35 CpGs. 
3.1.1: L1 promoter methylation assessment in the cell line hiPSC-CRL2429. 
All the studied elements, including the L1-Ta subfamily, were less methylated in 
hiPSCs as compared to fibroblasts in hiPSC-CRL2429, as expected (Table 5, Figure 32). 
They then gradually became methylated during neurodifferentiation. The donor L1 exhibited 
lower levels of CpG methylation (31.1%) than the L1-Ta subfamily and lineage progenitor 
L1 (67.3% and 67.0%, respectively). This methylation profile was consistent with results 
obtained from hiPSC-CRL1502 (see below). Below is summarised the CpG methylation 
percentages obtained in each cell lines (Table 5).  
 
Cell line 
     
 
hiPSC-
CRL2429 
 
Total CpG: 
 
L1-Ta 
subfamily 
 
Lineage 
progenitor  
 
Donor L1 
 
De novo L1 
T0 Fibroblasts (HDFs) 68.7 81.2 66.6 Not present 
T1 hiPSCs 67.3 67.0 31.1 * 
T2 Neural epithelial 69.1 82.2 45.3 40.2 
T3 Immature neurons and 
neural rosettes 
74.8 84.4 53.8 34.4 
T4 Neurons I and neural 
rosettes 
79.4 88.6 69.3 53.0 
T5 Neurons II and neural 
rosettes 
63.2 65.8 39.6 29.3 
T6 Neurons III and neural 
rosettes 
76.8 89.5 61.0 51.1 
 
hiPSC-
CRL1502 
 
Total CpG: 
 
L1-Ta 
subfamily 
 
Lineage 
progenitor  
 
Donor L1 
 
De novo L1 
Not present 
T0 Fibroblasts (HDFs) 69.8 83.2 59.5  
T1 hiPSCs 65.4 72.4 45.1  
T2 Neural epithelial 69.7 75.9 36.9  
T3 Immature neurons and 
neural rosettes 
73.3 79.9 41.0  
T4 Neurons I and neural 
rosettes 
75.8 84.4 55.0  
T5 Neurons II and neural 
rosettes 
67.7 74.0 59.1  
T6 Neurons III and neural 
rosettes 
70.1 81.7 70.1  
Table 5: Summary of the total CpG methytlation percentages in hiPSC-CRL2429 and in hiPSC-
CRL1502. T, time point. *; I did not recover enough distinct amplicons to reliably characterise this 
promoter. 
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In hiPSC-CRL2429, and its derivatives, the de novo L1 exhibited the lowest 
methylation percentage when compared to the donor L1, lineage progenitor and to the L1-
Ta subfamily across all time points where it could be detected (Figure 32). However, a 
sufficient cohort of distinct amplicons of the de novo L1 could not be generated in the 
hiPSCs, where it originated, to reliably characterise this promoter. The de novo was 
hypomethylated during early stages of differentiation, showing a minimum of 34.4% CpG 
dinucleotides methylated within the immature neurons and neural rosettes (T3) (Figure 32). 
From T2 to T6, the de novo L1 was dynamically methylated, with values of 40.2% (T2), 34.4% 
(T3), 53.0% (T4), 29.3% (T5) and 51.1% (T6). The drop at T5 from T4 was a general trend 
among all of the different promoters analysed and was statistically significant for each 
(paired t-test; p<0.001). I also observed significant re-methylation in T6 (paired t-test; 
p<0.01) among all elements (Figure 32 and 33). 
The donor L1 exhibited the lowest levels of CpG dinucleotide methylation in 
fibroblasts, 66.6%, compared to the overall L1-Ta subfamily, 68.7%, and to the lineage 
progenitor L1, 81.2% (Table 5). Indeed, the donor L1 promoter was fully unmethylated 
(CpGs in a row all represented as white circles) in numerous hiPSCs (T1), the context where 
the de novo L1 insertion was most likely to have occurred (Figures 32 and 34). By contrast, 
the lineage progenitor L1 was more methylated than the donor and de novo L1 across all 
the different time points. Additionally, L1 promoter methylation observed amongst the overall 
L1-Ta subfamily were higher in all the different time points than the values obtained for the 
donor L1 or the de novo L1 (Table 5). One potential explanation for this trend is the presence 
of a FOX (forkhead box) protein, a class of pioneer transcription factor, binding site in the 
10bp 5’ transduction carried by the de novo L1 [208]. This binding site may have facilitated 
hypomethylation of the donor L1 and de novo L1, in comparison to the lineage progenitor 
L1, which did not carry the upstream FOX binding motif. 
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A. L1-Ta subfamily, hiPSC-CRL2429 cell line 
 
 
 
B. Lineage progenitor, hiPSC-CRL2429 cell line 
 
 
 
C. Donor L1, hiPSC-CRL2429 cell line 
 
 
 
D. De novo L1, hiPSC-CRL2429 cell line 
 
Figure 32: Methylation of L1_1-14 family member 5’UTRs in the hiPSC-CRL2429 cell 
line. Cartoons represent the methylation status of 50 randomly selected bisulfite sequencing 
reads comprising locus-specific PCR products at the 5’ junctions of L1 sequences. 
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Transduction family members were analysed during hiPSC generation and 
neurodifferentiation in the hiPSC-CRL2429 cell line. Each column corresponds to a different 
time point (studied cell type, or time point, is indicated in the top of each column) (T0= 
fibroblasts; T1= hiPSCs; T2= Neural epithelial; T3= Immature neurons and neural rosettes; 
T4= Neurons I and neural rosettes; T5= Neurons II and neural rosettes; T6= Neurons III and 
neural rosettes); each line contains the same set of L1 5’UTR CpG dinucleotides: A. L1-Ta 
subfamily population; B. Lineage progenitor; C. Donor L1; D. de novo L1 insertion. Red 
numbers below each panel indicates the CpG percentage in each time point for each studied 
5’UTR. 
  
The following graphs (Figure 33) summarise the methylation dynamics of each CpG 
dinucleotide in each targeted element from T0 to T6. Note the low levels of methylation of 
the de novo L1 during the early stages of differentiation (Figure 33, C-D) and its progressive 
methylation from neural epithelial (T2) to mature neurons I, neural rosettes T4 and the drop 
at T5 to get methylated again in T6 mature neurons III, neural rosettes. Also note that 
differences in methylation amongst the various elements are due to broad changes, where 
the vast majority of CpGs are differentially methylated, rather than just one or two (e.g. 
compare the donor and lineage progenitor L1s in Figure 33B). 
 
 L1-Ta subfamily population 
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Figure 33: L1 promoter CpG methylation levels during neurodifferentiation time 
courses graphs I. A to G figures contain the methylation level (y-axis) in each time point 
the cell line hiPSC-CRL2429 along the L1 sequence (x-axis) of the different CpG 
dinucleotides. Graph legends: L1-Ta subfamily population (black lines); Donor L1 (blue 
lines); de novo L1 (red lines); Lineage progenitor (grey lines). 
 
3.1.2: L1 promoter methylation assessment in the cell line hiPSC-CRL1502. 
In the hiPSC-CRL1502 cell line, the donor L1, lineage progenitor L1 and L1-Ta 
subfamily population exhibited, in general, similar methylation patterns to those observed in 
the hiPSC-CRL2429 cell line (Figure 34). For instance, the donor L1 was less methylated 
in fibroblasts (59.5%) than in hiPSCs (45.1%). Overall, CpG dinucleotides in the donor L1 
5’UTR were less methylated than those present in the lineage progenitor L1 or the broader 
L1-Ta subfamily (Table 5). In the case of the lineage progenitor L1, CpG methylation levels 
were higher than for the donor L1 at each time point and, again as for hiPSC-CRL2429, the 
L1-Ta subfamily was less methylated than the lineage progenitor L1, and more methylated 
than the donor L1 (Table 5). Again, across all samples tested, methylation levels were 
higher at T0 than at T1, and the overall methylation state of most L1 promoters decreased 
between T4 to T5 and then increased between T5 to T6. 
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A. Overall L1-Ta population, hiPSC-CRL1502 cell line 
 
 
 
B. Lineage progenitor, hiPSC-CRL1502 cell line 
 
 
 
C. Donor L1, hiPSC-CRL1502 cell line 
 
 
Figure 34: Methylation of L1_1-14 family member 5’UTRs in the hiPSC-CRL1502 cell 
line. Cartoons represent the methylation status of 50 randomly selected bisulfite sequencing 
reads comprising locus-specific PCR products at the 5’ junctions of L1 sequences.  
Transduction family members were analysed during hiPSC generation and 
neurodifferentiation in the hiPSC-CRL1502 cell line. Each column corresponds to a different 
time point (studied cell type, or time point, is indicated in the top of each column), (T0= 
fibroblasts; T1= hiPSCs; T2= Neural epithelial; T3= Immature neurons and neural rosettes; 
T4= Neurons I and neural rosettes; T5= Neurons II and neural rosettes; T6= Neurons III and 
neural rosettes); each line contains the same set of CpG dinucleotides at L1 5’UTR region, 
each line contains a specific element of the family: A. L1-Ta subfamily population; B. 
Lineage progenitor; C. Donor L1; Red numbers below of each panel indicates the CpG 
percentage in each time point for each studied 5’ UTR. 
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3.2: Overall L1 promoter CpG methylation levels during neurodifferentiation. 
To facilitate comparisons amongst the various elements considered in the study, I 
generated average CpG methylation percentage values for each time point (Figure 35), 
Interestingly, in both cell line, the methylation status of the de novo L1 (hiPSC-CRL2429 
only), donor L1 and lineage progenitor L1 appeared to increase with the relative age of each 
element.  
A.                                         B.    
 
Figure 35: L1 promoter CpG methylation levels during neurodifferentiation time 
courses graphs II. (A and B) contain methylation level (y-axis) of the total CpG 
dinucleotides values in cell line hiPSC-CRL2429 (A) and in cell line hiPSC-CRL1502 (B) in 
each TP (T0= fibroblasts; T1= hiPSCs; T2= Neural epithelial; T3= Immature neurons and 
neural rosettes; T4= Neurons I and neural rosettes; T5= Neurons II and neural rosettes; T6= 
Neurons III and neural rosettes). Graph legends: Overall L1 population, L1-Ta subfamily 
population (black line); Donor L1 (blue line); de novo L1 (red line); Lineage progenitor (grey 
line). 
 
CONCLUSIONS CHAPTER 3: 
In summary, all of the elements were relatively hypomethylated in hiPSCs, as 
expected, and were gradually methylated upon induction of somatic differentiation. The de 
novo L1 was hypomethylated shortly after retrotransposition in neural epithelial cells and it 
was gradually methylated during somatic differentiation, consistently presenting less 
methylation than the rest of the family members. In addition, the methylation status of the 
de novo L1, donor L1 and lineage progenitor L1s was correlated with their relative age in 
hiPSC-CRL2429 and hiPSC-CRL1502. Remarkably, shifts in methylation levels in some 
instances generated L1 promoters that were fully unmethylated in some cells, making their 
transcriptional activation plausible. These results reveal dynamic and distinct changes in 
methylation applied to germline and de novo L1 insertions during neurodifferentiation.  
 
L1-Ta subfamily population 
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CHAPTER 4: DISCUSSION 
This project has significantly elucidated how closely related L1 elements are distinctly 
repressed by their host genome during cellular reprogramming and differentiation. To this 
end, I first identified a de novo reprogramming-associated L1 insertion in hiPSCs. I used the 
5’ and 3’ transduced sequences carried by this full-length L1 retrotransposition event as 
unique sequence tags to identify its immediate donor L1, and to then place these elements 
within an extended transduction family, composed of both reference and non-reference L1 
elements. Although most of the family members described in this study have been identified 
in isolation by prior reports, my work is the first to describe these elements together as a 14 
member family, which has expanded in the germline genomes of presumably healthy human 
individuals (Table 3).  
The first evidence of extended L1 transduction families was provided by Goodier et 
al. [81]. In this study, the authors analysed L1 sequences present in the human and mouse 
reference genomes. They concluded that 23% of the analysed human L1s carried a 3’ 
transduced sequence and, interestingly, they found a mouse L1 insertion bearing sequential 
transduction events. This finding pointed to the existence of L1 families where a daughter 
insertion retains the ability to mobilise again, resulting in more family members. Other 
transduction families have since been characterised by studying the L1 content of a subset 
of individuals [11, 12]. For example, by sequencing fosmid libraries generated from genomic 
DNA from 6 individuals, Beck et al., identified a cohort of polymorphic full-length L1s bearing 
3’ transductions, and proposed a model of L1 mobilisation where active L1s give rise to 
small subfamilies. A different study took advantage of the presence of 3’ transductions to 
develop a new method for the identification of active L1 lineages, named Transduction‐
Specific Amplification Typing of L1 Active Subfamilies (TS-ATLAS) [12]. This method 
combined the enzymatic digestion of genomic DNA with the creation of plasmid libraries and 
subsequent L1-specific PCR to identify L1-genome junctions. The authors identified three 
separate polymorphic L1 transduction families using this approach. Despite the prominent 
role these previous studies have played in the discovery of L1 transduction families, the 
L1_1-14 transduction family described in this thesis was not completely characterised 
previously, and it generated the first instance of an RC-L1 being associated with a de novo 
insertion in hiPSCs.  
It is possible the L1_1-14 transduction family could contain more members not 
identified in this study. Many of the family members identified here were polymorphic, and it 
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is unlikely that any individual would carry all of them. It follows that rarer polymorphic 
elements forming part of the transduction family are present in the global population. Also, 
to assign a particular L1 to this transduction family, I relied exclusively on the presence of 
transduced sequences. According to a prior estimate based on the presence of 3’ genomic 
transduced sequences downstream of 129 referenced full-length elements, only around 
10% of full-length L1s carry 3’ transductions [82]. Therefore, there are almost certainly L1 
insertions that originated from the family, but lacked transductions, and are therefore 
overlooked by my analysis. This highlights the importance of developing new methodologies 
to study the complete sequence of L1s, to identify internal nucleotide variants that allow 
classification of individual L1s into particular lineages [9, 87 ].  
Remarkably, 3 of the 14 family members carried 5ʹ transductions. This 5ʹ transduction 
frequency (21.4%) is exceptionally high, given how rarely such events are found in the 
human germline (<0.1% of L1-Ta insertions [15]) and to my knowledge, a de novo L1 
insertion with both 5’ and 3’ transduced sequences has never been reported before. It is 
presently unclear as to why 5ʹ transductions are so frequent in this family. Two of these 5ʹ 
transductions were relatively short (10nt, de novo L1; 18nt, Non-ref_ChrX_p11.4) and could 
be derived from the transcription initiating upstream of L1 position +1 directed by the L1 5’ 
promoter region [209]. In contrast, the third 5ʹ transduction identified in the element 
Ref_Chr1_p31.1_a was significantly longer, at 539 nucleotides, and is located ~126Kb 
upstream of the parental element. This suggests the transcription started at a distal promoter 
element and the regions between the transduced sequence and the L1 element were spliced 
out from the template mRNA. 
Notably, certain chromosomes appear to have been targeted with disproportionate 
frequency by members of this transduction family. To elaborate, de novo L1, 
Ref_Chr1_p31.1_a, Ref_Chr1_p31.1 and Non-ref_Chr1_p22.2 were found on Chromosome 
1, and the donor L1, Non-ref_Chr3_p24.3, Non-ref_Chr3_p12.2_a and Non-
ref_Chr3_p12.2_b landed on Chromosome 3. Therefore, I speculate that certain L1 
transduction families could have predisposition for inserting in genomic locations in physical 
proximity to their source element. Previous studies have described that proteins such as 
Hop1 and Red1, involved in resolving recombination intermediates during yeast meiosis, 
are influenced by chromosome structure [210]. Specific proteins and host factor with similar 
preferences could be directing nuclear L1-RNPs to certain chromosome locations with the 
appropriate structure, in this case the chromosomes 1 and 3.   
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  Of the 14 family members identified here, 2 were already reported and tested for 
retrotransposition activity in previous studies; the donor L1, polymorphic in the human 
population and absent from the reference genome sequencing, [11] and the lineage 
progenitor of the L1 family, reported to be fixed in the human population and inactive [13]. 
Consistent with the results from Beck et al. [11], I found that the donor L1 (and de novo L1) 
were retrotransposition competent in a cultured cell retrotransposition assay. Interestingly, I 
also observed retrotransposition competency for two different alleles of the lineage 
progenitor L1 in vitro, demonstrating allelic heterogeneity for this element in the human 
population, and the potential consequences of this variation. Exhaustive sequence analysis 
to discard PCR induced mutations was not performed by Brouha et al., where the lineage 
progenitor L1 was also assayed for retrotransposition [13]. In this thesis, I used a PCR based 
method, as for Brouha et al. [13], and by combining independent PCR amplification reactions 
to reconstruct elements. I performed Sanger sequencing on the entire length of the PCR 
fragment, identifying PCR induced mutations and reconstructing the L1s based on 
consensus sequences, where necessary. Via this method, I achieved similar levels of 
nucleotide sequence accuracy as the fosmid sequencing method used by Beck et al. [11]. 
Furthermore, I tested each of the two lineage progenitor L1 alleles in vitro. Brouha et al. did 
not publish the nucleotide sequences of the elements they tested [13], meaning I could not 
assess whether Brouha et al. tested one of the lineage progenitor L1 alleles considered 
here, or whether its previous assessment as an inactive element was due to point mutations 
introduced into the element’s nucleotide sequence during PCR amplification during the 
cloning process. This discrepancy in the retrotransposition capability of the lineage 
progenitor L1 emphasizes the importance of allele specific analysis and demonstrates that 
some previously reported inactive L1s may in fact have active alleles in the human 
population.  
 As noted above, the lineage progenitor L1 alleles described in this study showed 
different retrotransposition capacities. Allele 1 carried a missense mutation (D523H) in the 
reverse transcriptase domain, which could explain its reduced retrotransposition activity 
compared to allele 2. The effect of this mutation has not been described in the literature but 
its location within the reverse transcriptase domain leads me to speculate that it could impact 
ORF2p reverse transcriptase activity directly, or interfere with the interaction of the L1 mRNA 
with ORF2p, or perhaps alter the interaction of the ribonucleoparticle with host factors 
involved in L1 retrotransposition [14, 167, 211, 212]. 
Once I had characterised the de novo L1 and its source transduction family, I 
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exploited a multiplexed targeted L1 bisulfite sequencing strategy [6, 7] to survey CpG 
methylation amongst these elements during reprogramming and neurodifferentiation. DNA 
methylation is a critical mechanism of defence against retrotransposons [213, 214]. L1 
sequences are silenced via DNA methylation of the L1 5’ UTR promoter region very early in 
mammalian embryogenesis [1, 4, 10, 116, 215, 216] and this repression is maintained in 
mature neurons. However, the dynamics of this methylation during neurodevelopment is 
relatively unexplored. Broadly, I observed that L1 promoters were methylated in fibroblasts, 
demethylated in hiPSCs, and gradually remethylated during neurodifferentiation. However, 
the magnitude of these changes varied greatly amongst the elements. I found that the donor 
L1 was recurrently hypomethylated when compared to the lineage progenitor L1 and the 
overall L1-Ta population in hiPSCs, and presented numerous cells where its promoter was 
fully unmethylated. This hypomethylated status suggests that the donor L1 could be 
transcriptionally active, and thus has the potential to generate mRNAs and new insertions 
in hiPSCs, as demonstrated by the discovery of a de novo L1 insertion generated by the 
donor L1. The potential for endogenous L1 mobilisation in hiPSCs should therefore be taken 
into consideration in discussing their use in medical therapies [217]. 
Notably, I observed a decrease in L1 methylation coincident with a potential gliogenic 
switch at T5 [218, 219] that could potentially lead to the activation of L1. Although DNA 
methylation plays a prominent role in regulating this switch [220], the status of L1 promoter 
methylation has not been studied in gliogenesis. As L1 can be used as a surrogate of global 
DNA methylation [37, 221], I speculate the decrease in L1 promoter methylation relates to 
the genome-wide epigenetic changes associated with this gliogenic switch. 
Hypomethylation of L1 promoters suggests a window of opportunity may arise for L1 to 
mobilise in those cells entering the gliogenic switch. However, it is worth mentioning that the 
gliogenic switch observed in my neurodifferentiation does not necessarily resemble in vivo 
gliogenesis. In fact, Sun et al. described how older neural cultures enter glial differentiation 
processes in response to signals that induce neurodifferentiation in younger cultures [219]. 
Therefore, the gliogenic switch I observed in the final stages of the neurodifferentiation may 
not be the same as in vivo gliogenesis and thus, the window of opportunity for L1 
retrotransposition may not lead to accumulation of L1 insertions in glial cells. This view is 
broadly supported by the literature evidence for L1 mobilisation [4, 104, 107, 143]. Single-
cell in vivo studies have demonstrated that neurons accommodate more endogenous 
retrotransposition than glia [143]. 
Overall, I observed a correlation between the age and methylation level of the L1 
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promoters included here. While the de novo L1 was hypomethylated relatively shortly after 
its integration, the donor L1 was more methylated than this de novo L1 insertion. 
Interestingly, the lineage progenitor L1 was consistently more methylated than the donor L1, 
in hiPSCs and during neurodifferentiation. These findings suggest that younger L1s may be 
less methylated than older L1s during early embryogenesis, which hiPSCs are a model of. 
However, it is notable that I only interrogated the methylation state of these elements in 2 
hiPSC cell lines and therefore it is unknown whether the same patterns are observed in 
hESCs or, for that matter, during human development in vivo. L1 promoter methylation has 
not been previously explored for the multipotent and immature neuronal cell types arising 
during neurogenesis. Interestingly, I found that de novo L1 remained quite hypomethylated 
during neural induction and neurodifferentiation. This result is consistent with previous 
publications that found sustained hypomethylation of de novo full-length L1 insertions from 
an engineered L1 reporter [222]. Therefore, I speculate that host genomes may need some 
rounds of cell cycling to recognize a de novo retrotransposition event and activate their 
defence mechanisms, in this case at the epigenetic level. 
Given L1 hypomethylation was observed early in neuronal differentiation, it is perhaps 
surprising that I did not detect any additional de novo L1 insertions in mature neurons. 
However, this does not necessarily mean that L1 mobilisation did not take place, as any 
insertion would need to be present in enough cells to be detected at the RC-seq read count 
thresholds used here. Moreover, if a retrotransposition event took place during later 
neurodifferentiation, in immature or fully mature neurons, it would likely be present only in 
the cell where it arose because, at this stage of differentiation, the culture is composed of 
non-dividing cells. As I analysed genomic DNA from bulk cells, it is very difficult to achieve 
enough coverage to accurately identify an event which will only be present in one cell and 
PCR validate that event [127]. This could be partially solved by applying single-cell RC-seq 
[143] to a cohort of cells in different stages of neurodifferentiation. However, if a de novo L1 
event was identified in a particular mature neuron, it would be very difficult to accurately infer 
when during differentiation that retrotransposition event took place. By using clonally 
expanded hiPSCs and analysing enough single-cells from each time point of 
neurodifferentiation it could nonetheless be possible to establish the pattern of when de 
novo L1 insertions predominantly accumulate. This approach could inform our general 
picture of how and when neural somatic mosaicism arises in the human brain [127]. 
The de novo L1 insertion most likely arose during hiPSC generation and was 
maintained during neural induction and neurodifferentiation, indicating that such events can 
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be present in differentiated cell lines derived from hiPSCs. However, despite sensitive PCR 
reactions showing an absence of the de novo L1 in DNA extracted from the matching 
fibroblasts, it is impossible to be sure that this L1 insertion was not in fact mosaic in the 
parental fibroblasts. To take this to an extreme, perhaps the L1 insertion was present in only 
one cell, and that cell was consumed by reprogramming, removing it from the parental 
fibroblast population. Nonetheless, we considered the L1 insertion to be “most likely” de 
novo because: i) L1-Ta family promoter sequences are heavily methylated in fibroblasts and 
hypomethylated in hiPSCs [1, 116], ii) L1 expression increases greatly during 
reprogramming [1, 223], iii) a prior WGS analysis of 10 human fibroblast populations 
expanded from single cells found no de novo L1 insertions [224]. For these reasons, the L1 
insertion was very unlikely to occur in a fibroblast, supporting its annotation as being a de 
novo event during reprogramming. 
The de novo L1 was a full-length insertion with no disabling mutations in its ORFs, 
and, as predicted, was retrotransposition competent in cultured cells. This insertion, like 
other de novo full-length events, could continue to impact the host genome, creating new 
daughter insertions and disrupting the genome with a cascade effect. In this case, the de 
novo L1 was intergenic and the accompanying transductions did not include protein-coding 
exons or regulatory elements [83], lessening the probability of a functional impact in neurons 
carrying the L1. Nonetheless, it is plausible that in the future by screening more hiPSC lines 
we could identify whether this de novo L1 insertion, or other similar insertions, impact the 
phenotype of hiPSC-derived cells.  
Although DNA methylation strongly regulates the transcriptional activity of L1, there 
are other host factors able to restrict L1 activity. The adaptive methylation of 
retrotransposons seems to be influenced by the piRNA pathway [191, 192]. Piwi proteins 
act upstream of DNMT3L on repeats elements in mice [191, 192]. However, Piwi proteins 
are also known to regulate transposable elements (TEs) by targeting transcripts of active 
transposons [225]. In fact, a recent study showed the participation of Piwi proteins in 
controlling L1 retrotransposition in hiPSCs [159]. Piwi proteins also interact with the helicase 
MOV10-like-1 to silence retrotransposons in the mouse germline [193]. Thus, Piwi proteins 
could be regulating L1 activity in hiPSCs by targeting L1 mRNAs produced from the new L1 
insertions which escaped restriction at the epigenetic level.   
The findings described in this thesis support the hypothesis that L1 retrotransposition 
can have a multiplicative effect upon the genome, as a new L1 insertion can escape 
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repression and mobilise again and therefore have an exponential impact. Since the L1 family 
lineage described here is the largest transduction family discovered to date, it would be 
desirable to characterise it in additional hiPSC lines, and in hESCs. This approach could 
answer the following questions: i) Are there as-yet undescribed members of the L1_1-14 
transduction family in the human population? ii) Is the activity of the L1_1-14 family more 
prevalent in hiPSCs than in hESCs or other cell types? iii) Is the L1_1-14 family especially 
active in pluripotent cells compared to other L1 elements? And iv) Should L1 be considered 
a relevant mutagen when using hiPSCs in medical therapies? On this final point, the vast 
majority of L1 insertions found in hiPSCs and in hESCs are full length [1, 2, 115]. Do 
pluripotent cells hence provide a more “friendly” environment for L1 retrotransposition to 
generate full-length insertions. Although we lack a sufficient number of L1 insertions 
identified as de novo in hiPSCs to answer this question, it would nonetheless be sensible to 
further examine L1 mutagenesis during reprogramming as hiPSCs and their derivatives are 
being increasingly proposed as biomedical tools. It is also notable that other classes of 
mutation are encountered in hiPSCs, and that the epigenomic landscape can differ among 
hiPSC lines derived from the same cell type, leading to fluctuations in gene expression [226]. 
For these reasons, in the future it will be beneficial to fully characterise the genomes and 
epigenomes of numerous hiPSC lines and differentiate these into the broad range of mature 
cell types found in human organs. It would also be interesting to evaluate hiPSC genomes 
where retrotransposition is artificially bolstered and hindered, potentially using dCas9 fused 
to activator and repressor complexes [227]. 
In sum, this thesis identifies an L1 transduction family that is active during 
reprogramming, probably due to specific relaxation of DNA methylation via a mechanism 
that remains to be determined. More importantly, my results show how a new L1 insertion 
arising in a pluripotent stem cell can be recognized by the host genome and targeted for 
repression via DNA methylation, whilst still retaining capacity for further retrotransposition, 
even in mature neurons. This thesis therefore elucidates a key temporal aspect of the 
evolutionary “arms race” between mobile genetic elements and their host genome in somatic 
cells.  
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CONCLUSIONS 
1. A de novo, full-length L1 insertion which most likely arose during reprogramming 
or early during the culture of hiPSCs was detected by RC-seq and PCR validated. 
2. This is the first de novo L1 insertion described in hiPSCs carrying a 5’ transduced 
sequence and a 3’ transduced sequence. 
3. The donor for the de novo L1 insertion was the first such element identified in 
hiPSCs and retained retrotransposition capability in vitro.  
4. Further analysis revealed the donor L1 was related to numerous other L1s carrying 
a common 3’ transduction, elucidating an L1 “transduction family” I named L1_1-14. 
5. The lineage progenitor L1 of the L1_1-14 family was also active in vitro, and 
presented 2 allelic variants. 
6. Bisulfite sequencing revealed that the donor L1 was hypomethylated in hiPSCs 
and was gradually remethylated during neurodifferentiation. The donor L1 was less 
methylated than the lineage progenitor L1, but more methylated than the de novo L1 
insertion. 
7. The de novo L1 insertion was hypomethylated relatively shortly after 
retrotransposition, during neural induction, and also gradually more methylated upon 
neuronal differentiation, suggesting common mechanisms methylated the de novo and 
donor L1s. 
8. Cells carrying fully unmethylated L1-Ta sequences, including the de novo and 
donor L1s, were present throughout neurodifferentiation in vitro. This observation could 
explain somatic retrotransposition during human neurogenesis. 
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MATERIAL AND METHODS   
hiPSC generation and neuronal differentiation. 
The cell lines hiPSCs were episomally derived as described in [203]. as described by 
Shi et al., [203] Neuronal differentiation was performed with some minor changes in the 
protocol [203]. Feeder-free hiPSCs were cultured in MEF-conditioned KOSR medium 
(Gibco®) prior induction of neurodifferentiation, the cells were supplemented with 100ng/mL 
b-FGF. The addition of dual SMAD inhibitors SB431542 (10µM) and dorsomorphin (1µM) 
into the KOSR media initiated neurodifferentiation. The inhibitors were swapped for  3N 
medium (1:1 media mix of N2 and B27 containing media that contained of 1:1 
neurobasal/DMEM-F12 media which was supplemented with 2% B27, 1% N2 and 2mM 
GlutaMax, 2.5µg/mL Insulin, 0.05mM NEAA, 0.05mM beta-mercaptoethanol (all from the 
company LifeTechnologies) in 25% incremental steps on days 4, 6, 8, 10. Matrigel-coated 
TC dishes  were used to grow and harvest Neural rosettes , these cells were expanded in 
3N medium adding the grow factor 20ng/mL b-FGF. Neuronal progenitors, were grown, 
approximately at day 30 using StemPro Accutasse Dissociation reagent (Thermo Fisher 
scientific) to obtain single cell solution to further seeding them in coated dishes. The dishes 
were coated with poly-L-ornithine (0.01% weight/volume and laminin (20µg/mL, 
respectively). For the indicated time points of this experiments, neural progenitors were feed 
in 3N medium.  
Immunocytochemistry. 
Neural cultures were fixed using 4% paraformaldehyde (Sigma) in PBS for 15min at 
room temperature and they were permeabilised in 0.01% Triton-X100 (Ajax Finechem) on 
Matrigel coated plastic cover slips in 3N media and were fixed in 4% paraformaldehyde 
(Sigma) in PBS for 15min at room temperature and permeabilised in 0.01% Triton-X100 
(Ajax Finechem) in PBS for 15min at room temperature. All cells were blocked for 1hr with 
10% goat serum (Invitrogen) in PBS. Primary antibodies used were OCT4 (1:100, Millipore), 
NANOG (1:100, Millipore), CUX1 (1:100, Abcam), GFAP (1:250, DAKO), TUBB3/TUJ1 
(1:1000, Covance), BRN2 (1:100, Abcam), PAX6 (1:1000, DSHB), anti-phospho-histone H3 
(Ser10) (1:200, Cell Signaling Technology) and were applied for 3-4hr at room temperature 
or overnight at 4°C. Isotype- and species-matched Alexa-Fluor conjugated secondary 
antibodies (1:1000, Invitrogen) were applied for 1hr at room temperature. Cells were washed 
in PBS and mounted on glass slides with prolong gold antifade containing DAPI (Invitrogen) 
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and imaged using an Olympus IX51 (Olympus) fluorescent microscope equipped with 
MicroPublisher 3.3 RTV CCD camera (QImaging) using Q-Capture Pro v6.0 software. 
Nucleic acid extraction. 
Per time point, 500,000 cells approximately were pelleted (1000 rpm, for 5 minutes), 
then washed with Dulbecco’s Phospate Buffered Saline (DPBS) (-Calcium Chloride, -
Magnesium Chloride) 1x (Gibco®). Then, the cells were pelleted another time with the same 
conditions and resuspended in UltraPure™ DNase/RNase-Free Distilled Water (Gibco®) in 
a volume of 100uL of Cells were lysed in 10mM Tris pH 9.0, 1mM EDTA, with 2% SDS and 
100ug/mL proteinase K at 65°C. RNAse A was added to each sample in final concentration 
of 10ug/mL, samples were incubated at 37°C for 30 minutes. Using Phenol, DNA was 
extracted with phenol:chlorophorm:isoamyl alcohol (25:24:1) and chloroform:isoamyl 
alcohol (24:1). DNA was precipitated using with 0.1 volume of 3M sodium acetate and 2.5 
volumes of 100% isopropanol. DNA was precipitated and then washed in 0.8 mL 75% EtOH, 
slightly air dried and resuspended in 50 µL of UltraPure™ DNase/RNase-Free Distilled 
Water (Gibco®). The quality and quantity of DNA were assessed by NanoDrop (Thermo 
Fisher Scientific) and Qubit using Qubit ® dsDNA HS Assay kit (Thermo Fisher Scientific), 
Qubit ® Assay Tubes and Qubit ® Fluorometer, following the manufacturer instructions. 
Retrotransposon capture sequencing (RC-seq). 
Extracted gDNA from the two hiPSC cell lines, hiPS-CRL2429 and hiPS-CRL1502 
and from each time point, T0, T1, T2, T3, T4, T5 and T6 was analysed by RC-seq, as described 
previously [143]. Briefly, the gDNA was sheared aiming to obtain ~450 nucleotides length 
fragments in 110uL of buffer TE: 10mM Tris-HCl, 1mM EDTA, pH8, using Covaris M220 
Focused-ultrasonicator electronically controlled by Sonolab software with the protocol 
Covaris S220 (peak power, 50; duty factor, 10; cycles per burst, 200; duration, 90 seconds).  
Concentrate DNA: 
The sheared DNA was concentrated to the desired fragment size using 1.1 volumes 
of re-suspended room temperature Agentcourt® AMPure® XP beads (Beckman coulter), 
incubation was performed at room temperature for 15 minutes followed by separation of the 
beads with a DynaMag TM-2 Side magnetic rack (Thermo Fisher Scientific) for 2 minutes. 
Supernatant was transferred to new tubes and 400μL of 80% absolute ethanol (molecular 
grade) were added to wash the samples twice, supernatant was removed, and the tubes 
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were air dried removing them from the magnetic stand and allow them to dry for 15 minutes. 
52uL of resuspension buffer (RB) were added to the tubes, incubate them at room 
temperature for 2 minutes, then the tubes were placed again for 2 minutes in the magnetic 
stand to remove the beads. 
DNA quantification:  
After shearing the gDNA to perform library preparation gDNA was measured to 
equalise all the samples to the lowest concentration obtained to use the same amount of 
DNA in the library preps using Pico Green Assay Kit (Sigma Aldrich). 
Library Preparation: 
Library preparation was then proceeded performing Illumina® TruSeq® Nano DNA 
Sample Prep Kit (Illumina®FC-121-4001/2) from 2µg input gDNA following the manufacturer 
instructions with some few modifications in the performance of the LM-PCR. The Illumina kit 
contains End Repair Mix, A-Tailing Mix, Stop Ligation Mix, Resuspension Buffer and a set 
of 16 Illumina Barcoded Library Adapters to its further use. Prior LM-PCR reaction agarose 
size selection was performed on High Resolution Agarose (Sigma-Aldrich). The gel 
electrophoresis was run at 120mA until the fragments were separated were enough. Bands 
were cut aiming to obtain fragments of 380-410 bp. The gel cuts were purified with 
MiniElute® Gel Extraction Kit (Quiagen). The LM-PCR was performed using 50μl Phusion 
High-Fidelity PCR Master Mix (2x), 18μl molecular grade water,1μl of each primer (TS-F 
Primer TS-R Primer) at 100μM, 30μl DNA library in a final volume of 100μl with the following 
conditions: 92°C for 45s; then 6 cycles at 98°C for 15s, 60°C for 30s, 72°C for 30s and 72°C 
for 5min. Once the PCR was complete the PCR reaction was cleaned with 1:1.1 ratio of 
Agentcourt® AMPure® XP beads (Beckman coulter) as described above: incubation at 
room temperature for 15 minutes followed by separation of the beads with a DynaMag TM-2 
Side magnetic rack (Thermo Fisher Scientific) for 2 minutes. The supernatant was 
transferred to new tubes and washed twice with 400μL of 80% absolute ethanol (molecular 
grade), the supernatant was removed and the tubes were removed from the magnetic stand 
and air dried for 15min. 30uL of UltraPure™ DNase/RNase-Free Distilled Water (Gibco®) 
was added to the tubes and left toincubate at room temperature for 2 minutes. The tubes 
were then once again placed on the magnetic stand to separate the beads. 
Confirmation of the libraries was performed running with 1µlof each library on an 
Agilent 2100 Bioanalyser instrument using Agilent DNA 1000 Reagents and DNA Chips 
(Agilent Technologies), to obtain approximately a library concentration of 20ng/μl.  
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Hybridisation of samples to capture probes:  
The LNA capture probes (10 μM) were placed in 2 separated tubes with 4.5μl of LNA-
5’ and LNA-3’ on each tube and they were incubated for 3 days at 47°C, with the lid set at 
57°C in thermocycler block. 
Recovery of capture sequences: 
After the third day, Agentcourt® AMPure® XP beads (Beckman coulter) were 
prepared to perform another wash. Tubes with beads were incubated for 45 minutes, 
resuspending by flicking every 15 minutes. After the incubation, washes were performed at 
47°C with 1x wash buffers (I, II, III and Stringent) using NimbleGen hybridization and wash 
kit (Roche) in the following order: 100μl Wash buffer I and incubation for 10s, 200μl Stringent 
buffer mix by pipetting 10 times for 5min twice. Another round of washes was performed at 
room temperature: 200μl Wash buffer I and incubation for 2min, 200μl Wash buffer II and 
incubation for 1min, 200μl Wash buffer III and incubation for 30s. After the final wash 
samples were resuspended in 50 μl of UltraPure™ DNase/RNase-Free Distilled Water 
(Gibco®). 
Captured Sequences LM-PCR to amplify the post-hybridization library: 
To the previous 50 μl sample Phusion® High-Fidelity PCR MasterMix LM-PCR was 
added with: 100μl (2x) Phusion® High-Fidelity PCR MasterMix, 46μl UltraPure™ 
DNase/RNase-Free Distilled Water (Gibco®), 1 μl of TS-F Primer (100 μM) to perform the 
LM-PCR with the following conditions:   92°C for 45s; then 6 cycles at 98°C for 15s, 60°C 
for 30s, 72°C for 30s and 72°C for 5min.Once the PCR finished the samples were cleaned 
using MiniElute® Gel extraction Kit (Qiagen) and quantified with Qubit ® dsDNA HS Assay 
kit (Thermo Fisher Scientific), Qubit ® Assay Tubes and Qubit® Fluorometer, following the 
manufacturer instructions. Capture samples were pooled 5’ and 3’ enrichments in a ratio 3:7 
by molecular mass. Concentration and size distribution was measured again using Agilent 
DNA 1000 Assay (Sigma Aldrich). Enrichment of the samples was calculated by 
quantification by qPCR using Kapa Library Quantification qPCR kit Illumina®. 
 
Sequencing: 
The library was diluted and denaturalised following Illumina® manufacturer 
instructions for the specific run used in this study. Then, flow cell, sequencing cartridge and 
buffers for sequencing were prepared as Illumina® recommends.  
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Samples were sequenced in multiplex on an Illumina HiSeq2500 (Macrogen, South Korea). 
It was obtained a total of 726,181,832 paired-end 2×150mer reads across the 18 libraries 
(Appendix 1).  
The identified (PRJEB27103) was deposited to name the RC-seq FASTQ files in the 
European Nucleotide Archive (ENA). TEBreak (https://github.com/adamewing/tebreak) pipe 
line was used to analyse RC-seq data. The HRG was used to align the reads using BWA-
MEM [221] with parameters -Y –M. Those reads that were duplicates were indicated with 
Picard MarkDuplicates (http://broadinstitute.github.io/picard). In this analysis, TEBreak 
required a minimum read alignment of 30bp to the genome, and 30bp of L1 insertion, and 
in both cases at ≥95% identity. 
To analyse the different L1 insertion candidates to be considered as putative de novo 
retrotransposition events (Table 1) the following different parameters were used: a) they 
were only present in one of the two hiPSC cell lines, whether in hiPS-CRL2429 or hiPS-
CRL1502 or their derivatives but not in both cell lines at the same time, b) the insertions 
were absent from the T0 or fibroblasts, c) they were not a previously described non-reference 
germline L1 insertion [8, 86, 91, 170, 171, 205, 228, 229] and d) they were supported by at 
least 2 RC-seq reads. Those insertions that were non-reference were annotated as 
polymorphic L1 insertions. 
 
In silico analysis of consensus reads from RC-seq output data table. 
1. From the sequencing output data, a study of the consensus sequences at both ends was 
performed; 5’ end and 3’ end, seeking the 3 mentioned hallmarks of retrotransposition 
(RTSN) [230]. DNA sequences were identified within the human genome working draft 
(HGWD) sequence using the BLAT server [199], at the UCSC Genome Bioinformatics 
website. Both consensus sequences should present a piece of the L1 sequence at its 5’ or 
3’end as well as a part of genomic DNA depending on where the insertion landed. In some 
cases, the input sequence can map to multiple genomic locations due to different repetitive 
elements. Aberrant sequences at junctions of the gDNA sequences were avoided.    
 For example, different pieces of the input sequence map to different genomic 
locations which are found when performing BLAT [207] on the genomic consensus using 
UCSC genome browser. An example of this is when the first 50bp portion of a 100bp 
genomic sequence maps to chromosome 1 and the last 50 bp maps to chromosome 2. 
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Another example is when microhomologies between the gDNA consensus sequence are 
found and the sequence of the L1 insertion (both sequences from the output table) that 
can be indicative of a PCR recombination event. 
1. A.  5’end analysis:  The insert consensus 5p was copied from each possible new L1 
insertion and BLAST was performed using a sequence against an L1 reference sequence 
using Serial Cloner to check the quality of the alignment, and to know what part of the L1 
sequence is present in the consensus read. Then, the UCSC genome browser was used to 
BLAT [207] the gDNA from the consensus sequence and double check that the same 
chromosomal coordinates as shown in the table were obtained. Many times, it is found that 
some L1 elements landed in repetitive sequences as old retrotransposons, LTRs [14] or 
centromeres, making the task of designing primers for PCR validations quite difficult. Hence, 
in many cases primers cannot be designed. 
1. B.  3’end analysis:  as for the 5’ end analysis, the insert consensus 3p was copied from 
each possible new L1 insertion and BLAST was performed on this sequence against an L1 
reference sequence to check the quality of the alignment. Then, the portion of the L1 
sequence that is present within the consensus read was determined. A polyA tail should be 
found [74] followed by a TSD [64] and the gDNA where the insertion landed. As before, the 
UCSC database was used to BLAT [207] the gDNA from the consensus sequence. 
Once the list of candidates was fully analysed, primers to PCR validate the insertions 
were designed in unique genomic DNA sequences flanking the 5’ and the 3’ ends. To be 
able to do this design, the gDNA was copied from each consensus, and BLAT was 
performed on the UCSC genome browser [207]. Most of the gDNA consensus sequences 
from the table are not very long, hindering the ability to design good primers, and raising the 
necessity to add more genomic DNA. To do so, it was necessary to copy the gDNA 
consensus sequence from the table in the UCSC Genome Browser, zoom out and then 
make a bigger nucleotide window to be able to find possible primers for PCR validations.  
 
PCR validation of L1 insertions. 
RC-seq reads indicating putative de novo L1 insertions were manually inspected and 
primers (Appendix 2) as previously described (Figure 10) were designed to PCR amplify 
integration sites and identify the hallmarks of bona-fide L1 retrotransposition events [231]. 
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Empty/filled site, 5ʹ L1-genome junction and 3ʹ L1-genome junction PCRs were performed. 
Primers were situated within flanking genomic DNA sequences for empty/filled site PCRs. 
The same flanking primers were paired with appropriate L1-specific primers for L1-genome 
junction assays. Expand Long Range enzyme was used for empty/filled site PCRs using 
1.75U Expand Long Template enzyme, 5μL of 5x Buffer with 12.5mM MgCl2, 1.25μL DMSO 
100%, 1.25μL 10mM dNTPs, 1μL primer mix (25μM each primer), 4ng genomic DNA 
template, and UltraPure™ DNase/RNase-Free Distilled Water (Gibco®) in a final volume of 
25μL with the following PCR conditions: 92°C for 2min; then 10 cycles at 92°C for 10s, 59°C 
for 15s, 68°C for 6:30min, then 30 cycles at 92°C for 2min; 59°C for 15s, 68°C for 6:30min 
+20s/cycle and a single extension step of 68°C for 10min. 5ʹ and 3ʹ L1-genome junction PCR 
reactions were performed using 2U MyTaq hot-start DNA polymerase (Bioline #BIO-21112), 
1x PCR buffer, 1µM of each primer and 5ng genomic DNA template, and molecular grade 
water in a final volume of 25 µL. Cycling conditions were as follows: 95°C for 2min; then 35 
cycles at 95°C for 30s, 58°C for 30s, 72°C for 3min and a single extension step of 72°C for 
5min. Amplified fragments were resolved on 1% and 2% agarose gels (1x TAE buffer) 
stained with SyberSafe (Life Technologies) for empty/filled site and 5ʹ and 3ʹ junction PCR 
assays, respectively, and imaged using a Typhoon FLA 9500 (GE Health-care life science, 
US). Amplicons of the expected size were excised from gels and DNA extracted using a 
QIAquick Gel Extraction Kit, followed by capillary sequencing to confirm and characterise 
L1 insertion structural features. 
L1 genotyping and cloning. 
To discard induced PCR mutations along the L1 sequences of interest and to 
distinguish possible allelic variants, four independent PCR reactions were performed using 
gDNA from the cell line hiPSC-CRL2429 to amplify the different family members assessed 
in this study used in retrotransposition assay. Expand long Range PCR were performed to 
amplify full-length L1s using 1.75U Expand Long Template enzyme, 5μL of 5x Buffer with 
12.5mM MgCl2, 1.25μL DMSO 100%, 1.25μL 10mM dNTPs, 1μL primer mix (25μM each 
primer), 4ng genomic DNA template, and UltraPure™ DNase/RNase-Free Distilled Water 
(Gibco®) in a final volume of 25μL with the following PCR conditions: 92°C for 2min; then 
10 cycles at 92°C for 10s, 59°C for 15s, 68°C for 6:30min, then 30 cycles at 92°C for 2min; 
59°C for 15s, 68°C for 6:30min +20s/cycle and a single extension step of 68°C for 10min. A 
NotI restriction enzyme sequence (5’-GC/GGCC) was introduced at the 5ʹ end of each 
forward primer close to the L1-genome junction to facilitate cloning of full-length L1 
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insertions. Reverse primers were designed at each specific gDNA flanking regions. PCR 
amplification products were run in 1% agarose gel (1x TAE buffer) electrophoresis at 100mA 
for 1hour. Gel cutting of ~6Kb fragments were purified with Phenol, 
phenol:chlorophorm:isoamyl alcohol (25:24:1) and chlorophorm:isoamyl alcohol (24:1). 
DNA was precipitated using with 0.1 volume of 3M sodium acetate and 2.5 volumes 
of 100% isopropanol. DNA was precipitated and then washed in 0.8 mL 75% EtOH, slightly 
air dried and resuspended in 20 µL of UltraPure™ DNase/RNase-Free Distilled Water 
(Gibco®). 500ng of purified PCR products were quantified by Nanodrop (Thermo Fisher 
Scientific) to perform NotI and Bstz17I (New England Biolabs) digestions in 1x CutSmart 
buffer at 37°C for 1hr. Digestions reactions were run in 2% agarose gels (1x TAE buffer) at 
120mA for 45min and purified by Phenol, phenol:chlorophorm:isoamyl alcohol (25:24:1) and 
chlorophorm:isoamyl alcohol (24:1). DNA was precipitated using with 0.1 volume of 3M 
sodium acetate and 2.5 volumes of 100% isopropanol. DNA was precipitated and then 
washed in 0.8 mL 75% EtOH, slightly air dried and resuspended in 20µL of UltraPure™ 
DNase/RNase-Free Distilled Water (Gibco®). 
The inserts containing L1 sequences were cloned into the vector TOPO®-XL PCR 
Cloning Kit (Life Technologies) according to the manufacturer’s instructions. The ligation 
product was used to transform One ShotTOP10 electrocompetent bacteria as per the 
manufacturer’s instructions using 5µL of ligation product. Competent bacteria were plated 
in LB agar containing 0.5 µg/mL of Kanamycin and incubated at 37°C overnight. Single 
colonies were picked and transferred to 5mL LB liquid containing 0.5 µg/mL of Kanamycin 
for Miniprep plasmid purification (QIAGEN). Stepping primers (L1_452_fwd, L1_1020_fwd, 
L1_1532_fwd, L1_1966_fwd, L1_2494_fwd, L1_3014_fwd, L1_3502_fwd, L1_4022_fwd, 
L1_4472_fwd, L1_4973_fwd and L1_5492_fwd  (sequences are indicated in Appendix 2) 
were used to Sanger sequence the entire L1 sequences to reconstruct the consensus 
sequence from each element. Assemble of the 12 independent Sanger sequencing 
reactions was performed. The reactions were ~500 nucleotides in length and overlapping at 
both ends with the previous or the next sequencing read, excluding the first and the last 
sequencing reactions that only overlapped with the next and with the previous sequencing 
reaction respectively, to create the consensus of ~6 Kbs of each L1 element.  The L1 
sequences of the different elements were aligned to one another doing a multiple sequence 
alignment using Clustal omega software  (https://www.ebi.ac.uk/Tools/msa/clustalo/) to 
create a consensus in each case. At least four clones were generated for each L1. Those 
unique mutations which were only present in one clone were considered induced PCR 
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mutations. The allelic variants were identified when particular nucleotides changes where 
shared in 2 or more independent clones.  
Non-mutated nucleotide sequence fragments were chosen to reconstruct the original 
consensus for each element. The identical sequence of each element was rebuilt by paired 
strategic restriction digest of the PCR amplification products (all the restriction enzymes 
were from New England BioLabs®), those digestions were:  
Lineage Progenitor_Allele 1: NotI-NheI; NheI-AgeI; AgeI-EcoRI; EcoRI-SpeI; SpeI-Bstz17I 
Lineage Progenitor_Allele2: NotI-NheI; NheI-AgeI; AgeI-BamHI; BamHI-SpeI; SpeI-Bstz17I 
Donor L1: NotI-NheI; NheI-AgeI; HindIII-Bstz17I 
Non-Ref_Chr3_p24.3: NotI-SpeI; SpeI-Bstz17I 
Each paired restriction enzyme digestion was run in 2% agarose gel (1x TAE buffer) 
for fragment separation to further ligate the resultant pertinent fragments from each L1 
element and cleaned with MiniElute® Gel Extraction Kit (Quiagen). Ligation was realized 
into a pCEP4 vector using T4 ligase in the following (insert:vector) ratios.  
Lineage Progenitor_Allele 1: ratio 5:1 
Lineage Progenitor_Allele2: ratio 5:1 
Donor L1: ratio 3:1 
Non-Ref_Chr3_p24.3: ratio 2:1 
In all the cases for each L1 element, 5µL of the ligation product was added to One 
ShotTOP10 chemically competent bacteria (Invitrogen) and transformations were performed 
as per manufacturer’s instructions. 1µg/mL of ampicillin was added to LB agar were the 
bacteria were plated and incubated overnight at 37°C. Single colonies were grown in 5ml 
LB liquid for further Miniprep plasmid purification (QIAGEN). The elements were Sanger 
sequenced as previously described with stepping primers (L1_452_fwd, L1_1020_fwd, 
L1_1532_fwd, L1_1966_fwd, L1_2494_fwd, L1_3014_fwd, L1_3502_fwd, L1_4022_fwd, 
L1_4472_fwd, L1_4973_fwd and L1_5492_fwd, sequences are indicated in Appendix 2) to 
verify the re-built consensus sequences. The elements were digested using NotI and 
Bstz17I restriction enzymes (New England BioLab) and reconstructed into a 
retrotransposition indicator backbone. To verify resultant clones, these were capillary 
sequenced, as described above, using primers at both ends of the L1 sequence. While ~60 
somatic mutations are known to occur per cell division in cultured fibroblasts [224], this 
equates to a probability of less than 1/1000 for such a mutation to have arisen in each L1 
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sequence in the parental fibroblasts prior to reprogramming (Appendix 1). 
Retrotransposition cell-cultured assay 
Prior to cell transfection, DNAs containing the different L1 of interest, were purified 
and resuspended in UltraPure™ DNase/RNase-Free Distilled Water (Gibco®) to 0.5µg/µL. 
High-glucose Dulbecco’s modified Eagle’s medium (DEMEM) without pyruvate (Gibco®), 
supplemented with 10% fetal bovine serum (Gibco®), 2mM L-Glutamine and 100U/mL 
penicillin, 100µg/mL streptomycin (Gibco®) (DMEM complete) media was used to grow 
Hela-JVM cells at 37°C in a humidified, 5%CO2 incubator at 37°C. Once obtained 80% of 
confluent cells, cells were dissociated with 0.05 % Trypsin (Gibco®) for 2min in at 37°C, 
neutralized with the same volume of media and counted with Neubauer cell counting 
chamber to plate 5x103 cell/well in 6-well plates for the experiment and 4x104 cell/well for 
transfection efficiency both performed in parallel. Cell transfections were performed after 12 
hours at a ratio 4µL to 1µg plasmid DNA using FuGENE HD Transfection Reagent 
(Promega).  
To perform transfection efficiency calculations, L1 reporter plasmids were co-
transfected with 5µg of each construct and 0.5µg of pCAG-EGFP. After 48 hours cells were 
dissociated with 0.05 Trypsin (Gibco®) for 2min in at 37°C, neutralized with the DPBS 
Dubbecco’s Phosphate Buffered Saline (-Calcium Chloride, -Magnesium Chloride) 1x of 
media and 10% Fetal Bovine Serum (FBS) (Gibco®). Cells were pelleted at 1000rpm for 
4minutes and resuspended in 350µl of Dubbecco’s Phosphate Buffered Saline (DPBS) (-
Calcium Chloride, -Magnesium Chloride) 1x and taken to Cytoflex flow cytometer (Beckman-
Coulter) at the Translational Research Institute Flow Cytometry Core to be analysed by Flow 
cytometry. The results obtained from each EGFP positive L1 reporter construct were used 
to normalize G418-resistant colony counts obtained in the colony forming assay or 
retrotransposition assay [232]. To perform the experiment of the retrotransposition assay, 
72 hours after transfection, G418 (400µg/mL) (Sigma Aldrich) was added to the media to 
start the antibiotic selection [53], from that day, the antibiotic was added to the media every 
48 hours for 14 days. The last day cells were fixed with Fixing solution (2% Formaldehyde, 
0.2% Glutaraldehyde) 20minutes and stained with Crystal Violote Solution 1% 10min and 
washed with tap water and air dry over night to further manual colony count each well. 
L1 CpG methylation analyses 
Bisulfite sequencing of overall L1 population (L1-Ta subfamily-wide) and locus 
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specific was performed as previously described in Nguyen et al. [6]. Briefly, the gDNA on 
each time point, T0, T1, T2, T3, T4, T5 and T6 in on each cell line hiPS-CRL2429 and hiPS-
CRL1502 was bisulfite converted with EZ DNA Methylation-Lightning Kit (Zymo) following 
manufacturer instructions using 500ng of gDNA previously quantified by Nanodrop (Thermo 
Fisher Scientific) in a final volume of 20µl of UltraPure™ DNase/RNase-Free Distilled Water 
(Gibco®). A volume of 130µl of Lightening conversion reagent was used and samples were 
eluted in a final volume of 25µl of elution buffer. To PCR amplify the L1-Ta 5ʹUTR region 
containing a CpG island (Figure 31), I used L1_Bis-F and L1_Bis-R primers (Appendix 2). 
To amplify promoters in a locus-specific manner all the PCR amplifications were set up with 
the same reverse primer L1_Bis-R and a specific forward primer, designed in each case 
flanking the gDNA of each L1 promoter; Lineage progenitor, donor and de novo L1 insertions 
(L1_Bis-LP, L1_Bis-Donor, L1_Bis-DN, respectively). PCR reactions contained 1U of 
MyTaq hot-start DNA polymerase (Bioline), 2µl of bisulfite treated gDNA (1µg) from each 
sample, 1× reaction buffer and 2µM of each primer, in 20µL final volume. The cycling 
conditions used for PCR were the following: 95°C for 2min; then 40 cycles of 95°C for 30s, 
54°C for 30s, 72°C for 30s, then a single extension step at 72°C for 5min. The purification 
of DNA from gel cuts was performed using phenol, phenol:chlorophorm:isoamyl alcohol 
(25:24:1) and chlorophorm:isoamyl alcohol (24:1). DNA was precipitated using with 0.1 
volume of 3M sodium acetate and 2.5 volumes of 100% isopropanol. DNA was precipitated 
and then washed in 0.8 mL 75% EtOH, slightly air dried and resuspended in 30 µL of 
UltraPure™ DNase/RNase-Free Distilled Water (Gibco®). The quality and quantity of DNA 
were assessed by NanoDrop (Thermo Fisher Scientific). Library preparation was then 
performed with barcoded libraries following Illumina manufacturer instructions using TruSeq 
DNA PCR-free Library Preparation Kit (Illumina®) and subjected to multiplexed paired-end 
2×300mer sequencing in Illumina MiSeq platform. Data were processed and analysed as 
described previously [6]. Briefly, this involved assembling read pairs into contigs and aligning 
them to mock converted target sequences (L1-Ta family or specific L1 loci) across their 
entire length using blastn. For each target sequence, QUMA software [233] was then used 
to analyse a total of 50 randomly selected, non-identical bisulfite converted sequences with 
default parameters (≤10% alignment mismatches and ≤5 unconverted CpH nucleotides) to 
generate methylation cartoons. 
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APPENDIX 1.  
1. A Summary of RC-seq output read counts. 
Cell line 
iPSC 
Library DNA input Time point 
RC-seq reads (x2x150mer) 
Count Aligned % 
CRL1502 
Fibroblasts p4 T0 44033582 99.95 
hiPSCs p76 T1 42151994 99.74 
Neural epithelium T2 33972001 99.77 
Immature neurons T3 39766940 99.77 
Neurons I T4 47155514 99.78 
Neurons II T5 44381111 97.91 
Neurons III T6 36222610 99.77 
hiPSCs p15 Earlier hiPSC passage 24385022 99.88 
hiPSCs p40 Earlier hiPSC passage 63130772 99.88 
CRL2429 
Fibroblasts p4 T0 24386590 99.91 
hiPSCs p70 T1 38460241 99.63 
Neural epithelium T2 40174554 99.79 
Immature neurons T3 46646999 99.78 
Neurons I T4 27279492 99.79 
Neurons II T5 46018310 99.77 
Neurons III T6 36033944 99.54 
hiPSCs p11 Earlier hiPSC passage 64534189 99.40 
hiPSCs p40 Earlier hiPSC passage 27447967 99.39 
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APPENDIX 2.  
Primer sequences (5’-3’). 
LM PCR primers 
TS-F Primer                      AATGATACGGCGACCACCGAGA 
TS-R Primer                      CAAGCAGAAGACGGCATACGAG 
Genomic Primers for empty-filled validation of L1s 
LP_Chr11_fwd AGGAAACAGTGAGGGGAAGC 
 
LP_Chr11_rev TGAGGCCCAGGAGTCATATC 
 
Donor_Chr3_fwd TGTATGACAGTAAAATAATGGGTAGATGA 
 
Donor_Chr3_rev CTGGCCTCTTCACTGCATTT 
 
DeNovo_Chr1_fwd CTGGTAACCCCAGAATGACG 
 
DeNovo_Chr1_rev ATCCTGCCTCAGCGAACTTA 
 
Non-ref_Chr3_fwd TTGTGGGAAGGCAAAATGAT 
 
Non-ref_Chr3_rev TATTCAATCCCAACCCAGGA 
 
 
 
 
L1-specific primers for validation of 5' and 3' L1-genome junctions 
 
hL1_273_rev ACCCGATTTTCCAGGTGCGT 
 
hL1_ACshort_fwd AGATATACCTAATGCTAGATGACAC 
 
   
NotI/L1-genome junction spanning primers for cloning full-length L1s 
 
LP_Chr11_NotI_fwd CAAGCGGCCGCTTACATTTTTAAAGAATTGTAGGGGAG 
 
Donor_Chr3_NotI_fwd TAAAGCGGCCGCAACAGAATGAGTAAATAATGGAGGG 
 
DeNovo_Chr1_NotI_fw
d 
TTCGCGGCCGCATTAAAGAAATGACATCTGAAATAATG
GA 
 
Non-ref_Chr3_NotI_fwd CAACGCGGCCGCTTAAAGTTAAAGACACGG 
 
   
L1-specific primers for sequencing full-length L1 elements 
 
L1_452_fwd GCCCAGGCTTGCTTAGGTA 
 
L1_1020_fwd TGATTTTGACGAGCTGAGAGAA 
 
L1_1532_fwd CCTCGAGAAGAGCAACTCCA 
 
L1_1966_fwd GCAAAATCACCAGCTAACATCA 
 
L1_2494_fwd AACTCAGCTCTGCACCAAGC 
 
100 
 
L1_3014_fwd AAATCAGAGCAGAACTGAAGGAAA 
 
L1_3502_fwd GAGGCCAGCATCATTCTGATA 
 
L1_4022_fwd CAATCAGGCAGGAGAAGGAA 
 
L1_4472_fwd TCCCCATCAAGCTACCAATG 
 
L1_4973_fwd TGTCCAAAACACCAAAAGCA 
 
L1_5492_fwd TACCATTTGACCCAGCCATC 
 
   
Primers for amplification of L1 promoters from bisulfite converted DNA 
 
BiS_LP_Chr11_fwd GATTTGTTTTTGGATTGTAAAATGGTT 
 
BiS_Donor_Chr3_fwd TGGGTAGATGAACAGATAAGTAAA 
 
BiS_DeNovo_Chr1_fwd GTTATTTGATAGTATTTTAATGAAGATT 
 
BiS_OverallL1_fwd TAGGGAGTGTTAGATAGTGG 
 
BiS_hL1_rev ACTATAATAAACTCCACCCAAT 
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APPENDIX 3. Validation by PCR and Sanger sequencing of the insertion TC_18 (de 
novo L1). 
The amplification product of the insertion TC_18 at the 3’junction PCR was cloned and 
Sanger sequenced. Alignment with the 3’end of the L1 sequence was found as expected: 
Seq_1  5878  cgggggaggggggagggatagcattgggagatatacctaatgctagatgacacattagtg  5937 
                                         |||||||||||||||||||||||||||||||| 
Seq_2  115   ----------------------------AGATATACCTAATGCTAGATGACACATTAGTG  146 
 
 
Seq_1  5938  ggtgcagcgcaccagcatggcacatgtatacatatgtaactaacctgcacaatgtgcaca  5997 
             ||||||| |||||||||||||||||||||||||||||||||||||||||||||||||||| 
Seq_2  147   GGTGCAGTGCACCAGCATGGCACATGTATACATATGTAACTAACCTGCACAATGTGCACA  206 
 
 
Seq_1  5998  tgtaccctaaaacttagagtataataaaaaaaaaaaaaaaaa------------------  6039 
             ||||||||||||||||||||||||||||||||||||||||||                   
Seq_2  207   TGTACCCTAAAACTTAGAGTATAATAAAAAAAAAAAAAAAAAGAATTGTAAAAAAAAAAA  266 
 
 
Seq_1  6040  --------------------------aaaaaaaaaaaaaa--------------------  6053 
                                       ||||||||||||||                     
Seq_2  267   TTATAAATAAAACAAAGAAGAATATGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA  326 
 
 Seq_1: L1 consensus sequence; Seq_2: Sanger sequencing data from one 3’junction 
TC_18 cloned product. In orange; a 3’ transduced sequence of 44 nucleotides.  
Alignment in between the genomic 3 consensus sequence and the Sanger sequencing 
results from one 3’junction TC_18 cloned product. 
Seq_1  1     ---------------------------------------------------AAAAAAAAA  9 
                                                                ||||||||| 
Seq_2  181   TGTAACTAACCTGCACAATGTGCACATGTACCCTAAAACTTAGAGTATAATAAAAAAAAA  240 
 
 
Seq_1  10    AAAAAAAA--------------------------------------------AAAAAAAA  25 
             ||||||||                                            |||||||| 
Seq_2  241   AAAAAAAAGAATTGTAAAAAAAAAAATTATAAATAAAACAAAGAAGAATATGAAAAAAAA  300 
 
 
Seq_1  26    AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAATGACATCTGTTAATCTTATTAA  85 
             |||||||||||||||||||||||||||       |||||||||||||||||||||||||| 
Seq_2  301   AAAAAAAAAAAAAAAAAAAAAAAAAAA-------GAAATGACATCTGTTAATCTTATTAA  353 
 
 
Seq_1  86    GTTCGCTGAGGCAGGATGAGGCTGGGTGCT-GGTAAATGGAGCAGATAAATGATCTGAGA  144 
             |||||||||||||||||              ||  |||   |||||||   |  |  |   
Seq_2  354   GTTCGCTGAGGCAGGAT-----------AAGGGCGAATTCTGCAGATATCCGT-CACACT  401 
 
 
 Seq_1: 3’ end genomic consensus sequence; Seq_2: Sanger sequencing data from 
one 3’junction TC_18 cloned product; a 3’ transduced sequence of 44 nucleotides.  
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After PCR validations the filled site amplification products were cloned in Topo-XL vector 
and Sanger-sequenced twice. The consensus sequence of the de novo insertion is:  
Colour code of the sequence: 5’transduce sequence, green letters; L1 sequence of de 
novo L1, red letters; 3’ transduced sequence, purple letters. 
AAATAATGGAGGGGAGGAGCCAAGATGGCCGAATAGGAACAGCTCCGGTCTACAGCTCCCAGCGTGAGCGACGCAG
AAGACGGTGATTTCTGCATTTCCATCTGAGGTACCGGGTTCATCTCACTAGGGAGTGCCAGACAGTGGGCGCAGGCC
AGTGTGTGTGCGCACCGTGCGCGAGCCGAAGCAGGGCGAGGCATTGCCTCACCTGGGAAGCGCAAGGGGTCAGGG
AGTTCCCTTTCCGAGTCAAAGAAAGGGGTGACGGACGCACCTGGAAAATCGGGTCACTCCCACCCGAATATTGCGCTT
TTCAGACCGGCTTAAGAAACGGCGCACCACGAGACTATATCCCACACCTGGCTCGGAGGGTCCTACGCCCACGGAATC
TCGCTGATTGCTAGCACAGCAGTCTGAGATCAAACTGCAAGGCGGCAACGAGGCTGGGGGAGGGGCGCCCGCCATT
GCCCAGGCTTGCTTAGGTAAACAAAGCAGCCGGGAAGCTCGAACTGGGTGGAGCCCACCACAGCTCAAGGAGGCCT
GCCTGCCTCTGTAGGCTCCACCTCTGGGGGCAGGGCACAGACAAACAAAAAGACAGCAGTAACCTCTGCAGACTTAA
GTGTCCCTGTCTGACAGCTTTGAAGAGAGCAGTGGTTCTCCCAGCACGCAGCTGGAGATCTGAGAACGGGCAGACTG
CCTCCTCAAGTGGGTCCCTGACCCCTGACCCCCGAGCAGCCTAACTGGGAGGCACCCCCCAGCAGGGGCACACTGAC
ACCTCACACGGCAGGGTATTCCAACAGACCTGCAGCTGAGGGTCCTGTCTGTTAGAAGGAAAACTAACAACCAGAAA
GGACATCTACACCGAAAACCCATCTGTACATCACCATCATCAAAGACCAAAAGTAGATAAAACCACAAAGATGGGGA
AAAAACAGAACAGAAAAACTGGAAACTCTAAAACGCAGAGCGCCTCTCCTCCTCCAAAGGAACGCAGTTCCTCACCAG
CAACAGAACAAAGCTGGATGGAGAATGATTTTGACGAGCTGAGAGAAGAAGGCTTCAGACGATCAAATTACTCTGAG
CTACGGGAGGACATTCAAACCAAAGGCAAAGAAGTTGAAAACTTTGAAAAAAATTTAGAAGAATGTATAACTAGAAT
AACCAATACAGAGAAGTGCTTAAAGGAGCTGATGGAGCTGAAAACCAAGGCTCGAGAACTACGTGAAGAATGCAGA
AGCCTCAGGAGCCGATGCGATCAACTGGAAGAAAGGGTATCAGCAATGGAAGATGAAATGAATGAAATGAAGCGAG
AAGGGAAGTTTAGAGAAAAAAGAATAAAAAGAAATGAGCAAAGCCTCCAAGAAATATGGGACTATGTGAAAAGACC
AAATCTACGTCTGATTGGTGTACCTGAAAGTGATGTGGAGAATGGAACCAAGTTGGAAAACACTCTGCAGGATATTAT
CCAGGAGAACTTCCCCAATCTAGCAAGGCAGGCCAACGTTCAGATTCAGGAAATACAGAGAACGCCACAAAGATACT
CCTCGAGAAGAGCAACTCCAAGACACATAATTGTCAGATTCACCAAAGTTGAAATGAAGGAAAAAATGTTAAGGGCA
GCCAGAGAGAAAGGTCGGGTTACCCTCAAAGGAAAGCCCATCAGACTAACAGCGGATCTCTCGGCAGAAACCCTACA
AGCCAGAAGAGAGTGGGGGCCAATATTCAACATTCTTAAAGAAAAGAATTTTCAACCCAGAATTTCATATCCAGCCAA
ACTAAGCTTCATAAGTGAAGGAGAAATAAAATACTTTATAGACAAGCAAATGTTGAGAGATTTTGTCACCACCAGGCC
TGCCCTAAAAGAGCTCCTGAAGGAAGCGCTAAACATGGAAAGGAACAACCGGTACCAGCCGCTGCAAAATCATGCCA
AAATGTAAAGACCATCGAGACTAGGAAGAAACTGCATCAACTAATGAGCAAAATCACCAGCTAACATCATAATGACA
GGATCAAATTCACACATAACAATATTAACTTTAAATATAAATGGACTAAATTCTGCAATTAAAAGACACAGACTGGCAA
GTTGGATAAAGAGTCAAGACCCATCAGTGTGCTGTATTCAGGAAACCCATCTCACGTGCAGAGACACACATAGGCTCA
AAATAAAAGGATGGAGGAAGATCTACCAAGCCAATGGAAAACAAAAAAAGGCAGGGGTTGCAATCCTAGTCTCTGA
TAAAACAGACTTTAAACCAACAAAGATCAAAAGAGACAAAGAAGGCCATTACATAATGGTAAAGGGATCAATTCAAC
AAGAGGAGCTAACTATCCTAAATATTTATGCACCCAATACAGGAGCACCCAGATTCATAAAGCAAGTCCTCAGTGACC
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TACAAAGAGACTTAGACTCCCACACATTAATAATGGGAGACTTTAACACCCCACTGTCAACATTAGACAGATCAACGA
GACAGAAAGTCAACAAGGATACCCAGGAATTGAACTCAGCTCTGCACCAAGCAGACCTAATAGACATCTACAGAACT
CTCCACCCCAAATCAACAGAATATACATTTTTTTCAGCACCACACCACACCTATTCCAAAATTGACCACATAGTTGGAAG
TAAAGCTCTCCTCAGCAAATGTAAAAGAACAGAAATTATAACAAACTATCTCTCAGACCACAGTGCAATCAAACTAGA
ACTCAGGATTAAGAATCTCACTCAAAGCCGCTCAACTACATGGAAACTGAACAACCTGCTCCTGAATGACTACTGGGT
ACATAACGAAATGAAGGCAGAAATAAAGATGTTCTTTGAAACCAACGAGAACAAAGACACCACATACCAGAATCTCT
GGGACGCACTCAAAGCAGTGTGTAGAGGGAAATTTATAGCACTAAATGCCTACAAGAGAAAGCAGGAAAGATCCAA
AATTGACACCCTAACATCACAATTAAAAGAACTAGAAAAGCAAGAGCAAACACATTCAAAAGCTAGCAGAAGGCAAG
AAATAACTAAAATCAGAGCAGAACTGAAGGAAATAGAGACACAAAAAACCCTTCAAAAAATCAATGAATCCAGGAGC
TGGTTTTTTGAAAGGATCAACAAAATTGATAGACCGCTAGCAAGACTAATAAAGAAAAAAAGAGAGAAGAATCAAAT
AGACACAATAAAAAATGATAAAGGGGATATCACCACCGATCCCACAGAAATACAAACTACCATCAGAGAATACTACA
AACACCTCTACGCAAATAAACTAGAAAATCTAGAAGAAATGGATACATTCCTCGACACATACACTCTCCCAAGACTAAA
CCAGGAAGAAGTTGAATCTCTGAATCGACCAATAACAGGCTCTGAAATTGTGGCAATAATCAATAGTTTACCAACCAA
AAAGAGTCCAGGACCAGATGGATTCACAGCCGAATTCTACCAGGGGTACAAGGAGGAACTGGTACCATTCCTTCTGA
AACTATTCCAATCAATAGAAAAAGAGGGAATCCTCCCTAACTCATTTTATGAGGCCAGCATCATACTGATACCAAAGCC
GGGCAGAGACACAACCAAAAAAGAGAATTTTAGACCAATATCCTTGATGAACATTGATGCAAAAATCCTCAATAAAAT
ACTGGCAAACCGAATCCAGCAGCACATCAAAAAGCTTATCCACCATGATCAAGTGGGCTTCATCCCTGGGATGCAAGG
CTGGTTCAATACACGCAAATCAATAAATGTAATCCAGCATATAAACAGAGCCAAAGACAAAAACCACATGATTATCTC
AATAGATGCAGAAAAAGCCTTTGACAAAATTCAACAACCCTTCATGCTAAAAACTCTCAATAAATTAGGTATTGGTGG
GACGTATTTCAAAATAATAAGAGCTATCTATGACAAACCCACAGCCAATATCATACTGAATGGGCAAAAACTGGAAGC
ATTCCCTTTGAAAACCGGCACAAGACAGGGATGCCCTCTCTCACCACTCCTATTCAACATAGTGTTGGAAGTTCTGGCC
AGGGCAATCAGGCAGGAGAAGGAAATAAAGGGTATTCAATTAGGAAAAGAGGAAGTCAAATTGTCCCTGTTTGCAG
ACGACATGATTGTTTATCTAGAAAACCCCATCGTCTCAGCCCAAAATCTCCTTAAGCTGATAAGCAACTTCAGCAAAGT
CTCAGGATACAAAATCAATGTACAAAAATCACAAGCATTCTTATACACCAACAACAGACAAACAGAGAGCCAAATCAT
GGGTGAACTCCCATTCACAATTGCTTCAAAGAGAATAAAATACCTAGGAATCCAACTTACAAGGGATGTGAAGGACCT
CTTCAAGGAGAACTACAAACCACTGCTCAAGGAAATAAAAGAGGAGACAAACAAATGGAAGAACATTCCATGCTCAT
GGGTAGGAAGAATCAATATCGTGAAAATGGCCATACTGCCCAAGGTAATTTACAGATTCAATGCCATCCCCATCAAGC
TACCAATGACTTTCTTCACAGAATTGGAAAAAACTACTTTAAAGTTCATATGGAACCAAAAAAGAGCCCGCATTGCCAA
GTCAATCCTAAGCCAAAAGAACAAAGCTGGAGGCATCACACTACCTGACTTCAAACTATACTACAAGGCTACAGTAAC
CAAAACAGCATGGTACTGGTACCAAAACAGAGATATAGATCAATGGAACAGAACAGAGCCCTCAGAAATAATGCCGC
ATATCTACAACTATCTGATCTTTGACAAACCTGAGAAAAACAAGCAATGGGGAAAGGATTCCCTATTTAATAAATGGT
GCTGGGAAAACTGGCTAGCCATATGTAGAAAGCTGAAACTGGATCCCTTCCTTACACCTTATACAAAAATCAATTCAA
GATGGATTAAAGATTTAAACGTTAAACCTAAAACCATAAAAACCCTAGAAGAAAACCTAGGCATTACCATTCAGGACA
TAGGCGTGGGCAAGGACTTCATGTCCAAAACACCAAAAGCAATGGCAACAAAAGACAAAATTGACAAATGGGATCTA
ATTAAACTAAAGAGCTTCTGCACAGCAAAAGAAACTACCATCAGAGTGAACAGGCAACCTACAACATGGGAGAAAAT
TTTTGCAACCTACTCATCTGACAAAGGGCTAATATCCAGAATCTACAATGAACTCAAACAAATTTACAAGAAAAAAACA
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AACAACCCCATCAAAAAGTGGGCGAAGGACATGAACAGACACTTCTCAAAAGAAGACATTTATGCAGCCAAAAAACA
CATGAAGAAATGCTCATCATCACTGGCCATCAGAGAAATGCAAATCAAAACCACTATGAGATATCATCTCACACCAGT
TAGAATGGCAATCATTAAAAAGTCAGGAAACAACAGGTGCTGGAGAGGATGCGGAGAAATAGGAACACTTTTACACT
GTTGGTGGGACTGTAAACTAGTTCAACCATTGTGGAAGTCAGTGTGGCGATTCCTCAGGGATCTAGAACTAGAAATAC
CATTTGACCCAGCCATCCCATTACTGGGTATATACCCAAATGAGTATAAATCATGCTGCTATAAAGACACATGCACACG
TATGTTTATTGCGGCACTATTCACAATAGCAAAGACTTGGAACCAACCCAAATGCCCAACAATGATAGACTGGATTAA
GAAAATGTGGCACATATACACCATGGAATACTATGCAGCCATAAAAAATGATGAGTTCATATCCTTTGTAGGGACATG
GATGAAATTGGAAACCATCATTCTCAGTAAACTATCGCAAGAACAAAAAACCAAACACCGCATATTCTCACTCATAGG
TGGTAATTGAACAATGAGATCACATGGACACAGGAAGGGGAATATCACACTCTGGGGACTGTGGTGGGGTCGGGGG
AGGGGGGAGGGATAGCATTGGGAGATATACCTAATGCTAGATGACACATTAGTGGGTGCAGTGCACCAGCATGGCA
CATGTATACATATGTAACTAACCTGCACAATGTGCACATGTACCCTAAAACTTAGAGTATAATAAAAAAAAAAAAAAA
AAGAATTGTAAAAAAAAAAATTATAAATAAAACAAAGAAGAATATGAAAAAAAAAAAAAAATAAAAAAAAAAAAAA
AAAAAA 
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APPENDIX 4. Putative de novo L1 insertions data of: TSD_3prime, TSD_5prime, 
Genomic Consensus_5p and Genomic Consensus_3p RC-seq output data table. 
Timecourse_1 
TSD_5prime:  
ATCTTGG 
TSD_3prime: 
ATCTTGG 
Genomic_Consensus_5p: 
AAAGAAACTACCATCAGAGTGAACAGACAACCTGCAGAATGAAAGAAAATATTTATAA
ACTATGCATCTGACAAAGGACTAATATCCAGAATCTGTAAGGAACTCACACATCTCAG
CAACAACAATGAAAAATAACCCCATTAAAAGGTGGGAAAGGGCCGTGCGCGGTGGCT
CACACCTGTAATCCCAGCACTTTGGGAGGCCAATGCGGGCGGATCACAAAGCCAAG
AGATCGAGACCATCTTGGAGA 
Genomic_Consensus_3p: 
TTCAGACGTGTGCTCTTCCGATCTTGGCTAACATGGTGAAACCCCGTCTCTACTAAAA
ATACAAAAAAAATTAGCTGGGCATGGTGGCAGATGCCCATAGTCCCAGCTACTCGGG
AGGCTGAGGCAGGAGAATGGCGTGAACCCGGGAGGC 
 
Timecourse_2 
TSD_5prime:  
NA 
TSD_3prime: 
NA 
Genomic_Consensus_5p: 
AATATCCTTGATGAATATTGATGCAAAAATCCTCAATAAAATACTGGCAAACTGAATCC
AGCAGCACATCAAAAAGCTTATCCACCATGATCAAGTGGGCTTCATCCCTGGGATGC
AAGGCTGGTTCAATATACACAAATCAATAAATGTAATCCAGCATATAAACAGAACCAAA
GACAAAAACCACATGATTATCTCAATAGATGCAGAAAAGGCCTGTGACAAAATTCAAC
AACACTTCATGCTAAAAACTCTCAAGAAATTAGGAATAAGTTTACAAAGCTCATGGAAA
CCATGAACAAAGAGCTAAAGGACCATGAGAACAATGTCTCAATAAATAGAGTATATTG
ATAAAGAAACAGAACTTATATAAAG 
Genomic_Consensus_3p: 
106 
 
GCAGATTTTACAAAAAAATAGTTTATAAAAAGCAATAAACAAAAACAACTACAACTGAT
GGCAAACAGCAAACACTCCTGAGAGGACAGAAAGGAAGAAATCTAATTTCTAGAGTT
GTTACATATAATATTCAAAATGTCCAGTATTTACCAAAAAATTATGTATCATGTGAAGAA
AAAATAAGTTATGGCCCATGGATAGGAGAAAGTAACAGAAATTGTGCCTGAGGAAGAT
CGGAAGAGCG 
 
Timecourse_3 
TSD_5prime:  
AAGACA 
TSD_3prime: 
AAGACA 
Genomic_Consensus_5p: 
AAAGTTAATATTTCTCAGCCCAAAATCTCCTTAAGCTGATAAGCAACTTCAGCAAAGTC
TCAAGATACAAAATCAATGTACAAAAATCACAAGCATTCTTATACACCAACAACAGACA
AGGATCCCTCTCTCACCACTCCTATTCAACATAGTATTGGAAGTTCTGGCCAAGGCAA
TCAGTCAAGAGAAGGAAATAAAGCTATTCAAATAGGAAAAGA 
Genomic_Consensus_3p: 
GAGAATGGCGTGAACCTGAGAGGCGGAGCTTGCAGTGAGCCGAGATCCGCCACTGC
ACTCCAGCCTGGGCAACAGAGTGAGACTCCGTCTCAAAAAAAAAAAAAAAGAAAAAA
GAAAACTGGCACAAGACAAAGAACCCCCCCCCACCACC 
 
Timecourse_4 
TSD_5prime:  
CAGGGGCAGTGACTCACATCTGTAATTCCAGCACACCTGTAATTCCAACACTTTGTGG
GGCCAAGATAGGAG 
TSD_3prime: 
CAGGGGCAGTGACTCACATCTGTAATTCCAGCACACCTGTAATTCCAACACTTTGTGG
GGCCAAGATAGGAG 
Genomic_Consensus_5p: 
GATCAGAATCACCTCAGAAGCTTTAAAAAACAATCTATAGGCCAGGGGCAGTGACTCA
CATCTGTAATTCCAGCACACCTGTAATTCCAACACTTTGTGGGGCCAAGATAGGAGTT
TTCCTTCTAACAGACAGGACCCTCAGCTGCAGGTC 
Genomic_Consensus_3p: 
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CTACACGACGCTCTTCCGATCTCAGGGGCAGTGACTCACATCTGTAATTCCAGCACA
CCTGTAATTCCAACACTTTGTGGGGCCAAGATAGGAGGATCACTTGAGCCCAGGAGT
TCGAGACCAGCCTGGGTAACAGAGGGAGACTGCCCCC 
 
Timecourse_5 
TSD_5prime:  
AAAAAACATGCCAAATTGTAAAGACCATCAAGGCTAGGAAGAAACTGCATCAA 
TSD_3prime: 
AAAAAACATGCCAAATTGTAAAGACCATCAAGGCTAGGAAGAAACTGCATCAA 
Genomic_Consensus_5p: 
GTCACCACCACGCCTGCCCTACAAGAGCTCCTGAAAGAAGCACTAAACATGGAAAGG
AACAACCGGTACCAGCCACTGAAAAAACATGCCAAATTGTAAAGACCATCAAGGCTA
GGAAGAAACTGCATCAATTAAAGATCGGAAGAGCGTC 
Genomic_Consensus_3p: 
GGGTGCAGCGCACCAGCATGGCACATGTATACATATGTAACTAACCTGCACAATGTG
CACATGTACCCTAAAACTTAGAGTATAATAAAAAAAACAAAAAAACAAAAAAAACAAAA
AAAAACATGCCAAATTGTAAAGACCATCAAGGCTAGGAAGAAACTGCATCAA 
 
Timecourse_6 
TSD_5prime: 
NA 
TSD_3prime:  
NA 
Genomic_Consensus_5p: 
CCCATAGCTCGGAGTAATTTGATCGTCTGAAGCCTTCTTCTCTCAGCTCATCAAAGTC
ATTCTCCATCCAGCTTTGTTCCATTGCTGGTGAGGAACTGCGTTCCTTTGGAGGAAAA
GAGGCATTCTGGTTTTTGGAACTTTCCGCATTTTTGCACTGGGTTTTCCTCATCTTCAT
GGATTTATCTACCTTTGGTCTTTGATGTTGGTGACCTTTGGATGGGGTCTCTGAGTGG
AAGTGCT 
Genomic_Consensus_3p: 
CTTCCTTGCATTGAGTTAGAACATGCTCCTTTAGCTTGGAGGAGTTTGTTATTACCTAC
CTTCTGAAGCCTACTTCTGTCAATTCACCAAACTCATTCTCTATCCAGTTTTGTTCCCT
TGCTGTCAAGGAAGATCGGAAGAGCGTCGTGTA 
 
108 
 
Timecourse_7 
TSD_5prime: 
CATTCTTTTTTTTTTTTTTTT 
TSD_3prime:  
CATTCTTTTTTTTTTTTTTTT 
Genomic_Consensus_5p: 
AAAGTCACCCTAAATTCATTGGGAAAAGTTATACAAAAGAAGGGCCAATACCATTCTTT
TTTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTGGCCCAGGCGGGACTG
CAGTGGCGCGATCTCGGCTCACTGCAAGCTCCG 
Genomic_Consensus_3p: 
ATCTCCTTAAGCTGATAAGCACTTCAGCAAAGTCTCAGGATACAAAATCAATGTGCAA
AAATCACAAGCATTCTTTTTTTTTTTTTTTTCCATTTTTTTTCTTTTTTATTGATCATTCTT
GGGTGTTTCTCGCAGAGGGGGATTTGGCAGGGTCACAGGACAATAGTGGAGGGAAG
G 
 
Timecourse_8 
TSD_5prime: 
GGCGACAGAGCGA 
TSD_3prime:  
GGTGACAGCGCCA 
Genomic_Consensus_5p: 
GGGGAGTTTGCAGTGAGCCAAGATCGTACCTCCGCACTCCAGCCTGGGCGACAGAG
CGATACTCCATCTCAAAAAACAAAACGAAACAGGTCGGAAGATCACACGTCTTAAGTG
CACTGAGGAAGACAGCAGGAATGGCGACTTCGGCTTG 
Genomic_Consensus_3p: 
GATGACAGGATACTGGGTGCAGCGCACCAGCATGGCACGTGTATACATATGTAACTA
ACCTGCACAACGTGCACAGGTGACAGCGCCAGACTTGGTCTCAAGAAAAAAAGAAAT
AGAGGAGGGGGCTTCAGTCTGTGTAGGGGAGCTGGGG 
 
Timecourse_9 
TSD_5prime: 
AAAAAAAAAAAAAAAAA 
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TSD_3prime:  
AAAAAAAAGAAAAAAAA 
Genomic_Consensus_5p: 
ACTGGATTTTTGGCCAGGTGCAGTGGCTCATGCCTGTAATCCCAGCATTTTGGGAGC
CTGAGGCGGGAGAATCACTTGAAGTCAGGAGTTTGAGACAAGCCTAGCCAACATAGT
GAAACTCTGTCTCTACAAAAAAAAAAAAAAAAACACATTAGCGAGGCAAAGAGGGGG
GGACCGGTGGACCCCGGCACGGGGGGGGGGGAATGAGCAAAACACCCCACCCCAG
GCAGCAAGGGGTCGCG 
Genomic_Consensus_3p: 
GATGACACATTAGTGGGTGCAGCGCACCAGCATGGCACATGTATACATATGTAACTA
ACCTGCACAATGTGCACATGTACCCTAAAACTTAGAGTATAATAAAAAAAAAAAAAAGA
AAAAAAAAAAAAAACAAAACAAAACAAAAAAAAAAAAAAAAA 
 
Timecourse_10 
TSD_5prime:  
NA 
TSD_3prime: 
NA 
Genomic_Consensus_5p: 
ACAAAGACCCTGTCTAATAAAGAAAAACAAACCAAAAAACTACCGATACCTCTTGGCT
GGGCAGACTATAATATCCTAAAGAATTGCAGAGTCTGGGTAAATGCCTGATTTGGAG
GAAAGTGCCCCAAAGGGCAGCCTGTCCAACCTAAGGGGGTCCTTGTGACCCTTTGAT
GGAAATGCAGAAATCACCCGTCTTCTGCGTCGCTCACGCTGGGAGCTGTAGACCGG
AGCTGTTCCTATTCGGCCATCTTGGCTCC 
Genomic_Consensus_3p: 
AGTTCAGACGTGTGCTCTTCCGATCTAGTGGGAGCAACAACTACCTCTTCAGCTTCCA
GGGATTTGCTAGGGAGCTTGCTACAGCCATACATACGCCTGGTAGGTCTTGTCCCAG
AGGACATACGTTTTGAGATGAACTCAAACACTTGGA 
 
 
 
 
110 
 
Timecourse_11 
TSD_5prime:  
GAAAAT 
TSD_3prime: 
GAAAAT 
Genomic_Consensus_5p: 
ACTAGAAATGACTCATCCATTGAATTAAGTTAAGCATTTGACATAACATGATTTCATTAT
GTAGAATGATTTTAAATGCATTTGAGTCATATTTCATTATTAGAATTAAACTTATGTTTG
TGTTCTATTATATCAGTGATATTGTAGTAATATAGTAAAAAGAAAAGTTTTGGAATACTA
TTCCAGTCAACATAATTCTGAGGAAGTTGTTTGAAAATTTTTGCAACCTACTCATCTGA
CAAAGGGCTAATATCCAGAATCTACAATGAACTCAAACAAATTTATAAGAAAAAAACAA
ACAACCCCATCAAAAAGTGGGCGAAGGACATGAACAGACACTTCTCAAAAGAAGACA
TTTATGCAGCCAAAAAACACATGAAGAAATGCTCATCATCACTGGCCATCAGAGAAAT
GCAAATCAAAACCACTATGAGATATCATCTCACACCGGTTAGAATGGCAATCATTAAG
AAGTCAGGAAACAACAGGTGCTGGAGAGGATGCGGAGAAATAGGAACACTTTTACAC
TGTTGGTGGGACTGTAAACTAGT 
Genomic_Consensus_3p: 
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAAAATGGCAGGTTACATTTC
CTCACAACAGTGTCACTACTGCTACACAAATAAAAAAAATCAATTTTTAAAAAGTGCTG
TAATCTGCTACTTCACACTAATGCCATATGGTCATCATTTTATAATTAATTGATAAATTA
GCA 
 
Timecourse_12 
TSD_5prime: 
ATTTCCTTAGACATATTCTTGGAAATAGAAT  
TSD_3prime:  
ATTTCCTTAGACATATTCTTGGAAATAGAAT 
Genomic_Consensus_5p: 
TGGTGCGCTGCACCCACCAATGTGTCATCTAGCATTAGGTATATCAATAGCTTCAGAT
TTTCCATAATTTTTGATATAGCAATTCCATTTCCTTAGACATATTCTTGGAAATAGAATT
GCTATATCAAAAATTATGGAAAATCTGAAGCTA 
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Genomic_Consensus_3p: 
ATCCATTCTGTGGATTCAAAATCATGTAGATCACCAGTCTCTAATGGTTGGACATTTAG
GATTTATCTGGTTTCTCATCTGAGTGTTTATTAGATGACTATTGGATTTCCTTAGACAT
ATTCTTGGAAATAGAATGCAATCATCAAATGGA 
 
Timecourse_13 
TSD_5prime: 
AAAAAAACAAAACAACT 
TSD_3prime:  
AAAAAAACAAAACAACT 
Genomic_Consensus_5p: 
CATTGAATACACATGTTAAGATGGGAACAAGAGACACTGGGGACCACTAGATTGGGG
AGGAAAGGTAGGGGTTGTGGGCTGAAGAATTACCTGTTGGGTACTGTGTTTACTGCC
TGGGTGGTAGGATCACTGGGAGTCCAAGCCTCAGCATCACACAACTACTCATGTAAC
AGTCTTTCATTAACCTATAATAAAAGTTGAAATTAATTAAAAAAACAAAACAACTTTTGA
GAAGTGTCTGTTCATGTCCTTCGCCCACTTTTTGATGGGGTTGTTTGTTTTTTTCTTGT
AAATTTGTTTGAGTTCATTGTAGATTCTGGATATTAGCCCTTTGTCAGATGAGTAGGTT
GCAAAAATTTTCTCCCATGTTGTAGGTTGCCTGTTCACTCTGATGGAAGACATTTATG
CAGCCAAAAAACACATGAAGAAATGCTCATCATCACTGGCCAT 
Genomic_Consensus_3p: 
ACCGTGAAACTCAGAGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACAAAACAA
CTACACTGTTTCATTGCTCTAGATTTCTTTTTGTCTCCATTTAATTATGGAGAGACTTG
CAGAGACAGAAATGACTGTCACGTGTTCTTATACACATAAAGCCCTAGAAACAGAAGC
CACAGCACAT 
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Timecourse_14 
TSD_5prime: 
NA 
TSD_3prime:  
NA 
Genomic_Consensus_5p: 
NA 
Genomic_Consensus_3p: 
AGATGACATGATTGTATATTTAGAAAACCCCATGTATACATATGTAACTAACCTGCACA
ATGTGCACATGTACCCTAAAACTTAGAGTATAATAAAAAAAAAAAATTAAAAAAAAAAA
AAAAAAAAAACTTAAAAAAAACTTTGGCAATTAAA 
 
Timecourse_15 
TSD_5prime: 
AGTTCTTT 
TSD_3prime:  
AGTTCTTT 
Genomic_Consensus_5p: 
ACCAAGGTTGAAATGAAGGAAAAAATGTTAAGATCAGCCAGAGAGAAAGGTCGGGTT
ACCCACAGTGTTGTATTTTATAAAGAACTCTGCTCTATGCTTATTAAACTGGACATTAC
TAAAACATAATGACAGAGAAATGTTGAAAGTAAATAGATGAAAAAATAAACACCAGACA
AATATTAACTTAAAAATTTTGGTTTAGGCAATAGTTGACAAAATATATATTAATGACCAA
AGCATCATTAAAAATAAAGAAGGACATTACTTAATGATACAATGAATAATTTCATACAC
AAAATAA 
Genomic_Consensus_3p: 
TTGCAAAAATTTTCTTCCATTCTGTAGGTTGCCAGTTCACTCTGATGGTAGTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTTGAAGTTCTTTTTTTTTCTTTTTTTTTTT
TTTTCTGTTTTTGGTTTTTTTTTTTTT 
 
 
 
 
113 
 
Timecourse_16 
TSD_5prime: 
AAAGAAAATGTG 
TSD_3prime:  
AAAGAAAATGTG 
Genomic_Consensus_5p: 
ATACCCAAAGATTTATAAATCATTCTGCTATAAAGACACATGCACATGTATGTGTATTG
CAGCACTGTTCGCAATAGCAAAGACTTGGAACCAACACAAATGCCCATCAATGACAG
ACTGGATAAAGAAAATGTGAGATCGGAAGAGCACA 
Genomic_Consensus_3p: 
AGATGACACATTAGTGGGTGCAGCGCACCAGCATGGCACATGTATACATATGTAACT
AACCTGCACAATGTGCACATGTACCCTAAAACTTAGAGTATAATAAAAAAAAAAAAAAA
AAAAAAGAAAATGTGGCACATAAACACCATGAAAA 
 
Timecourse_17 
TSD_5prime: 
AAAGAAAAAGTG 
 
TSD_3prime:  
AAAGAAAAAGTG 
Genomic_Consensus_5p: 
CTAGCAATTACTAGGATTATAAATCATGCTACTATAAAGACACATGCACACATATGTTT
ATTGCAGCACTATTCACAATAGCAAAGACTTGCAACCAACCCAAATCCCCATCAATGA
TAGACTGGATAAAGAAAAAGTGAGATCGGAAGAG 
Genomic_Consensus_3p: 
AGATGACACATTAGTGGGTGCAGCGCACCAGCATGGCACATGTATACATATGTAACT
AACCTGCACAATGTGCACATGTACCCTAAAACTTAGAGTATAATAAAAAAAAAAAAAAA
AAAAAGAAAAAGTGGCACATATACACCATGAAATA 
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Timecourse_18 
TSD_5prime: 
CAGATGTCATTTCTTT 
TSD_3prime:  
CAGATGTCATTTCTTT 
Genomic_Consensus_5p: 
CCATATTTTACATAATTTATAATTTATGAAATAGAATATTTGAATAATAAACCAATTCCAT
TTTGAAGGCTTCTGATGTAGTACTCTGTTAAAAAAAAAAAAAAAAACTACTTGAGAAAA
GTATGGATTGACTATATTGGAAGTTGCAAGGCCTGAGGAATGTTTTCCCGTGATTTTA
GTCCCTCTCATCAGTGTTCTATGCCTCAGTTCTGGTAACCCCAGAATGACGCTGTTAC
CTGACAGTATTCTAATGAAGATTAAAGAAATGACATCTGAAATAATGGAGGGGAGGAG
CCAAGATGGCCGAATAGGAACAGCTCCGGTCTACAGCTCCCAGCGTGAGCGACGCA
GAAGACGGTGATTTCTGCATTTCCATCTGAGGTACCGGGTTCATCTCACTAGGGAGT
GCCAGACAGTGGGCGCAGGCCAGTGTGTGTGCGCACCGTGCGCGAGCCGAAGCAG
GGCGAGGCATTGCCTCACCTGGGAAGCGCAAGGGGTCAGGGAGTTCCCTTTCCGAG
TCAAAGAAAGGGGTGACGGACGCACCTGGAAAATCGGGTCACTCCCAC 
Genomic_Consensus_3p: 
ACCAAAGGAGAAAGTTTCTCTATGATGACTTTTCAACATGAAAAATAAAGTGTAGATGT
CTCAGATCATTTATCTGCTCCATTTACCAGCACCCAGCCTCATCCTGCCTCAGCGAAC
TTAATAAGATTAACAGATGTCATTTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTTTTTTTTTT 
 
Timecourse_19 
TSD_5prime:  
NA 
TSD_3prime: 
NA 
Genomic_Consensus_5p: 
GCAGGCCAACATTCAAATTCAGGAAATTCAGAGAACACCACAAAGATACTCCTTGAGA
AGAGCAACCCCAAGACACATAATTGTCAGATTCACTAAGGTTGAAATAAGGAAAAAAT
GTTAAGGGCAAGATCGGAAGAGCGTCGTGTAGGGA 
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Genomic_Consensus_3p: 
ACATATGCAACTAACCTGCACAATGTGCACATGTACCCTAAAACTTAGAGTATAATAAA
AAAAAAAAAAAAAAAAAAAAAAACAAAATACAAGCCAGAAGAAGAAGGGGAACAATAC
TCAACATTCTTAAAGAAAAAAAATATCAACCCAG 
Timecourse_20 
TSD_5prime: 
AAAAAAAAAAAAAAAGAAAAGAAAAGAAAAAAAA 
TSD_3prime:  
AAAAAAAAAAAAAAAAAAAGAAAAGAAAAAAAA 
Genomic_Consensus_5p: 
AATTGACAAATGGGATCTAATTAAACTAAAGAGCTTCTGCACAGCAAAAGAAACTACC
ATCAGAGTGAACAGGCAACCTACAACATGGGAGAAAATTTTCGCAACCTACTCATCTG
ACAAAGGGCTAATATCCAGAATCTACAATGAACTCAAACAAATCGGCAAGAGAAAAAC
AAGCATTCCTATCAAAACGTGTGCTAAGAACATGACTAAACAATTCTTTTTTTTCTTTTC
TTTTCTTTTTTTTTTTTTTTCTTTACGGGGCCTTGCCCTTCCGACCGGACTGG 
Genomic_Consensus_3p: 
CGGAACTTGCAGTGAGCCGAGAATGCGCCACTGCACTCCAGCCTGGTCGACAGAGC
AAGACTCCGTCAAGAAAAAAAAAAAAAAAAAAAAAGAAAAGAAAAAAAAAAAAAAAAGT
GTTATTTCAATTTATTAAGACACATTTTAAAAAAAC 
Timecourse_21 
TSD_5prime: 
TTTTTTTTTTTTT 
TSD_3prime:  
TTTTTTTTTTTTT 
Genomic_Consensus_5p: 
AGGGTAATGTTGGCTGGGTTTTTCTCCAAAAAATTCTTTTTTTCCTCTTTTTTTTTTTTT
ATTATACTTGAAGTCCTAGGGTACATGTGCACAATGTGCAGGTTTGTTACATATGAATA
CATGTGCCATGTTGGTGTGCTGCACCCATTAA 
Genomic_Consensus_3p: 
TGGCCAAGGTAATGTCTGCTAGGTTTCTCTACAGAAAATTACTATCTTCCTCTTTTTTT
TTTTTTTTTTTTTACTTTAAGTCCTGGGGCAATTGTGCCAAATTTGCGGGTTTTTTACAT
ATGATTAGAGGTCGCGTTTTGGTGGGGTGCGC 
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Timecourse_22 
TSD_5prime: 
NA 
TSD_3prime:  
NA 
Genomic_Consensus_5p: 
NA 
Genomic_Consensus_3p: 
GAGCCAATTTCTAGCATGGCTTATTAGGACAATGTTTTACTGTCAAGAAGTGCAGTGG
TCACTCAGTACTGCTTTTTCTAGGTGTATTTTTTTTTTTTTTTTTTCTTTTTTTTTTTTTAT
TATACTCTAAGTTTTAGGAAAAGTTCTTATTTTTAAGAGATATATACTGAGAAGTCTCAT
ATGTGCCTTTTATTGTCAATTTT 
Timecourse_23 
TSD_5prime: 
AATTATTAATAAATAATTAAATTATTTATTAATTAATTT 
TSD_3prime:  
AATTATTAATAAATAATTAAATTATTTATTAATTAATTT 
Genomic_Consensus_5p: 
CCTTTATTTCCTTCGCCTGCCTGATTGCCCTGGCCAGAACTTCCAACACTATGTTGAA
TAGGAGTGGTGAGAGAGGGCATCCCTGTCTTGTGCCGGTTTTCAAAGGGAAATTATT
AATAAATAATTAAATTATTTATTAATTAATTTCAAGTTGACATTTAAGTTGAGGCGTGGA
GGTGAAGGAGACAGTTGGATAAATAAG 
Genomic_Consensus_3p: 
GACATTAATTATTAATAAATAATTAAATTATTTATTAATTAATTTATTTTTTTTTTTTTTTTT
TTTTTTTTTTTTTATTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT
TTTTTTTGTTATTTCTTTTTTTT 
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